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SUMMARY 
Inflammation is a self-defensive process by the immune system that helps the body to 
return to homeostasis [1]. Professional innate immune cells with pivotal functions in 
the immune defense like human monocytes, M1 and M2 macrophages produce 
abundant levels of mediators including cytokines, pro-inflammatory eicosanoids, as 
well as specialized proresolving mediators (SPMs). These inflammation-related 
mediators play indispensable roles in the inflammation process. Acute inflammation is 
governed by the production of pro-inflammatory eicosanoids like leukotrienes (LTs) and 
prostaglandins (PGs). Excessive production of pro-inflammatory mediators sustains 
the inflammation process to a chronic inflammation state that is closely related to the 
pathogenesis of various diseases including Alzheimer´s diseases, cardiovascular 
diseases, rheumatoid arthritis, atherosclerosis and cancer [2]. The resolution of 
inflammation is an active process governed by the anti-inflammatory and proresolving 
SPMs [3].  
The vacuolar (H+)-ATPase (V-ATPase) is a universal proton pump that is involved in 
pH homeostasis, pathogen entry and protein degradation [4]. Although V-ATPase is 
fundamental in cytokine trafficking and secretion in human monocytes and was 
implicated in the M2 polarization of murine macrophages [5, 6], its functional roles in 
the biosynthesis of inflammation-related lipid mediators in human immune cells like 
monocytes, M1 and M2 macrophages remained elusive.  
First, we discovered a differential role of V-ATPase in the expression and in the activity 
of cyclooxygenase (COX)-2 in human monocytes. Pharmacological targeting of V-
ATPase with archazolid A (ArchA) or bafilomycin increased the expression of the COX-
2 protein in lipopolysaccharide (LPS)-stimulated monocytes, which was paralleled by 
enhanced phosphorylation of p38 mitogen-activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK)-1/2, without impacting the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and stress-activated protein 
kinase/Jun amino-terminal kinases (SAPK/JNK) pathways. Targeting of both p38 
MAPK and ERK-1/2 pathways suggest that these kinase pathways are crucial for COX-
2 expression in human monocytes. Despite increased COX-2 protein levels, however, 
suppression of V-ATPase activity impaired the biosynthesis of COX-related LM in 
monocytes without affecting 12-/15-lipoxygenase (LOX) products and only minor 
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suppression of 5-LOX activity. Our results indicate that changes in the intracellular pH 
may contribute to suppression of COX-2 activity and that V-ATPase on one hand 
restricts COX-2 protein levels by limiting p38 MAPK and ERK-1/2 activation, while on 
the other hand it governs the cellular COX-2 activity through an appropriate 
intracellular pH. 
Next, we focused on the role of V-ATPase in the polarization of M1 macrophages. We 
show that targeting V-ATPase by ArchA elevated TNF-α mRNA levels and TNF-α 
secretion in M1 macrophages. By contrast, ArchA failed to increase TNF-α levels in 
uncommitted M0 or M2. Production of other relevant cytokines like IL-1β, IL-6, IL-10 or 
chemokines as IL-8 and monocyte chemotactic protein-1 from M1 macrophages was 
not affected by ArchA. Of interest, targeting V-ATPase prevented the degradation of 
COX-2 protein and elevated the production of related PG, which contrasts the role in 
monocytes. Notably, we show that the phosphorylation and nuclear translocation of the 
p65 subunit of NF-κB as well as phosphorylation of SAPK/JNK is enhanced by ArchA. 
V-ATPase is overexpressed in various types of tumor cells and targeting V-ATPase 
induces tumor cell apoptosis [7]. To evaluate possible benefits of V-ATPase inhibition 
to the anti-tumoral effects of M1 macrophages, a microfluidically-supported three-
dimensional human tumor biochip model was introduced. ArchA-treated M1 
macrophages significantly reduced MCF-7 tumor cell viability due to elevated TNFα 
secretion, whereas in models containing M2 macrophages or in models devoid of 
macrophages, ArchA failed in this respect. Conclusively, pharmacologically targeting 
V-ATPase induces COX-2 protein expression and production of PG and TNF-α levels, 
thus supporting the anti-tumoral effects of M1 macrophages.  
Finally, IL-4-stimulated M2 macrophages possess a different LM profile compared to 
classical activated M1 macrophages upon challenge with pathogenic bacteria [8]. 
Classical M1 macrophages produce predominately pro-inflammatory LTs and PGs, 
while M2 macrophages biosynthesize abundant levels of SPM. V-ATPase was shown 
to be involved in the polarization of murine macrophages [5]. Therefore, we focused 
on the role of V-ATPase in LM biosynthetic pathways in human M2 macrophages. 
Blockade of V-ATPase during polarization of human M2 macrophages abrogated 15-
lipoxygenase-1 (15-LOX-1) expression, the key enzyme in SPM biosynthesis and thus 
prevented the formation of 15-LOX-1-derived SPM precursors and related SPM. 
Targeting V-ATPase neither influenced the IL-4-triggered JAK-STAT6 pathway nor the 
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mTORC1 signaling cascade, but strongly suppressed phosphorylation of MEK and 
ERK-1/2 in M2 macrophages. The MEK inhibitor U0126 and c-Myc inhibitor JQ-1 
abrogated 15-LOX-1 expression as well as SPM biosynthesis, indicating an essential 
role of V-ATPase in 15-LOX-1 expression and SPM formation through the MEK/ERK-
1/2-c-Myc cascade in human M2 macrophages. Inhibition of V-ATPase in vivo delayed 
inflammatory resolution of zymosan-induced murine peritonitis accompanied by an 
increased neutrophil infiltration and decreased SPM levels without affecting the pro-
inflammatory LTs or PGs. Collectively, our data propose a critical role of V-ATPase in 
the regulation of SPM biosynthetic pathways in M2 macrophages and has a crucial 
role in resolution of inflammation.  
Together, this thesis provides evidence that V-ATPase differentially regulates the 
biosynthetic pathways of inflammation-related lipid mediators in human immune cells 
like monocytes, M1 and M2 macrophages. In a cell-specific manner, V-ATPase i) limits 
the expression of COX-2 enzyme but governs COX-2 activity via the regulation of the 
intracellular pH in monocytes, but ii) limits the expression of COX-2 enzyme and 
production of PG in M1 macrophages, and iii) is crucial for IL-4 induced expression of 
15-LOX-1 as well as related SPM precursor and SPM in M2 macrophages with an 
essential role in resolution of inflammation. 
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ZUSAMMENFASSUNG 
Entzündung ist ein selbstverteidigender Prozess des Immunsystems, der dem Körper 
hilft, zur Homöostase zurückzukehren [1]. Professionelle Zellen des angeborenen 
Immunsystems mit zentralen Funktionen in der Immunabwehr wie menschliche 
Monozyten, M1- und M2-Makrophagen produzieren reichlich Mediatoren, 
einschließlich Zytokine, entzündungsfördernde Eicosanoide sowie spezialisierte Pro-
resolving-Mediatoren (SPMs). Diese entzündungsrelevanten Mediatoren spielen eine 
unverzichtbare Rolle in der Regulation des Entzündungsprozesses. Akute 
Entzündungen werden durch die Produktion entzündungsfördernder Eicosanoide wie 
Leukotriene (LTs) und Prostaglandine (PGs) gesteuert. Die übermäßige Produktion 
entzündungsfördernder Mediatoren führt zu einem chronischen Entzündungszustand, 
der eng mit der Pathogenese verschiedener Krankheiten wie Alzheimer, Herz-
Kreislauf-Erkrankungen, rheumatoider Arthritis, Atherosklerose und Krebs 
zusammenhängt [2]. Die Auflösung der Entzündung ist ein aktiver Prozess, der von 
entzündungshemmenden SPMs geregelt wird [3]. 
Die vakuoläre (H+) - ATPase (V-ATPase) ist eine universelle Protonenpumpe, die an 
der pH-Homöostase, dem Eindringen von Krankheitserregern und dem Proteinabbau 
beteiligt ist [4]. Die V-ATPase ist für den Zytokintransport und die Sekretion in 
menschlichen Monozyten von grundlegender Bedeutung und ist auch in die M2-
Polarisation von Maus-Makrophagen involviert [5, 6]. Die Rolle des Enzyms bei der 
Biosynthese entzündungsbedingter Lipidmediatoren in menschlichen Immunzellen wie 
Monozyten, M1 und M2-Makrophagen ist bislang nicht geklärt. 
Zunächst entdeckten wir eine unterschiedliche Rolle der V-ATPase bei der Expression 
und Aktivität von Cyclooxygenase (COX)-2 in menschlichen Monozyten. Das 
pharmakologische Targeting von V-ATPase mit Archazolid A (ArchA) oder Bafilomycin 
erhöhte die Expression des COX-2-Proteins in Lipopolysaccharid (LPS) -stimulierten 
Monozyten, was mit einer verstärkten Phosphorylierung von p38-Mitogen-aktivierter 
Proteinkinase (MAPK) und extrazellulär signalregulierte Kinase (ERK)-1/2 einherging, 
ohne den Kernfaktor kappa-light chain enhancer von aktivierten B-Zellen (NF-κB) und 
stressaktivierten Proteinkinase/Jun-Amino-terminalen Kinasen (SAPK/JNK) zu 
beeinflussen. Das Targeting von sowohl p38 MAPK- als auch ERK-1/2-Pfaden legt 
nahe, dass diese Kinase-Pfade für die COX-2-Expression in menschlichen Monozyten 
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entscheidend sind. Trotz erhöhter COX-2-Proteinspiegel beeinträchtigte die 
Unterdrückung der V-ATPase-Aktivität jedoch die Biosynthese von COX- abgeleiteten 
LM in Monozyten, ohne 12-/15-Lipoxygenase (LOX)-Produkte und, nur geringfügig, die 
5-LOX-Aktivität zu beeinträchtigen. Unsere Ergebnisse deuten darauf hin, dass 
Änderungen des intrazellulären pH-Werts zur Unterdrückung der COX-2-Aktivität 
beitragen können und dass V-ATPase einerseits die COX-2-Proteinspiegel einschränkt, 
indem sie die Aktivierung von p38 MAPK und ERK-1/2 eingrenzt, andererseits regelt 
sie die zelluläre COX-2-Aktivität durch einen geeigneten intrazellulären pH-Wert. 
Als nächstes konzentrierten wir uns auf die Rolle der V-ATPase bei der Polarisation 
von M1-Makrophagen. Wir zeigen, dass das Targeting von V-ATPase durch ArchA die 
TNF-α-mRNA-Spiegel und die TNF-α-Sekretion in M1-Makrophagen erhöht. Im 
Gegensatz dazu konnte ArchA die TNF-α-Spiegel in M0 oder M2 nicht erhöhen. Die 
Produktion anderer relevanter Zytokine wie IL-1β, IL-6, IL-10 oder Chemokine wie IL-
8 und chemotaktisches Monozytenprotein-1 aus M1-Makrophagen wurde von ArchA 
nicht beeinflusst. Interessanterweise verhinderte das Targeting von V-ATPase den 
Abbau von COX-2-Protein und erhöhte die Produktion von verwandtem PG, was der 
Rolle der V-ATPase in Monozyten entgegensteht. Insbesondere zeigen wir, dass die 
Phosphorylierung und Kerntranslokation der p65-Untereinheit von NF-κB sowie die 
Phosphorylierung von SAPK/JNK durch ArchA verstärkt werden. V-ATPase wird in 
verschiedenen Tumorzelltypen überexprimiert und durch gezielte V-ATPase wird eine 
Tumorzellapoptose induziert [7]. Um die möglichen Vorteile der V-ATPase-Hemmung 
für die Antitumorwirkung von M1-Makrophagen zu bewerten, wurde ein mikrofluidisch 
unterstütztes dreidimensionales Biochip-Modell für menschliche Tumoren etabliert. 
ArchA-behandelte M1-Makrophagen reduzierten die Lebensfähigkeit von MCF-7-
Tumorzellen aufgrund einer erhöhten TNFα-Sekretion signifikant, wohingegen ArchA 
in Modellen, die M2-Makrophagen enthielten, oder in Modellen, die keine 
Makrophagen enthielten, diesbezüglich versagte. Zusammenfassend induziert die 
pharmakologisch Hemmung der V-ATPase die COX-2-Proteinexpression und die 
Produktion von PG- und TNF-α-Spiegeln, wodurch die Antitumorwirkung von M1-
Makrophagen unterstützt wird. 
IL-4-stimulierte M2-Makrophagen produzieren bei Exposition mit pathogenen 
Bakterien ein anderes LM-Profil als klassisch aktivierte M1-Makrophagen [8]. 
Klassische M1-Makrophagen produzieren hauptsächlich entzündungsfördernde LTs 
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und PGs, während M2-Makrophagen reichlich SPM biosynthetisieren. Es wurde 
gezeigt, dass V-ATPase an der Polarisation von Maus-Makrophagen beteiligt ist [5]. 
Daher konzentrierten wir uns auf die Rolle der V-ATPase in LM-Biosynthesewegen in 
humanen M2-Makrophagen. Die Blockade der V-ATPase während der Polarisation von 
humanen M2-Makrophagen hob die 15-Lipoxygenase-1 (15-LOX-1)-Expression auf, 
welches das Schlüsselenzym in der SPM-Biosynthese ist, und verhinderte somit die 
Bildung von 15-LOX-1-abgeleiteten SPM-Vorläufern und verwandten SPM. Die 
Hemmung der V-ATPase beeinflusste weder den IL-4-induzierten JAK-STAT6-
Signalweg noch die mTORC1-Signalkaskade, verringerte jedoch die Phosphorylierung 
von MEK und ERK-1/2 in M2-Makrophagen stark. Der MEK-Inhibitor U0126 und der c-
Myc-Inhibitor JQ-1 verhinderten die 15-LOX-1-Expression sowie die SPM-Biosynthese, 
was auf eine wesentliche Rolle der V-ATPase bei der 15-LOX-1-Expression und der 
SPM-Bildung durch die MEK/ERK-1/2-c-Myc-Kaskade in humanen M2-Makrophagen 
hindeutet. Die Hemmung der V-ATPase in vivo verzögerte die Auflösung der Zymosan-
induzierten murinen Peritonitis, was einherging mit einer erhöhten Neutrophilen-
Infiltration und verringerten SPM-Spiegeln, ohne die proinflammatorischen LT oder PG 
zu beeinflussen. In der Gesamtheit zeigen unsere Daten, dass die V-ATPase eine 
entscheidende Rolle in der Regulation von SPM-Biosynthesewegen in M2-
Makrophagen und bei der Auflösung von Entzündungen spielt. 
Zusammenfassend liefert diese Arbeit Hinweise darauf, dass die V-ATPase die 
Biosynthesewege entzündungsbedingter Lipidmediatoren in menschlichen 
Immunzellen wie Monozyten, M1- und M2-Makrophagen unterschiedlich reguliert. In 
einer zellspezifischer Weise i) begrenzt die V-ATPase die Expression des COX-2-
Enzyms in Monozyten, reguliert jedoch die COX-2-Aktivität mittels des intrazellulären 
pH-Wertes, ii) begrenzt die V-ATPase die Expression des COX-2-Enzyms und die 
Produktion von PG in M1-Makrophagen und iii) ist die V-ATPase entscheidend für die 
IL-4-induzierte Expression von 15-LOX-1, sowie verwandten SPM-Vorläufern und 
SPM in M2-Makrophagen mit einer wesentlichen Rolle bei der Auflösung von 
Entzündungen. 
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1. INTRODUCTION 
1.1 Inflammation 
Inflammation is a self-protective process during which the immune system defenses 
against exterior stimulus including tissue injury, microbial infection and many others. 
On challenge of harmful stimuli, various cellular processes are evoked like increase of 
blood flow, enhancement of capillaries permeability as well as elevated production of 
pro-inflammatory cytokines and eicosanoids (prostaglandins (PGs) and leukotrienes 
(LTs) ) [1]. Cardinal signs like rubor (redness), tumor (swelling or edema), and dolor 
(pain) are formed during acute inflammation. One major event that governs the acute 
inflammatory process is the migration of neutrophils out of the capillary venules to the 
inflamed sites [9].  
 
Fig.1.1 The inflammation process. Exterior stimuli (microbial infection, tissue injury and barrier break) 
which trigger various biological processes including increase of blood flow and vascular permeability, 
neutrophil transmigration, production of pro-inflammatory prostaglandins (PGs), leukotrienes (LTs) and 
cytokines as well as formation of cardinal signs. Excessive pro-inflammatory mediators sustain the 
inflammation to chronic inflammatory ones, which leads to tissue damage and is related to the 
pathogenesis of various diseases. Lipid mediator (LM) class switch alters the biosynthesis of PG/LT 
towards LXA4, which inhibits the pro-inflammatory process and programs the resolution for homeostasis. 
Ideally, the inflammation process is self-limiting and acute inflammation always 
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accompanies with the resolution phase that helps the body return to a healthy state 
[10]. In the resolution phase, lipid mediators (LM) class switch signal triggered by PGE2 
and PGD2 switches the production of pro-inflammatory LTB4 to proresolving LXA4 that 
inhibits neutrophil transmigration, recruits monocytes and programs the resolution 
phase for homeostasis [11]. However, unresolved inflammation would turn into a 
chronic inflammation state, which subsequently leads to chronic diseases such as 
Alzheimer´s diseases, cardiovascular diseases, rheumatoid arthritis, atherosclerosis 
and cancer [2]. 
1.1.1 Eicosanoids and inflammation 
During acute inflammation, endogenously released mediators (like eicosanoids 
including LTs and PGs) and cytokines play pivotal roles in regulating the initiation and 
maintenance of the inflammatory process.  
 
Fig.1.2 The eicosanoid biosynthesis pathway. Utilizing phospholipid-derived arachidonic acid (AA) 
as substrate, production of leukotrienes (LTs), prostaglandins (PGs) and thromboxane (TX) are 
catalyzed by various eicosanoid biosynthetic enzymes. 5-lipoxygenase (5-LOX) and 5-lipoxygenase-
activating protein (FLAP) catalyze the formation of intermediate 5-HPETE, which is further converted to 
5-HETE by glutathione peroxidases (GPx), to LTB4 by LTA4 hydrolase (LTA4H) and Cys-LT by LTC4 
Synthase (LTC4S). Cyclooxygenases (COX-1 and COX-2) catalyze the formation of intermediate PGH2, 
which is further converted to PG and TXB2 by PGE synthase (mPGES, cPGES), PGD synthase (PGDS), 
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PGF synthase (PGFS) and thromboxane synthase (TxS). 
1.1.1.1 Leukotrienes 
Leukotrienes (LTs) are biosynthetic eicosanoids synthesized from phospholipid- 
derived arachidonic acid (AA) via the 5-lipoxygenase (5-LOX) pathway [12, 13]. The 
catalytic activity of 5-LOX is dependent on multiple processes including the presence 
of 5-lipoxygenase-activating protein (FLAP), cellular AA supply, the presence of 
calcium ions (Ca2+) and ERK-1/2 activity [14]. In the resting state, 5-LOX resides in the 
cytosol or the nucleoplasm. Once activated by stimuli, 5-LOX will be phosphorylated 
and translocated to the nuclear membrane with the help with its helper protein FLAP. 
Activated 5-LOX together with FLAP catalyze the formation of intermediates 5(S)-
hydroperoxyeicosatetraenoic acid (HPETE) and LTA4 from AA. Then LTA4 is further 
converted to LTB4 and cysteinyl LT (Cys-LT, including LTC4, LTD4 and LTE4) with the 
help of LTA4 hydrolase (LTA4H) and LTC4 synthases (LTC4S) [15, 16]. Alternatively, 
5(S)-HPETE can also be metabolized to 5(S)-hydroxyeicosatetraenoic acid (HETE) by 
glutathione peroxidase (GPx) [17]. LT are generated from a large variety of 
inflammatory cells including polymorphonuclear neutrophils (PMNL), eosinophils, 
monocytes, macrophages and mast cells. Neutrophils produce mainly LTB4 and 
eosinophils produce higher amounts of LTC4, while monocytes and macrophages 
produce balanced amounts of LTB4 and cys-LTs [18, 19]. LTB4 is among one of the 
most potent chemoattractant mediators that were shown to stimulate and amplify 
neutrophil chemotaxis in various in vitro and in vivo studies [20]. LTB4 was shown to 
increase interleukin-6 (IL-6) production through activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and NF-IL-6 in human monocytes [21]. 
Cys-LT are described as “slow-reacting substance of anaphylaxis” since they were 
shown to contract airway smooth muscles in both animal and human in vitro studies 
[22, 23]. Excessive production of leukotrienes maintains the inflammatory process and 
stimulates the progression of chronic inflammation, which contributes the pathogenesis 
of various diseases including cancer [24]. LT are critically involved in the pathogenesis 
of asthma, they are recognized as common therapeutic targets in the treatment of 
 
4 
asthma [25, 26]. The marketed drug zileuton is a common therapy for treating asthma 
by blockade of LT formation via inhibition of 5-LOX activity [27].  
1.1.1.2 Prostanoids 
Prostanoids (PG and thromboxane) are derived from AA. Cyclooxygenases (COX or 
named as prostaglandin H synthase) catalyze the rate-limiting step from AA to form the 
intermediate PGH2. Afterwards PGH2 is converted to PG (PGE2, PGD2 and PGF2) and 
thromboxane (TXB2) by specific enzymes like PGE synthase (mPGES, cPGES), PGD 
synthase (PGDS), PGF synthase (PGFS) and thromboxane synthase (TxS) [28]. In 
humans, two isoforms of COX exits, namely COX-1 and COX-2, respectively.  
The COX-1 enzyme is considered to be constitutively expressed in most cells and 
tissues. COX-1 is responsible for the formation of gastric PG that show protective 
functions in stomach and intestine homeostasis. Recent evidences showed that COX-
1 is also inducible upon IL-4 stimulation in alternative activated M2 macrophages [29]. 
However, COX-2, an inducible enzyme that can be activated by various pro-
inflammatory stimuli including TNF-α, LPS and IL-1β, is critically involved in the 
formation of the excessive PG in inflammation. 
PG play pivotal role in the initiation of inflammation, they are involved in the formation 
of the cardinal signs like rubor (redness), tumor (swelling or edema), and dolor (pain) 
in inflammation [30]. PG increase the blood flow and the permeability of venules, which 
cause redness and edema, and they trigger the infiltration of neutrophils to inflamed 
sites [31]. Their actions on peripheral sensory neurons and brain central sites are 
related to pain in inflammation [30]. In clinic, steroidal glucocorticoids, non-steroidal 
anti-inflammatory drugs (NSAIDs, like aspirin, indomethacin, ibuprofen) and selective 
COX-2 inhibitors coxibs (celecoxib and rofecoxib) are used to inhibit the activity of COX 
enzymes, especially COX-2 activity as anti-inflammatory therapy [32-35]. As doubled-
edged sword, PG display dual pro-inflammatory and anti-inflammatory roles. PG as 
modulators rather than only mediators of inflammation down-regulate host responses 
and reverse the enhancement of acute allergic inflammation in vivo. PGE2 triggers the 
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LM class switch signal and switches the production of pro-inflammatory LTB4 to 
proresolving LXA4 that inhibits neutrophil infiltration, recruits monocytes and programs 
the resolution phase [11]. In the gastrointestinal mucosa, abundant levels of PG are 
detected and play crucial cytoprotective roles to avoid gastric mucosal damage [36, 
37].  
1.1.2 Cytokines and inflammation 
During acute inflammation, immune cells like monocytes and macrophages produce 
abundant levels of pro-inflammatory cytokines including interleukin-1β (IL-1β), 
interleukin-6 (IL-6), tumor necrosis factor (TNF-α), to name a few. Vice versa, these 
pro-inflammatory cytokines also stimulate and amplify the acute inflammation. Studies 
revealed that these pro-inflammatory cytokines are related to initiation and 
maintenance of the neuropathic pain [38]. IL-1β stimulates the production of other pro-
inflammatory molecules like substance P and PGE2 in neuronal cells [39, 40]. 
Overproduction of IL-1β and IL-6 are related to the pathogenesis of various chronic 
diseases like rheumatoid arthritis, inflammatory bowel disease, Alzheimer's disease 
and cancer [41]. TNF-α as key regulator of the inflammatory response binds TNF-α 
receptors and triggers cellular responses by activation of subsequent signaling. For 
example, TNF-α enhances leukocyte adhesion and transmigration in vascular 
endothelial cells [42]. TNF-α is involved in the activation of NF-κB signaling and thus 
induces COX-2 expression and production of PG [43].  
Depending on the microenvironment, various cytokines display also anti-inflammatory 
effects. IL-4 is a highly pleiotropic cytokine that is produced mainly by T-helper cell 
type-2 (Th2) lymphocytes and in turn regulates the Th2 differentiation [44]. IL-4 
displays significant anti-inflammatory roles by inhibition of production of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α [45]. Various studies indicated 
that IL-6, IL-10 and IL-13 are potent deactivators of pro-inflammatory cytokine 
synthesis. For example, evidences proved that IL-6 stimulates anti-inflammatory 
responses including the synthesis of glucocorticoids and IL-1ra while it inhibited the 
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LPS-induced production of IL-1β and TNF-α [46]. IL-10 inhibited the activation of NF-
κB and the production of TNF-α in RAW 264.7 macrophages [47]. IL-13 suppressed 
the production of pro-inflammatory cytokines like IL-1β, IL-6, IL-8 and TNF-α in human 
monocytes [48]. 
 
1.2 Resolution of inflammation 
For a long period, the resolution phase was thought to be a passive process by the 
innate immune system. However, recent studies showed that the resolution of 
inflammation is an active process, which is governed by the anti-inflammatory and 
proresolving effects of endogenously produced specialized proresolving mediators 
(SPMs) [3, 49]. As functional mediators, SPMs trigger anti-inflammatory responses in 
acute inflammation and proresolving actions during resolution of inflammation. They 
are actively involved in mediating various inflammation-related processes like 
neutrophils transepithelial migration, phagocytosis and tissue regeneration.  
1.2.1 Biosynthesis and biological function of SPM 
Depending on the substrate, the SPM include lipoxins (LXs) that are derived from AA, 
maresins (MaRs), protectins (PDs) and resolvin D/E-series (RvDs and RvEs) that are 
bioactive metabolites from omega-3 essential fatty acids DHA and EPA.  
1.2.1.1 Lipoxins and aspirin-triggered lipoxins 
LXs are the first class of lipid mediators which are characterized to be actively involved 
in resolution of inflammation. Triggered by a lipid mediator class switch signal, these 
SPM offer “stop” signals to block the infiltration of neutrophils, end the acute 
inflammation and program the resolution of inflammation [11]. Other than the formation 
of LTs, 5-LOX derived-arachidonic acid (AA) intermediate LTA4 can be converted to 
LXs (LXA4 and LXB4) with the help of 15-LOX-1 in human macrophages or 12-
lipoxygenase (12-LOX) in platelets [50, 51]. Besides the classical biosynthetic pathway 
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for SPM, specific aspirin-triggered lipoxins (AT-LXs) are produced via the aspirin-
triggered pathways when COX-2 is acetylated by aspirin [52]. The acetylated COX-2 
generates 15R-H(p)ETE, which is the precursor for AT-LXs (AT-LXA4 and LT-LXB4).  
 
Fig.1.3 The biosynthetic pathway of specialized proresolving mediators. Various bio-functional 
enzymes (5-LOX, FLAP, COX-2, CYP450, 15-LOX-1 and 12-LOX) catalyze the formation of different 
series of specialized proresolving mediators (SPMs) including lipoxins (LXs), resolvin E-series (RvEs), 
protectins (PDs), resolvin D-series (RvDs), maresins (MaRs) and aspirin-triggered 
lipoxins/resolvins/protectins (AT-LXs, AT-RvDs and AT-PD1) from fatty acid substrates (AA, EPA and 
DHA). 
LXs and AT-LXs achieve their biological functions via binding a specific G-protein 
coupled receptor (GPCR) named ALX (or called FPR) [53]. In both, in vitro cellular 
systems and in vivo animal disease models, LXA4 and AT-LXs are actively involved in 
various multicellular processes in resolution of inflammation. Various in vitro studies 
indicated that LXA4 and LXA4-derivatives inhibit human neutrophils chemotaxis and 
transmigration and stimulates phagocytosis of apoptotic neutrophils [54-56]. In vivo, 
LXA4-derivatives treatment showed protective roles in reducing the weight loss, 
intestinal bleeding and overall mice mortality in a DSS-induced murine colitis [57].  
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Fig.1.4 Dual anti-inflammatory and proresolving actions of specialized proresolving mediators. 
Specialized proresolving mediators (SPM) show dual anti-inflammatory actions including inhibition of 
polymorphonuclear neutrophils (PMNL) infiltration and proresolving effects including stimulation of 
monocyte recruitment, facilitate of macrophage phagocytosis and phagocyte removal, which help the 
body return to homeostasis. Figure adjusted from Serhan.CN et.al [10]. 
1.2.1.2 Resolvin E-series 
It is well known that diets rich in essential omega-3 fatty acids including EPA and DHA 
are beneficial to human health, with therapeutic effects in controlling inflammation-
related diseases that might even trigger cancer [58]. Several new classes of SPM 
derived from EPA were characterized and their connection to resolution of inflammation 
were investigated. Serhan et al. identified the first endogenously produced RvE1 that 
was proved to impede inflammation and stimulate resolution both in vitro and in vivo 
[59]. For the biosynthesis of EPA-derived RvEs, cytochrome P450 monooxygenase 
(CYP450) or aspirin-triggered acetylated COX-2 converts EPA first to 18-HEPE. Then 
5-LOX catalyzes the formation of RvE1 [59] or RvE2 [60], respectively, from the mono-
hydroxy precursor 18-HEPE. Alternatively, 18-HEPE can be converted by 15-LOX-
1/12-LOX to RvE3 [61]. RvE2 and RvE3 exhibit potent anti-inflammatory activities by 
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inhibition of neutrophil chemotaxis in vitro and neutrophils transmigration in vivo in 
murine peritonitis [60, 61].  
1.2.1.3 Resolvin D-series, protectins and maresins 
In resolving exudates, other classes of SPM denoted resolvin D-series (RvDs), 
protectins (PDs) and maresins (MaRs) that are metabolites from DHA were discovered. 
For the formation of DHA derived RvDs and PDs, DHA is first metabolized to 17S-
H(p)DHA by 15-LOX-1 or 17R-H(p)DHA by acetylated COX-2 [62, 63]. These 
intermediates are further converted to RvDs and AT-RvDs with the help of 5-LOX or to 
PD1 and AT-PD1 [62, 63]. RvD1 binds to ALX and GPR32 and show proresolving 
functions like inhibition of eosinophilia and pro-inflammatory mediators, enhancement 
of phagocytosis, which promotes the resolution of acute inflammation [64]. Recent 
reports also indicated that RvD1 is able to manipulate the polarization of macrophages 
by reprogramming pro-inflammatory M1 macrophages towards a proresolving 
phenotype [65]. Studies revealed that RvD3 and AT-RvD3 inhibit neutrophil 
transmigration, stimulate phagocytosis and efferocytosis and accelerate epithelial 
injury recovery [66, 67]. PD1 and its analogues exhibited potent anti-inflammatory and 
proresolving activities by blocking neutrophil transmigration and enhancing the 
recruitment of monocytes and lymphocytes in vivo in murine peritonitis [68]. 
Alternatively, DHA can also be converted to intermediate 14-H(p)DHA by 15-LOX-1/12-
LOX. Then 14-H(p)DHA is further metabolized to its epoxy derivative and finally to 
MaR1 and MaR2. MaR1 and MaR2 display anti-inflammatory and proresolving actions 
like enhancement of human macrophage phagocytosis in vitro and inhibition of murine 
PMNL infiltration in vivo [69, 70]. 
 
1.3 Monocytes and macrophages 
1.3.1 Monocytes 
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Monocytes are myeloid cells that develop in the bone marrow, circulate in the 
peripheral blood and migrate to specific tissues during inflammation [71, 72]. They 
further differentiate into various types of immune cells including macrophages and 
dendritic cells, mediated by specific cytokines or growth factors depending on the 
microenvironment [73]. For example, dendritic cells can be achieved from monocytes 
upon stimulation of granulocyte/macrophage colony-stimulating factor (GM-CSF) and 
interleukin-4 (IL-4) [74]. Monocytes can also differentiate to M1 macrophages in 
presence of interferon gamma (IFN-γ) and lipopolysaccharide (LPS) or to M2 
macrophages after IL-4/IL-13 stimulation [75].  
Human primary monocytes can be subdivided into several subsets based on their 
antigenic surface markers CD14 and CD16 expression. CD14++CD16- monocytes are 
usually referred to as classical monocytes because they resemble more the original 
description of monocytes, which contribute around 90% of total circulating monocytes, 
express CCR2 and possess high phagocytic activity [76]. CD14+CD16+ monocytes are 
usually considered as non-classical monocytes while CD14++CD16+ monocytes are 
characterized as an intermediate phenotype [77]. CD16+ monocytes represent around 
10% of circulating monocytes and express higher CD32 and MHC class II [78]. These 
cells have been referred to as “resident” monocytes since they maintain the 
replenishment of tissue-resident macrophages and dendritic cells.  
Murine monocytes subsets are distinguished based on their differential expression of 
Ly6C, CX3CR1 and CCR2. Ly6C+CX3CR1lowCCR2+ monocytes express high amounts 
of CD11c and MHC class II and resemble classical human CD14highCD16- cells, which 
are larger in size and highly phagocytic [79]. They have a short circulation time in the 
bloodstream and are recruited to inflamed tissues upon inflammatory stimulation. 
During infection, recruited monocytes activate phagolysosome actions to display 
bacterial killing and clearance functions and stimulates the production of cytokines to 
initiate acute inflammation [80]. Ly6C-CX3CR1highCCR2- monocytes have longer 
circulation periods in bloodstream and resemble CD14+CD16+ human monocytes, 
which are smaller in size. They circulate in the peripheral blood, return to the bone 
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marrow, differentiate and constitutively replenish the tissue-resident macrophages and 
dendritic cells under homeostasis [79].  
1.3.2 Macrophages 
 
Fig.1.5 M1 and M2 macrophage polarization. Classical activated (M1) macrophages (stimulated by 
LPS and IFN-γ) and alternative activated (M2) macrophages (M2a stimulated in presence of IL-4 or IL-
13) display distinct roles with different surface marker expression, cytokines release and gene 
expression.  
Macrophages as prominent immune cells are widely distributed in tissues. These adult 
tissue macrophages were thought to be derived from circulating monocytes but recent 
evidence indicated that they originate mostly during embryonic development [81]. 
Under inflammatory conditions, circulating monocytes infiltrate from peripheral blood 
to inflamed tissues and polarize to macrophages [71]. Both the tissue resident 
macrophages and recruited monocyte-derived macrophages display indispensable 
roles in maintaining immune functions and homeostasis. Macrophages are 
professional antigen-presenting cells that collaborate with T and B cells [82]. They are 
also prominent phagocytic cells that phagocytose invaded microbe debris and 
apoptotic cells like apoptotic neutrophils [83].  
Due to their plasticity and heterogeneity, macrophages can be polarized differently for 
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specific physiological functions depending on the microenvironment [84]. They are 
divided into two major functional phenotypes, classically activated M1 macrophages 
and alternative activated M2 macrophages. Basically, M1 macrophages are more pro-
inflammatory and anti-tumoral in tumor milieu, while M2 macrophages are more anti-
inflammatory but pro-tumoral in tumor microenvironment.                                         
1.3.2.1 M1 macrophages 
Classically activated M1 macrophages are developed from T-helper type 1 (Th1) 
cytokines interferon gamma (IFN-γ) and lipopolysaccharide (LPS) stimulation [85]. 
They are professional antigen-presenting cells with elevated expression of major 
histocompatibility complex II (MHC-II) [86, 87]. In addition, M1 macrophages express 
high levels of cluster of differentiation 86 (CD86) and CD80 [86]. Notably, they are 
responsible for the production of abundant pro-inflammatory cytokines like IL-12, IL-1β, 
IL-6 and TNF-α, and chemokines such as CCL15, CCL20, CXCL9, CXCL 10, CXCL11 
and CXCL13 [75, 88].  
Functionally, M1 macrophages are phagocytic cells that phagocytose apoptotic 
neutrophils and clear invaded bacterial or pathogen debris [89]. They coordinate with 
DC cells, natural killer cells and T cells to regulate immune cell recruitment in Th1 
inflammatory responses [90]. M1 macrophages are characterized by increased 
microbicidal ability since they release nitric oxide and synthesize reactive oxygen 
intermediates (ROI) due to higher inducible nitric oxide synthase (iNOS) activity [91]. 
Classical M1 polarization with LPS and IFN-γ also upregulates the expression of COX-
2 [92], the key enzyme in the biosynthesis of pro-inflammatory PGs. Upon challenge 
of pathogenic bacteria, classical M1 stimulation produces predominately pro-
inflammatory LTs and PGs [8].  
1.3.2.2 M2 macrophages 
Different from the classical activated M1 macrophages, M2 macrophages are originally 
described as alternative activated macrophages that are stimulated by Th2 cytokines 
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IL-4 or IL-13 [93, 94]. Afterwards more stimuli including IL-10, transforming growth 
factor beta (TGF-β) and glucocorticoids were found to stimulate the alternative 
activation. M2 macrophages can be further divided into M2a (after IL-4 or IL-13 
stimulation), M2b (by immune complexes and IL-1 or LPS stimulation) and M2c (by IL-
10, TGF-β or glucocorticoids treatment) subtypes [95]. M2 macrophages are 
considered anti-inflammatory since they inhibit the production of pro-inflammatory 
mediators including TNF-α, IL-1β, IL-6, IL-12 and MCP-1 [96]. IL-4/IL-13 activated M2a 
macrophages express high levels of the mannose receptor CD206, several scavenger 
receptors including CD163 and class A scavenger receptor (SRA) [97]. They produce 
higher amounts of IL-1 receptor antagonist (IL-1ra) and the decoy IL-1β type II receptor 
(IL-1RII), which suppresses the release and activity of IL-1β [96, 98]. M2a 
macrophages express low levels of iNOS but high levels of arginase 1, which 
compromise the microbicidal function but stimulate tissue repair [99, 100]. Studies 
revealed that the expression of coagulation factor XIII-A (FXIIIA) and insulin like growth 
factor 1 (IGF-1) that are crucial for tissue regeneration, are mediated by IL-4 stimulated 
alternative macrophage activation instead of the classical activation [101]. M2a 
macrophages are also referred to as “wound healing macrophages” according to a 
functional classification proposed by Mooser et al. [90].  
The Th2 cytokines IL-4/IL-13 stimulation stimulates the expression of M2-specific 
genes in various mammalian cells including human orbital fibroblasts, human 
endothelial cells, A549 cells, murine bone marrow derived macrophages and human 
peripheral blood monocytes [102-105]. In a gene analysis study, ALOX15 was 
characterized as the most strongly upregulated gene among all the genes regulated 
after IL-4/IL-13 mediated alternative stimulation of human monocytes [106]. ALOX15 
displays dual pro-inflammatory and anti-inflammatory roles in inflammation. On the one 
hand, ALOX15 converts arachidonic acid (AA) to mono-hydroxylated metabolites 15-
HETE, 12-HETE or 13-HODE, which were shown to be pro-inflammatory in various 
animal inflammation models [107]. Aberrant function of ALOX15 is also related to the 
pathogenesis of atherosclerosis [108]. On the other hand, 15-LOX-1 is involved in the 
biosynthesis of specialized proresolving mediators (SPM) that are actively involved in 
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the inflammation process [49]. Recent study revealed that IL-4-stimulated M2 
macrophages possess different lipid mediator profile compared to classical activated 
M1 macrophages upon pathogenic bacterial stimulation [8]. Alternative stimulated M2 
macrophages stimulate the production of bioactive SPM that are dual anti-inflammatory 
and proresolving. 
There are several signaling pathways that might be involved in the regulation of 15-
LOX-1 expression in IL-4/IL-13 stimulated macrophages. The classical IL-4/IL-13 
stimulated 15-LOX-1 regulating pathway is the Janus kinases-signal transducer and 
activator of transcription 6 (JAK-STAT6) pathway. IL-4 or IL-13 stimulation binds the IL-
4 receptor and activates JAK1 and JAK3, which phosphorylates STAT6 [109]. 
Phospho-STAT6 is then translocated to the nucleus and triggers the expression of IL-
4 responsible genes including ALOX15 [110]. 
 
The PI3K-Akt-mTORC1 pathway, another pathway recognized recently, was shown to  
be involved in the regulation of M2-related genes expression in IL-4 stimulated bone-
marrow-derived macrophages [5]. The assembly and activation of mechanistic target 
of rapamycin complex 1 (mTORC1) is essential for lysosomal nutrient sensing. With 
abundant amino acids, vacuolar H+-ATPase (V-ATPase) interacts with the regulators 
and triggers the recruitment and activation of mTORC1 from the cytoplasm to the 
surface of lysosomes [111]. Recent study revealed that mTORC1 is involved in the 
regulation of IL-4 stimulated bone marrow derived macrophages polarization. 
Fig.1.6 IL-4 stimulated 15-LOX-1 
regulating pathway. Three signaling 
pathways (the JAK-STAT6 pathway, 
PI3K-Akt-mTORC1 pathway and the 
MEK/ERK-1/2 cascade) that might be 
involved in regulating the expression of 
15-LOX-1 in IL-4 stimulated 
macrophages.  
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Dysfunction of mTORC1 by pharmacological interference of V-ATPase with bafilomycin 
blocked the expression of IL-4 triggered M2-specific genes [5]. However, the role of the 
PI3K-Akt-mTORC1 pathway remains to be explored in the regulation of 15-LOX-1 
expression. Apart from these two pathways, Ashish Bhattacharjee et al. revealed the 
involvement of ERK-1/2 MAPK activity in IL-13 stimulated ALOX15 gene expression in 
human monocytes [112]. 
1.3.2.3 Tumor associated macrophages 
It is well known that chronic inflammation is closely related to tumor progression. In the 
tumor milieu, tumor associated macrophages (TAMs) as major infiltrated inflammatory 
cells are present [113]. TAMs origin from both in situ proliferation and polarization of 
recruited circulating monocytes from peripheral blood [114, 115]. They contribute to the 
tumor milieu and were found to promote tumor growth, progression and angiogenesis 
in various tumor models [116-118]. TAMs resemble M2 macrophages with higher 
expression of anti-inflammatory IL-10 but low pro-inflammatory cytokine IL-12, which 
are immunosuppressive and pro-tumoral with low tumoricidal activity [119, 120]. TAMs 
release various cytokines and chemokines into the tumor environment, with higher 
levels of anti-inflammatory IL-10, CD163, VEGF and TGF-β. High levels of IL-10 and 
TGF-β were found to suppress dendritic cells (DCs) differentiation and maturation [121]. 
As anti-cancer therapy, novel strategies have been focused on reprogramming the 
TAMs to pro-inflammatory but anti-tumoral M1 macrophages in tumor milieu [122-124]. 
 
1.4 V-ATPase 
The Vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump, which has 
been recognized to play fundamental roles in maintaining pH homeostasis in various 
cell organelles in almost all eukaryotic organisms [125].  
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Fig.1.7 The structure of V-ATPase. V-ATPase is 
composed of two major domains, V0 (six subunits: a, c, c′, 
c′′, d, and e) and V1 (eight subunits: A, B, C, D, E, F, G and 
H). V1 domain participates in ATP hydrolysis, which drives 
the rotation of central stalk D-F-d and proteolipid ring (c, c′ 
and c′′). Rotation of the proteolipid ring in V0 triggers the 
proton transportation. Figure modified from Forgac et.al [4]. 
 
1.4.1 Structure of V-ATPase 
The structure of V-ATPase is highly conserved in plants, animals and fungi [126]. 
Structurally, V-ATPase is a complex composed of two different domains with multiple 
subunits [127]. In detail, V-ATPase is composed of two domains V0 and V1. Anchored 
into the cytoplasm membrane, the transmembrane V0 domain is composed of six 
subunits (a, c, c′, c′′, d, and e in yeast) [128]. Subunits c, c′ and c′′ form a rotatory ring 
structure connected to subunits a, d and e [129]. The V1 domain includes eight 
subunits (A, B, C, D, E, F, G and H) and is located at the peripheral areas of the 
cytoplasm membrane [4]. The core structure of the V1 domain is a symmetric 
hexametric structure composed of subunits A and B [130]. The connection of the V1 
domain and the V0 domain are accomplished by multiple stalks that are arranged 
around the hexametric A-B structure. These stalks include a central stalk D-F-d, 
peripheral stalks G-E-H, peripheral stalks G-E-C and the N-terminal of V0a. V-ATPase 
operates its proton-translocating function by a rotary mechanism driven by ATP binding 
and hydrolysis in the V1 domain, which cause the rotation of central stalk D-F-d as well 
as the connected proteolipid ring in the V0 domain. Rotation of the proteolipid ring then 
further activates proton transportation from the cytoplasm into the lumen or organelles 
in V0a [127, 129].  
1.4.2 Biological function of V-ATPase 
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V-ATPase is functional within the membranes of various organelles (like lysosomes, 
endosomes and Golgi apparatus) and regulates multiple cellular processes [4]. The 
ATP-driven proton pump is fundamental for pH homeostasis of intracellular 
compartments that is crucial for various biological functions. The complete function of 
endosomes, lysosomes and phagolysosomes that are responsible for degradation of 
internalized extracellular materials as well as protein depend largely on the acidic pH 
environment maintained by the membrane V-ATPases [131, 132]. Autophagosomes 
and lysosomes mediate autophagy during which cellular dysfunctional components are 
degraded and recycled in order to maintain energy homeostasis [133]. V-ATPases also 
mediate the entry of pathogens, toxins or viruses into the cells. This process is 
mediated by the endosomal compartments, where the acidic pH facilitates membrane 
pores formation that allows entry of viral mRNA or toxins into the cytosol [134]. In our 
previous work, the role of V-ATPase in cytokines trafficking and secretion in human 
monocytes was investigated [6]. Inhibition of V-ATPase lowered the cytosolic pH but 
elevated the lysosomal pH and triggered endoplasmic reticulum (ER) stress, which is 
responsible for the accumulation of cytokines like IL-8 in ER [6]. Additionally, V-ATPase 
is also located at the plasma membrane in some specialized cells like renal cells, 
neutrophils, macrophages and osteoclasts. Plasma membrane V-ATPase is critical in 
maintaining cellular functions like bone resorption [135], renal acidification [136], sperm 
maturation [137] and neurotransmission [138]. Moreover, V-ATPases are key 
components and regulators of various signaling pathways including the Notch signaling, 
Wnt signaling and mTORC pathway [139]. In a pH-dependent manner, V-ATPase 
acidifies the endosomes and lysosomes and maintains low pH environment that is 
favorable for Notch signaling and Wnt signaling [140]. Both pathways are critically 
involved in cellular processes like organ development, cell proliferation and 
differentiation. In a pH-independent manner, V-ATPase is required in the assembly and 
activation of mechanistic target of rapamycin complex 1 (mTORC1) that is responsible 
for lysosomal nutrient sensing, protein synthesis and cell growth [141, 142].  
Due to the indispensable biological roles of V-ATPase in cellular homeostasis, 
dysfunction or abnormal function of V-ATPase contributes to pathogenesis of diseases. 
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For example, the development of neurodegenerative diseases is closely related to 
defective lysosome function, which depends on the lysosome membrane V-ATPase 
machinery [143]. Intensive studies have focused on the role of V-ATPase in cancer 
development. Overexpression of membrane V-ATPase and particular V-ATPase 
subunits are detected in various cancers [144]. In tumor cells, plasma membrane V-
ATPase maintains high intracellular pH that supports tumor growth and acidic 
extracellular environment that contributes to angiogenesis [7].  
1.4.3 Pharmacological targeting V-ATPase 
V-ATPase is overexpressed in tumor cells and supports tumor cells survival and 
angiogenesis. Additionally, tumor cells exhibit higher sensitivity to V-ATPase inhibition. 
Therefore, V-ATPase is characterized as interesting target for anti-cancer therapy [145]. 
Although not applied in clinic yet, various V-ATPase inhibitors have been developed 
and intensively studied for potential therapeutic purposes. In 1984, researchers 
characterized several new types of macrolide antibiotics including the bafilomycin 
derivatives and concanamycin derivatives from streptomyces [146-148]. These two 
new sets of antibiotics bear similar structures with a 16- or 18-membered lactone ring. 
Four years later, bafilomycin A1 was characterized as the first specific inhibitor of 
membrane V-ATPase from microorganisms, plant cells and animals [149]. Later in 
1993, structure-activity relationship (SAR) studies revealed that the concanamycin 
derivatives were also specific inhibitors of V-ATPase [150, 151]. Both bafilomycin and 
concanamycin derivatives inhibits the V-ATPase activity at concentrations in the 
nanomolar (nM) range. Intensive studies uncovered the potential binding sites of 
bafilomycin and concanamycin. They bind the V0c subunit of V-ATPase and inhibit the 
V-ATPase function via blocking the rotatory machinery for proton transportation [152-
155]. 
Between 1997 and 1999, researchers characterized another series of V-ATPase 
inhibitors from various species like murine sponge, murine tunicate, microorganisms 
and myxobacterium. These natural compounds are referred to as salicylihalamides, 
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lobatamides, oximidines and apicularens, bearing a common benzolactone enamide 
structure [156-159]. They show potent inhibitory effects against V-ATPase from various 
sources except the fungal V-ATPase at a concentration of nanomolar (nM) range [160-
162]. Recently, apicularen was confirmed to bind the vicinity areas between subunit a 
and c of V0 domain of V-ATPase, which is a little different from the binding sites of 
bafilomycin and concanamycin [163]. 
 
Fig.1.8 Structure of V-ATPase inhibitors Bafilomycin A1, concanamycin A, Archazolid A/B and 
Apicularen A. 
Recently discovered from myxobacteria Archangium gephyra and Cystobacter 
violaceus, the archazolid derivatives represent a new class of antibiotics that target V-
ATPase [164, 165]. Structurally, archazolid derivatives carry a macrocyclic lactone ring 
with a thiazole side chain. They are potent V-ATPase inhibitors that inhibit the activity 
of isolated V-ATPase enzyme and lysosomal acidification in in vitro cellular assays at 
nM range [162]. SAR studies reveal that among all archazolid derivatives that target V-
ATPase, archazolid A (ArchA) and archazolid B (ArchB) are the most potent ones. 
These two compounds inhibit isolated V-ATPase enzyme activity with IC50 < 10 nM 
[166]. Recently, the binding site of archazolid was characterized, it binds proteolipid c 
ring in the V0 domain of V-ATPase, which overlaps the sites for bafilomycin and 
concanamycin [167].   
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2. AIM OF THESIS 
Monocytes and macrophages as main innate immune cells play important roles in host 
defense during infectious inflammation. Depending on their phenotype, monocytes and 
M1 macrophages produce mainly pro-inflammatory PGs and LTs, while M2 
macrophages produce predominantly 15-LOX-1-related LM and SPM. Acute 
inflammation is governed by the production of pro-inflammatory PGs and LTs. 
Excessive production of PGs and LTs maintains acute inflammation to a chronic state, 
which is related to the pathogenesis of various diseases. The resolution of inflammation 
is an active process governed by anti-inflammatory and proresolving SPM. Previously 
the role of V-ATPase in modulating cytokines release was elucidated in human primary 
cells. Recently V-ATPase was shown to be involved in the regulation of IL-4 stimulated 
polarization of murine bone-marrow-derived macrophage. However, how V-ATPase 
regulates human monocytes function, M1 and M2 macrophages polarization with 
particular respect to LM remained elusive. Therefore, we here aimed to reveal the role 
of V-ATPase in the regulation of LM biosynthesis in human monocytes and during 
human M1 and M2 macrophage polarization. 
Specific objectives: 
1. Explore the role of V-ATPase on LM biosynthetic pathways especially 
eicosanoids biosynthesis in human monocytes (manuscript I). 
2. Explore the role of V-ATPase on the biosynthesis of inflammation-related 
mediators including cytokines and eicosanoids in human M1 macrophages 
(manuscript II).  
3. Investigate the anti-tumoral effects of ArchA treated M1 macrophages in a 
microfluidically-supported tumor biochip model (manuscript II).  
4. Uncover the role of V-ATPase on lipid mediator (LM) profile and LM biosynthetic 
enzyme expression in human M1 and M2 macrophages (manuscript III).  
5. Study the signaling pathways involved in the abrogation of 15-LOX-1 by V-
ATPase inhibition in human M2 macrophages (manuscript III).  
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Differential role of vacuolar (H+)-ATPase in the expression and activity of 
cyclooxygenase-2 in human monocytes 
Zhigang Rao, Paul M. Jordan, Yan Wang, Simona Pace, Dirk Menche, Jana 
Gerstmeier and Oliver Werz (2019) Submitted. 
 
In this paper, we presented a differential role of V-ATPase in the expression and in the 
activity of COX-2 in human monocytes. Pharmacological targeting of V-ATPase 
elevated the expression of COX-2 protein in LPS-stimulated primary monocytes, which 
was paralleled by enhanced phosphorylation of p38 MAPK and ERK-1/2, with no 
significant impact on NF-κB and SAPK/JNK pathways. Targeting of both p38 MAPK 
and ERK-1/2 pathways with specific inhibitors showed that these kinase pathways are 
crucial for COX-2 expression in human monocytes. Despite elevated COX-2 protein 
levels, however, blockade of V-ATPase activity impaired the biosynthesis of COX-
derived lipid mediators in monocytes without affecting 12-/15-lipoxygenase (LOX) 
products with minor suppression of 5-LOX activity, assessed by a metabololipidomics 
approach using UPLC-MS-MS analysis. Manipulation of the intracellular pH with pH 
modulators chloroquine confirms the contribution of changes of intracellular pH for 
COX-2 activity. Our data suggest contrasting roles of V-ATPase on the expression and 
in the activity of COX-2. On one hand V-ATPase restricts COX-2 protein levels by 
limiting p38 MAPK and ERK-1/2 activation, while on the other hand it governs the 
cellular activity of COX-2 through appropriate adjustment of the intracellular pH. 
 
Contribution (75%):  Cell culture and performance of blood cell isolation, 
determination of cell viability and cytokine levels, flow cytometry, SDS-PAGE and 
Western Blot, UPLC-MS-MS, analysis of data and preparation of graphs, analysis of 
statistics, co-writing of the manuscript.  
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Abstract 
Monocytes as professional immune cells produce abundant levels of pro-inflammatory eicosanoids 
including prostaglandins and leukotrienes during inflammation. Vacuolar (H+)-ATPase (V-ATPase) is 
critically involved in a variety of inflammatory processes including cytokine trafficking and lipid 
mediator biosynthesis. However, its role in eicosanoid biosynthetic pathways in monocytes remain 
elusive. In this study, we presented a differential role of V-ATPase in the expression and in the activity 
of COX-2 in human monocytes. Pharmacological targeting of V-ATPase increased the expression of 
COX-2 protein in lipopolysaccharide-stimulated primary monocytes, which was paralleled by enhanced 
phosphorylation of p38 MAPK and ERK-1/2, without impacting the NF-κB and SAPK/JNK pathways. 
Targeting of both p38 MAPK and ERK-1/2 pathways showed that the kinase pathways are crucial for 
COX-2 expression in human monocytes. Despite increased COX-2 protein levels, however, suppression 
of V-ATPase activity impaired the biosynthesis of COX-related lipid mediators in monocytes without 
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affecting 12-/15-lipoxygenase (LOX) products and minor suppression of 5-LOX activity, assessed by a 
metabololipidomics approach using UPLC-MS-MS analysis. Our results indicate that changes in the 
intracellular pH may contribute to suppression of COX-2 activity. Our data suggest that V-ATPase on 
one hand restricts COX-2 protein levels by limiting p38 MAPK and ERK-1/2 activation, while on the 
other hand it governs the cellular activity of COX-2 through appropriate adjustment of the intracellular 
pH. 
Keywords: Vacuolar (H+)-ATPase, cyclooxygenase, prostaglandin, p38 MAPK, ERK-1/2, intracellular 
pH 
Abbreviations: 
AA, arachidonic acid; ArchA, archazolid A; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; 
CYP, cytochrome P450; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ERK, extracellular 
signal-regulated protein kinase; FLAP, 5-lipoxygenase-activating protein; HDHA, hydroxy-DHA; 
HETE, hydroxyeicosatetraenoic acid; HEPE, hydroxy-EPA; LM, lipid mediator; LPS, 
lipopolysaccharide; LOX, lipoxygenase; LT, leukotriene; MEK, mitogen-activated protein kinase 
kinase; p38 MAPK, p38 mitogen-activated protein kinase; PBMC, peripheral blood mononuclear cells; 
PG, prostaglandin; SAPK/JNK, stress-activated protein kinase/c-Jun N-terminal kinase; TLR, toll-like 
receptors. 
 
 1. Introduction 
Monocytes are professional innate immune 
cells that circulate in the bloodstream and traffic 
into specific tissues upon recruitment to evoke 
pivotal roles in the immune defense [1]. Upon 
challenges like bacterial infection, monocytes 
produce abundant levels of pro-inflammatory 
eicosanoids including prostaglandins (PG) and 
leukotrienes (LT) that maintain the 
inflammatory microenvironment and promote 
neutrophil chemotaxis [2]. Excessive and 
persistent production of pro-inflammatory 
eicosanoids sustain acute inflammation that 
turns into a chronic state which is closely related 
to various diseases including rheumatoid 
arthritis, diabetes, asthma, Alzheimer or cancer 
[3]. Therefore, targeting the eicosanoid 
biosynthetic pathway by suppression of PG and 
LT the production has emerged as promising 
strategy to limit the undesired shift from acute 
to chronic inflammation. The biosynthesis of 
eicosanoids involves key enzymes including 
cyclooxygenase (COX) to initiate the 
production of PG and 5-lipoxygenase (5-LOX), 
the enzyme responsible for initiation of LT 
biosynthesis. For COX, two isoforms exist, 
namely COX-1 and COX-2 [4]. While COX-1 
is constitutively expressed in most cells and 
tissues, COX-2 is an inducible enzyme whose 
expression is induced by various 
proinflammatory stimuli (i.e. LPS, TNF-α and 
IL-1β), and which is responsible for excessive 
PG formation during inflammation [5]. Thus, 
various anti-inflammatory drugs including non-
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steroidal anti-inflammatory drugs (NSAIDs) 
have been developed to inhibit COX-2 activity 
[6-8].  
Interestingly, our previous work showed that 
inhibition of V-ATPase activity caused 
increased COX-2 expression and formation of 
COX-derived PG in human M1-like monocyte-
derived macrophages (MDM) [9], indicating a 
detrimental role of V-ATPase for COX-2 
biology. V-ATPase is a universal proton pump 
that is crucial for intracellular pH homeostasis, 
entry of pathogens, toxins or viruses, and 
protein degradation in various cell organelles in 
almost all eukaryotic organisms [10]. V-
ATPase pumps protons from the cytosol 
especially into late endosomes and lysosomes, 
which serve as major intracellular proton stores 
with acidic pH [11]. Therefore, V-ATPase 
contributes to the establishment and 
maintenance of the reversed pH gradient by 
elevating the pH in the cytosol while the pH in 
lysosomes is decreased. Inhibition of V-ATPase 
elevated TNF-α production, which facilitates 
the anti-tumoral activities of M1-like MDM 
[12], while in human M2-like MDM, V-ATPase 
critically regulates the inflammatory resolution 
pathway [12]. However, how V-ATPase 
regulates biosynthesis of lipid mediators (LM) 
especially the eicosanoid biosynthetic pathway 
in human monocytes remained elusive. Here, 
we reveal contrasting roles of V-ATPase in 
regulating the expression and activity of COX-
2 in LPS-stimulated human monocytes: while 
V-ATPase may limit LPS-induced COX-2 
protein levels in a p38 MAPK- and ERK-1/2-
dependent manner, it is required for efficient 
biosynthesis of COX-related PGs.  
 
2. Materials and Methods 
2.1. Reagents 
Deuterated and non-deuterated LM standards 
for ultra-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS-MS) 
quantification were purchased from Cayman 
Chemical/Biomol GmbH (Hamburg, 
Germany). Archazolid A was isolated from 
Archangium gephyra as previously described. 
Apicularen A was from the natural compound 
library of HZI/HIPS (Braunschweig, Germany). 
Skepinone-L was purchased from Cayman 
Chemical (Ann Arbor, MI), and U0126 was 
from Enzo Life Sciences (Farmingdale, NY). 
Bafilomycin A1, chloroquine, dexamethasone, 
lipopolysaccharide (LPS) and all other reagents 
were obtained from Sigma-Aldrich 
(Taufkirchen, Germany) unless mentioned 
otherwise.  
2.2. Methods 
2.2.1. Cell isolation and incubation of human 
monocytes 
Freshly prepared leukocyte concentrates from 
withdrawn peripheral blood of male and female 
healthy adult donors (age 18-65 years) were 
provided by the Institute of Transfusion 
Medicine at the University Hospital Jena, 
Germany. The experimental protocol was 
approved by the ethical committee of the 
University Hospital Jena. All methods were 
performed in accordance with the relevant 
guidelines and regulations. PBMC were 
separated using dextran sedimentation, 
followed by centrifugation on lymphocyte 
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separation medium (Histopaque®-1077, Sigma-
Aldrich). PBMC were seeded in RPMI 1640 
(Sigma-Aldrich) containing 10% (v/v) heat-
inactivated FCS, 100 U/mL penicillin, and 100 
µg/mL streptomycin in cell culture flasks 
(Greiner Bio-one, Frickenhausen, Germany) for 
1.5 h at 37 °C and 5% CO2 for adherence of 
monocytes. Human monocytes were collected 
and incubated in RPMI 1640 (Sigma-Aldrich) 
containing 5% (v/v) heat-inactivated FCS, 100 
U/mL penicillin, and 100 µg/mL streptomycin 
in well plates (Greiner Bio-one, Frickenhausen, 
Germany). 
2.2.2. Analysis of human monocytes for LM 
metabololipidomics 
Human primary monocytes (2 × 106/mL) were 
incubated in PBS containing 1 mM CaCl2. To 
evoke LM biosynthesis pathogenic E. coli 
(serotype O6:K2:H1, ratio 1:50) was added for 
180 min at 37 °C. The supernatants were then 
transferred to 2 mL of ice-cold methanol 
containing 10 µL of deuterium-labeled internal 
standards (200 nM d8-5S-HETE, d4-LTB4, d5-
LXA4, d5-RvD2, d4-PGE2 and 10 µM d8-AA) 
to facilitate quantification and sample recovery. 
Sample preparation was conducted by adapting 
published criteria [13]. In brief, samples were 
kept at −20 °C for 60 min to allow protein 
precipitation. After centrifugation (1200 g, 4 
°C, 10 min) 8 mL acidified H2O was added 
(final pH = 3.5) and samples were subjected to 
solid phase extraction. Solid phase cartridges 
(Sep-Pak® Vac 6cc 500 mg/ 6 mL C18; Waters, 
Milford, MA) were equilibrated with 6 mL 
methanol and 2 mL H2O before samples were 
loaded onto columns. After washing with 6 mL 
H2O and additional 6 mL n-hexane, LM were 
eluted with 6 mL methyl formate. Finally, the 
samples were brought to dryness using an 
evaporation system (TurboVap LV, Biotage, 
Uppsala, Sweden) and resuspended in 100 µL 
methanol-water (50/50, v/v) for UPLC-MS-MS 
automated injections. LM profiling was 
analyzed with an Acquity UPLC system 
(Waters, Milford, MA, USA) and a QTRAP 
5500 Mass Spectrometer (ABSciex, Darmstadt, 
Germany) equipped with a Turbo V™ Source 
and electrospray ionization. LM were eluted 
using an Acquity UPLC BEH C18 column (1.7 
µm, 2.1 × 100 mm; Waters, Eschborn, 
Germany) at 50 °C with a flow rate of 
0.3 mL/min and a mobile phase consisting of 
methanol-water-acetic acid of 42:58:0.01 
(v/v/v) that was ramped to 86:14:0.01 (v/v/v) 
over 12.5 min and then to 98:2:0.01 (v/v/v) for 
3 min [14]. The QTrap 5500 was operated in 
negative ionization mode using scheduled 
multiple reaction monitoring coupled with 
information-dependent acquisition. The 
scheduled multiple reaction monitoring window 
was 60 sec, optimized LM parameters (CE, EP, 
DP, CXP) were adopted [15], and the curtain 
gas pressure was set to 35 psi. The retention 
time and at least six diagnostic ions for each LM 
were confirmed by means of an external 
standard (Cayman Chemical/Biomol GmbH, 
Hamburg, Germany). Quantification was 
achieved by calibration curves for each LM.  
2.2.3. SDS-PAGE and Western blot 
Cell lysates of human monocytes, 
corresponding to 2 × 106 cells, were separated 
on 8% (for cPLA2-α), 10% (for 5-LOX, COX-
27 
 
1, COX-2, ERK-1/2, phospho-ERK-1/2, p38 
MAPK, phospho-p38 MAPK, NF-κB, phospho-
NF-κB, JNK, phospho-JNK, β-actin and 
GAPDH) and 16% (for FLAP) polyacrylamide 
gels, and blotted onto nitrocellulose membranes 
(Amersham Protran Supported 0.45 µm 
nitrocellulose, GE Healthcare, Freiburg, 
Germany). The membranes were incubated 
with the following primary antibodies: rabbit 
polyclonal anti-cPLA2-α, 1:1000 (2832S, Cell 
Signaling, MA); rabbit polyclonal anti-5-LOX, 
1:1000 (to a peptide with the C-terminal 12 
amino acids of 5-LOX: CSPDRIPNSVA; 
kindly provided by Dr. Marcia E. Newcomer, 
Louisiana State University, LA); rabbit 
polyclonal anti-COX-1, 1:1000 (4841S, Cell 
Signaling); rabbit polyclonal anti-COX-2, 
1:1000 (4842S, Cell Signaling); rabbit 
monoclonal anti-ERK1/2, 1:1000 (4695S, Cell 
Signaling); mouse monoclonal anti-phospho-
ERK1/2 (Thr202/Tyr204), 1:1000 (9106, Cell 
Signaling); rabbit monoclonal anti-p38 MAPK, 
1:1000 (8690S, Cell Signaling); rabbit 
polyclonal anti-phospho-p38 MAPK 
(Thr180/Tyr182), 1:1000 (9211S, Cell 
Signaling); rabbit monoclonal anti-NF-κB p65 
(C22B4), 1:1000 (4764S, Cell Signaling); 
mouse monoclonal anti-phospho-NF-κB 
(Ser536), 1:1000 (13346S, Cell Signaling); 
rabbit monoclonal anti-phospho-SAPK/JNK 
(Thr183/Tyr185), 1:1000 (4668S, Cell 
Signaling); rabbit polyclonal anti-SAPK/JNK, 
1:1000 (9252S, Cell Signaling); rabbit 
polyclonal anti-FLAP, 1:1000 (ab85227, 
Abcam); mouse monoclonal anti-β-actin, 
1:1000 (3700S, Cell Signaling); rabbit 
polyclonal anti-β-actin, 1:1000 (4967S, Cell 
Signaling) and rabbit monoclonal anti-GAPDH, 
1:1000 (5174S, Cell Signaling). 
Immunoreactive bands were stained with 
IRDye 800CW Goat anti-Mouse IgG (H+L), 
1:10,000 (926-32210, LI-COR Biosciences, 
Lincoln, NE), IRDye 800CW Goat anti-Rabbit 
IgG (H+L), 1:15,000 (926-32211, LI-COR 
Biosciences) and/or IRDye 680LT Goat anti-
Mouse IgG (H+L), 1:40,000 (926-68020, LI-
COR Biosciences), and visualized by an 
Odyssey infrared imager (LI-COR 
Biosciences). Data from densitometric analysis 
were background-corrected. 
2.2.4. Determination of cytokine levels  
Human monocytes were treated with 
compounds or vehicle (0.1% DMSO) 30 min 
before cells were stimulated with LPS (100 
ng/mL) for 24 h. For measurement of 
extracellular cytokine levels, cell supernatants 
were collected by centrifugation (15,000 rpm, 4 
°C, 5 min). The cytokines IL-6, IL-10, IL-1β 
and TNFα were analyzed using in-house made 
ELISA kits of (R&D system, Bio-Techne, MN).  
2.2.5. Flow cytometry  
Fluorescent staining for flow cytometric 
analysis of monocytes was performed in FACS 
buffer (PBS with 0.5% BSA, 2 mM EDTA and 
0.1% sodium azide). Monocytes were treated 
with 100 ng/mL LPS and with either 10 nM 
ArchA or 10 nM bafilomycin for 24 h at 37 °C. 
Subsequently, monocytes were stained with 
fluorochrome-labelled antibody mixtures at 4 
°C for 20 min. Non-specific antibody binding 
was blocked by using mouse serum for 10 min 
at 4°C prior antibody staining. The following 
antibody was used: FITC anti-human CD14 (2 
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µg/test, clone M5E2, Biolegend, San Diego, 
CA). To determine cell viability, monocytes 
were detached after the respective treatment 
with PBS plus 0.5% BSA, 5 mM EDTA and 
0.4% lidocaine for 20 min. Cells were 
resuspended in 300 µL FACS buffer containing 
propidium iodide staining solution (40 ng/test, 
eBioscience, San Diego, CA). Upon staining, 
monocytes were assessed using BD LSR 
Fortessa (BD Bioscience), and data analyzed 
using FlowJo X Software (BD Bioscience). 
2.2.6. Statistical analyses 
Results are expressed as mean ± S.E.M. of n 
observations, where n represents the number of 
experiments with separate donors performed on 
different days as indicated. Analyses of data 
were conducted using GraphPad Prism 8 
software (San Diego, CA). Paired t-test was 
used for comparison of two groups. For multiple 
comparisons, ANOVA with Bonferroni or 
Dunnett post hoc tests were applied as 
indicated. The criterion for statistically 
significant is p < 0.05. 
 
3. Results 
3.1. Targeting of V-ATPase in human 
monocytes blocks formation of COX-derived 
lipid mediators  
We used the well-established V-ATPase 
inhibitor archazolid A (ArchA, [16]) at 3-100 
nM as chemical tool to study the role of V-
ATPase in the biosynthesis of lipid mediators 
(LM) in human monocytes. Previous studies of 
ArchA and the V-ATPase inhibitors 
bafilomycin and apicularen revealed direct 
inhibition of 5-LOX and mPGES-1 by ArchA at 
fairly high concentrations (> 5 µM) but clearly 
excluded direct inhibition of COX-1 and COX-
2 by ArchA in cell-free assays [17]. Human 
monocytes, freshly isolated from peripheral 
blood of healthy volunteers, were pretreated 
with ArchA (3, 10, 30 or 100 nM) for 15 min 
prior stimulation with LPS. 24 h after LPS 
addition, high levels of prostanoids (PGD2, 
PGE2, PGF2-α, TXB2) were detected in the 
supernatant of the monocyte cultures in the 
absence of ArchA, which were clearly reduced 
when cells were pretreated with ArchA in a 
concentration-dependent manner (Fig. 1B). 
Dexamethasone, used as positive control, 
strongly abolished prostanoid formation (Fig. 
1B) as expected [18]. Next, the monocytes were 
harvested after 24 h treatment with LPS in the 
absence or presence of ArchA, and then 
incubated for 90 min with pathogenic E. coli 
(serotype O6:K2:H1, ratio 1:50) as stimulus to 
provoke marked LM biosynthesis. LM 
metabololipidomics using UPLC-MS-MS 
revealed strong formation of COX-derived 
prostanoids as well as of 5-LOX- and 12/15-
LOX-derived products (Fig. 1C). In monocytes 
that had been pretreated with ArchA prior to 
LPS, the biosynthesis of COX-derived 
prostanoids, i.e., PGE2, PGD2, PGF2-α and 
TXB2 was strongly reduced (Fig. 1C), whereas 
formation of 5-LOX-derived products (e.g. 
LTB4, t-LTB4 and 5-HETE) was only slightly 
influenced by ArchA treatment and the release 
of fatty acids and of other LOX-derived LM like 
17-HDHA, 14-HDHA, 12-HETE, 12-HEPE or 
4-HDHA was unchanged (Fig. 1C). Again, for 
cells that received dexamethasone prior LPS, 
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PG biosynthesis was strongly suppressed 
without marked impairment of LOX-derived 
LM (Fig. 1C). 
To explore the role V-ATPase in prostanoid 
formation in other relevant cellular models, we 
investigated the effects of ArchA on PGE2 
production in human whole blood using 
different stimuli. Pretreatment with ArchA for 
24 hrs also blocked PGE2 biosynthesis in LPS-
stimulated human whole blood (Fig. 1D). To 
confirm the on-target effects of ArchA and thus 
the role of V-ATPase, we investigated the two 
structurally different V-ATPase inhibitors 
bafilomycin [19] and apicularen [20] for their 
influence of the LM profile in human primary 
monocytes. Both compounds caused 
comparable effects as ArchA and significantly 
blocked the biosynthesis of COX-derived LM 
during 24 h treatment with LPS as well as in 
LPS-treated monocytes that were subsequently 
challenged with E. coli (Fig. 2A, B). Again, 
formation of LOX-derived LM were not or less 
affected by the V-ATPase inhibitors (Fig. 2 B). 
Together, we show that pharmacological 
targeting of V-ATPase efficiently blocks the 
biosynthesis of prostanoids in human 
monocytes and other COX-2-expressing cells 
with minor effects on LOX-derived LM 
formation. 
3.2. Targeting of V-ATPase enhances COX-2 
expression in human monocytes 
Our results prompted us to investigate how 
suppression of V-ATPase activity would impact 
the expression of biosynthetic enzymes 
involved in LM formation in human monocytes. 
Surprisingly, targeting of V-ATPase by ArchA, 
bafilomycin or apicularen strongly elevated 
LPS-induced COX-2 expression in human 
primary monocytes within 24 h (Fig. 3A, C). In 
contrast, blockade of V-ATPase by ArchA had 
little impact on the expression of other LM 
biosynthetic enzymes/proteins such as COX-1, 
5-LOX, FLAP and cPLA2-α (Fig. 3A). In 
parallel, we checked how V-ATPase 
interference would modulate the release of 
cytokines upon LPS stimulation. Pretreatment 
of monocytes with ArchA prior LPS also 
elevated the release of TNF-α and IL-1β levels 
while IL-10 production was inhibited and IL-6 
release was not affected (Fig. 3B). To address if 
targeting V-ATPase modulates the phenotype 
of human monocytes, we analyzed the 
expression of the monocytes surface marker 
CD14 by flow cytometry [21]. In fact, ArchA 
and bafilomycin reduced the population of total 
CD14+ cells (Fig.3D). In conclusion, targeting 
of V-ATPase elevates the expression of the 
COX-2 enzyme along with increased 
production of TNF-α and IL-1β but at the same 
time reduces the formation of COX-2-derived 
LM.  
3.3. Temporal modulation of COX-2 
expression and LM biosynthesis by V-
ATPase inhibition 
We recently showed that in M1-like monocyte-
derived macrophages the expression of COX-2 
was time-dependently induced by LPS 
treatment, which peaked after 6 h and degraded 
again after 24 h to 72 h. This finding prompted 
us to explore the temporal modulation of COX-
2 expression along with LM biosynthesis upon 
V-ATPase inhibition in human monocytes. The 
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monocytes were pretreated with ArchA for 30 
min before LPS stimulation for 6, 24 or 48 h. 
High and maximal levels of COX-2 protein 
were induced 6 h after LPS stimulation and 
declined afterwards (Fig. 4A). Of interest, 
pretreatment with ArchA slightly elevated 
COX-2 protein levels after 6 h with more 
pronounced increase after 24 and 48 h, implying 
the V-ATPase inhibition seemingly prevents the 
decline of COX-2 expression over time (Fig. 
4A). Compared to the temporal expression of 
COX-2, the formation of prostanoids was 
somewhat delayed, peaking at 24 h with 
subsequent decline at 48 h LPS treatment (Fig. 
4B). Again, ArchA consistently blocked the 
biosynthesis of COX-2-derived prostanoids 
regardless of the time point (6, 24, or 48 h) to a 
comparable degree. Also 5-LOX-derived 
products (5-HETE, 5-HEPE and LTB4) were 
inhibited by ArchA but only after 24 h or 48 h 
(Fig. 4B). By contrast, 12/15-LOX-related 
products (17-HDHA, 14-HDHA and 12-HETE) 
as well as fatty acids and 4-HDHA that were 
most prominent after 6 h with subsequent 
impairment, remained unchanged after ArchA 
treatment (Fig. 4B). Together, we conclude that 
pharmacologically targeting of V-ATPase 
prevents the degradation of COX-2 protein 
expression but despite elevated enzyme levels 
suppresses COX-2-derived LM formation. 
3.4. Elevated COX-2 expression by V-
ATPase inhibition is regulated by the p38 
MAPK and ERK-1/2 pathway  
Toll-like receptor (TLR) activation by TLR 
ligands including LPS, TNF-α or IL-1β induces 
COX-2 expression involving different signaling 
routes and protein kinases like MKK3/6-p38 
MAPK, MEK-ERK-1/2, NF-κB and MKK-4/7-
SAPK/JNK pathways (Fig. 5A, [22-26]). 
Therefore, we assumed that elevated COX-2 
expression due to V-ATPase inhibition in 
human monocytes may involve (some of) these 
pathways. In LPS-stimulated monocytes, 
pretreatment with ArchA for 15 min prior LPS 
significantly increased the phosphorylation of 
p38 MAPK and ERK-1/2 after 24 h, whereas 
phosphorylation of SAPK/JNK and NF-κB was 
moderately increased but not yet significantly 
(Fig. 5B). Pre-incubation of monocytes with 
ArchA for 15 min and subsequent short-term 
treatment with LPS for 15 min or 1 h only did 
not affect the phosphorylation of these kinases 
(Fig. 5C). Since increased activation of the p38 
MAPK and ERK-1/2 pathway by ArchA may 
account for the elevated COX-2 expression, we 
used the specific p38 MAPK inhibitor 
skepinone-L [27] and ERK-1/2 inhibitor U0126 
[28] to confirm their involvement, respectively. 
In particular skepinone-L strongly abrogated 
COX-2 expression, regardless of ArchA 
treatment (Fig. 5D), and also efficiently blocked 
the biosynthesis of COX-derived prostanoids 
upon E. coli challenge (Fig. 5E). Similar 
suppressive effects were observed with the 
ERK-1/2 pathway inhibitor U0126. Moreover, 
also LPS- and LPS/ArchA-induced 5-LOX 
product formation was slightly reduced by 
skepinone-L under these conditions, albeit not 
significant; note that neither skepinone-L nor 
U0126 affected 12/15-LOX product formation 
or release of AA (Fig. 5E). Together, we 
conclude that the elevated COX-2 expression 
due to targeting of V-ATPase is mediated 
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through activation of the p38 MAPK and ERK-
1/2 pathway. 
3.5. COX-2 activity is regulated by V-
ATPase through modulation of lysosomal pH  
Next, we explored the mechanisms underlying 
the suppression of COX-derived LM formation 
due to interference with V-ATPase. Our 
previous work showed that V-ATPase 
inhibition in human monocytes causes 
accumulation of IL-8 in the endoplasmic 
reticulum (ER), connected to reduced release of 
this chemokine [29]. Thus, we assumed that the 
in situ biosynthesized COX-derived LM might 
be trapped inside the cell as well. However, only 
low amounts of intracellular prostanoids were 
evident in human monocytes whereas high 
levels were released into the extracellular 
medium, regardless of V-ATPase inhibition 
(Fig. 6A, B). V-ATPase is a universal proton 
pump that is critically involved in the regulation 
of the intracellular pH [10], and we previously 
showed that V-ATPase inhibitors elevate the 
lysosomal pH in human monocytes and 
macrophages [12, 29]. Therefore, we speculated 
that decreased cytosolic but increased 
lysosomal pH due to V-ATPase inhibition 
might be related to increased COX-2 expression 
and/or suppressed biosynthesis of prostanoids 
in human monocytes. As tool compound we 
used the well-known pH modulator chloroquine 
[30] that we showed before to increase the 
lysosomal pH in human monocytes, like ArchA 
[29]. Propidium iodide staining in human 
monocytes revealed that neither ArchA nor 
chloroquine had detrimental effects on cell 
viability (Fig. 7A). In contrast to ArchA 
treatment, chloroquine strongly blocked the 
expression of COX-2 protein within 24 h (Fig. 
7B). In analogy to ArchA, however, 
chloroquine strongly suppressed the release of 
COX-derived prostanoids into the medium 
during 24 h (Fig. 7C). Also when monocytes, 
after 24 h treatment with ArchA, were further 
stimulated with E. coli for another 90 min, 
formation of COX-derived LM and to a minor 
degree also of 5-LOX products and AA release 
were impaired (Fig. 7D). Other LOX- or 
cytochrome P450 (CYP)-derived LM (e.g. 12-
HETE, 4-HDHA or 18-HEPE) were not 
suppressed (Fig. 7D). Together, chloroquine 
mimics the effects of ArchA on the biosynthesis 
on LM with strong suppression of prostanoids, 
suggesting that elevation of lysosomal pH is 
causative for reduced activity of COX-2 and 
thus impaired prostanoid formation.  
 
4. Discussion 
Inflammation is a process in which the immune 
system defends against exterior stimuli and 
invaders, and helps the body to return to its 
healthy state [31]. Acute inflammation is 
governed by the excessive production of pro-
inflammatory LM such as PGs and LTs as well 
as of cytokines [2]. Our previous research 
indicates that V-ATPase is involved in the 
regulation of various inflammatory processes. 
Thus, we showed that V-ATPase (I) is crucial 
for cytokine and chemokine trafficking in 
human monocytes [29], (II) elevates TNF-α 
production in M1-like MDM to govern anti-
tumoral activities [12], and (III) promotes the 
inflammatory resolution process in M2-like-
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MDM by accomplishing 15-LOX-1 expression 
and SPM formation [9]. Therefore, depending 
on the cell type, V-ATPase has opposing roles 
in the regulation of inflammation. 
Here, we aimed to investigate how V-ATPase 
regulates pro-inflammatory LM biosynthetic 
pathways in human monocytes that are 
professional innate immune cells with pivotal 
functions in the immune defense. Our data 
imply crucial but differential roles of V-ATPase 
in the regulation of the COX-2 pathway in 
human monocytes: while V-ATPase has an 
negative impact on prostanoid biosynthesis by 
limiting the de novo-induced COX-2 protein 
levels, this proton pump accomplishes efficient 
COX-2-derived prostanoid formation by 
favoring cellular COX-2 activity.  
We hypothesize that V-ATPase negatively 
regulates de novo biosynthesized COX-2 
protein levels in monocytes by rapidly lowering 
the protein amount of this inducible enzyme 
over time. This is supported by our previous 
studies of M1-like MDM, where inhibition of 
V-ATPase prevents the degradation of COX-2 
protein expression that was initially induced by 
LPS [9]. Also in RAW264 macrophages of 
murine origin inhibition of V-ATPase was 
reported to elevate COX-2 levels [32]. Besides 
higher COX-2 levels, V-ATPase inhibition also 
increased the amounts of TNF-α and IL-1β  that 
were shown to stimulate COX-2 expression [33, 
34] involving p38 MAPK [35] and this kinase 
seemingly mediates the increased COX-2 levels 
in the present scenario as well. In fact, several 
studies reported a crucial role of  p38 MAPK in 
LPS-induced COX-2 expression in human 
monocytes [22, 23, 36], and it was shown before 
that both p38 MAPK and ERK-1/2 are essential 
in the induction of COX-2 protein in LPS-
stimulated human neutrophils [26]. In our 
hands, ArchA increased the phosphorylation of 
p38 MAPK after 24 h LPS stimulation in human 
monocytes, and also activation of ERK-1/2 was 
evident, whereas other relevant signaling 
pathways like NF-κB and SAPK/JNK were not 
affected. This suggests that V-ATPase limits 
p38 MAPK and ERK-1/2 activation in 
monocytes. Since the p38 MAPK inhibitor 
skepinone-L as well as the ERK-1/2 inhibitor 
U0126 abrogated the LPS-induced COX-2 
expression, we propose that the enhancement of 
the p38 MAPK and ERK-1/2 pathway by 
ArchA is causative for the elevated COX-2 
levels in human monocytes.  
Although targeting of V-ATPase increased 
COX-2 protein levels in human monocytes, the 
concomitant biosynthesis of COX-2-derived 
prostanoids was surprisingly decreased, 
suggesting that V-ATPase is overall beneficial 
for cellular COX-2 activity. Results from 
previous studies exclude direct interference of 
the V-ATPase inhibitors ArchA, bafilomycin A 
and apicularen with the enzymatic activity of 
COX-2 activity [17], indicating that the 
suppression of prostanoid formation in 
monocytes is not the consequence of direct 
inhibition of the COX-2 enzyme. In contrast to 
monocytes, in M1-like MDM ArchA (and 
bafilomycin) elevated COX-2 activity [9], 
suggesting that the prostanoid-suppressive 
effects of V-ATPase inhibitors in monocytes is 
cell type-dependent and due to modulation of 
processes that govern cellular COX-2 activity. 
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Since V-ATPase was shown to regulate 
cytokine and chemokine trafficking in 
monocytes, where ArchA treatment led to 
accumulation of IL-8 in the endoplasmic 
reticulum (ER) [29], it appeared possible that de 
novo biosynthesized prostanoids might be 
trapped inside the cell. However, only low 
amounts of intracellular PGs were evident in E. 
coli-stimulated monocytes whereas high levels 
were released into the cell supernatant, 
regardless of V-ATPase inhibition. Together, 
V-ATPase governs COX-2 activity in 
monocytes, explaining why V-ATPase 
interference impairs prostanoid formation.  
The main function of V-ATPase is to regulate 
cellular pH homeostasis by promoting the 
transport of protons from the cytosol to 
lysosomes that become acidic [10], and 
accordingly, targeting of V-ATPase in 
monocytes led to an elevated lysosomal pH 
[29]. Therefore, we hypothesized that the 
reduction of COX-derived prostanoids might be 
due to intracellular pH changes upon V-ATPase 
inhibition. Indeed, the pH modulator 
chloroquine that alkalizes lysosomes and 
acidifies the cytosol [30] mimicked the effects 
of V-ATPase inhibitors on the LM profile, as it 
strongly suppressed COX-dependent LM 
formation without suppressing 12/15-LOX 
products and with minor impairment of 5-LOX-
derived LM. Cellular activity of 5-LOX is 
affected by many factors including AA supply, 
its helper protein FLAP, phosphorylation by 
MAPKAPK-2 and ERK-1/2 [37]. Note that 
ArchA did not alter 5-LOX, FLAP or cPLA2-α 
expression and substrate supply. Thus, the 
intracellular pH might be crucial for the activity 
of both the COX-2 and the 5-LOX pathway. In 
fact, the pH optimum for the enzymatic 
activities of COX-2 and 5-LOX in cell-free 
assays is around pH 8.0 [38, 39], implying that 
cytosolic or nuclear membrane-associated 5-
LOX [37] and ER/nuclear envelope-inserted 
COX-2 [40] may benefit from V-ATPase 
activity accomplishing alkaline pH in the 
cytosol. It appeared possible that changes in the 
intracellular pH might be also the cause for the 
increased COX-2 expression by ArchA, 
implying a detrimental role of V-ATPase in this 
respect. In fact, it was reported before for a 
human osteoblastic cell line that sensing of pH 
changes would regulate COX-2 expression and 
PGE2 formation [41]. However, the pH 
modulator chloroquine did not induce COX-2 
expression and rather abrogated it, suggesting 
other mechanisms responsible for elevation of 
COX-2 levels by ArchA in human monocytes 
which are mediated by p38 MAPK and ERK-
1/2.  
In summary, we reveal a crucial role of V-
ATPase in the regulation of the biosynthesis of 
COX-2- and, to a minor extent, in 5-LOX-
derived LM in human monocytes. Surprisingly, 
our V-ATPase-targeting approach implies 
contrasting requirements of this proton pump: 
V-ATPase causes an impairment of the protein 
levels of COX-2 seemingly by suppression of 
p38 MAPK and ERK-1/2 signaling but 
accomplishes substantial cellular activity of 
COX-2 possibly by adjusting a favorable 
intracellular pH for this enzyme.  
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Fig. 1. Targeting of lipid mediator biosynthetic pathways by archazolid A in human monocytes. Human
monocytes were pretreated with archazolid A (ArchA, 3-100 nM), dexamethasone (Dex, 1 µM) or
vehicle (DMSO 0.1%) for 15 min before stimulation with LPS (100 ng/ml) for 24 h. A) Schematic
representation of the investigated LM biosynthetic pathways involving COX, 15-LOX, 5-LOX/FLAP, or
12-LOX leading to respective LM. B) LM released from monocytes into the cell culture medium after 24
h were isolated by solid phase extraction and analyzed by UPLC-MS-MS; detection limit: 0.5 pg.
Results are given as means ± S.E.M, n = 4. C) LM generated from monocytes after exposure to E.
coli (ratio 1:50, 90 min) were isolated by solid phase extraction and analyzed by UPLC-MS-MS;
detection limit: 0.5 pg. Results are given as means ± S.E.M in the bar charts and as ratio to vehicle in
the heatmap; n = 7. D) Effect of ArchA (1-100 nM) and dexamethasone (Dex, 1 µM) on PGE2
biosynthesis in human whole blood stimulated with LPS (100 ng/ml, 24 h, n = 6 ). Results are given as
percentage of LPS-vehicle control (= 100%), means ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 vs.
LPS-vehicle (veh.), one-way analysis of variance (ANOVA) with Bonferroni test.
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Fig. 3. Pharmacological targeting of V-ATPase induces COX-2 expression in human monocytes.
Human monocytes were pretreated with A, B) archazolid A (ArchA, 3-100 nM), dexamethasone
(Dex, 1 µM), C) bafilomycin (Bafi, 10 nM) or apicularen (Api, 10 nM) or vehicle (DMSO 0.1%) for 15
min before stimulation with LPS (100 ng/ml) for 24 h. A). Monocyte lysates were immunoblotted for
COX-2 (n = 9), COX-1 (n = 6), 5-LOX (n = 6), FLAP (n = 5), cPLA2-α (n = 6) and normalized to β-
actin for densitometric analysis. Data are shown as means ± S.E.M, *p < 0.05, **p < 0.01, ***p <
0.001 vs. vehicle (veh.), one-way analysis of variance (ANOVA) with Bonferroni test. B) Cytokines
released from monocyte supernatants were analyzed by ELISA; results are given as means ±
S.E.M., n = 4. *p < 0.05, **p < 0.01 vs. vehicle (veh.), one-way analysis of variance (ANOVA) with
Bonferroni test. C) Cell lysates were immunoblotted for COX-2 and β-actin for densitometric
analysis. Data are shown as means ± S.E.M, n = 5. *p < 0.05 vs. vehicle (veh.), one-way analysis of
variance (ANOVA) with Bonferroni test. D) Human monocytes were pretreated with ArchA (10 nM),
bafilomycin (Bafi, 10 nM) or vehicle (DMSO 0.1%) for 15 min before stimulation with LPS (100 ng/ml)
for 24 h. Expression of monocytes surface marker (CD14) analyzed by flow cytometry. Results are
shown as percentage of vehicle control (= 100%), means ± S.E.M., n = 3. Representative figure is
shown from n = 3 independent experiments.
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Fig. 4. Temporal modulation of LM biosynthetic pathways by ArchA in human monocytes. Human
monocytes were pretreated with archazolid A (ArchA, 10 nM) or vehicle (DMSO 0.1%) for 15 min
before stimulation with LPS (100 ng/ml) for 6, 24 or 48 h. A) Monocyte lysates were immunoblotted
for COX-2, normalized to β-actin for densitometric analysis. Data are shown as means ± S.E.M, n =
4. *p < 0.05 vs. vehicle, paired t test. B) LM generated from monocytes after exposure to E. coli (ratio
1:50, 90 min) were isolated by solid phase extraction and analyzed by UPLC-MS-MS; detection limit:
0.5 pg. Results are given as means ± S.E.M in the bar charts and as ratio to vehicle in the heatmap,
n = 4 for 6 h and n = 7 for 24 h/48 h. *p < 0.05, **p < 0.01 vs. vehicle (veh.), data are log-transformed
for statistical analysis, paired t test.
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Fig. 5. ArchA-induced COX-2 expression is regulated by p38 MAPK and ERK-1/2. A) Proposed scheme of
the COX-2-regulating pathway in monocytes. B, C) Human monocytes were pretreated with archazolid A
(ArchA, 10 nM) for 15 min before stimulation with LPS (100 ng/ml) for B) 24 h or C) 15 min and 1 h. Cell
lysates were immunoblotted for phospho-p38 MAPK, p38 MAPK, phospho-ERK-1/2, ERK-1/2, phospho-NF-
κB, NF-κB, phospho-JNK and JNK for densitometric analysis. Data are shown as means ± S.E.M, n = 6. *p
< 0.05, **p < 0.01, vs. LPS-vehicle, paired t test. D, E) Human monocytes were pretreated with ArchA (30
nM), skepinone-L (skepi, 1 µM), U0126 (3 µM) or vehicle (DMSO 0.1%) for 15 min before stimulation with
LPS (100 ng/ml) for 24 hrs. D) Monocyte lysates were immunoblotted for COX-2 and β-actin for
densitometric analysis. Data are shown as means ± S.E.M from n = 6. E) LM generated from monocytes
after exposure to E. coli (ratio 1:50, 90 min) were isolated by solid phase extraction and analyzed by UPLC-
MS-MS; detection limit: 0.5 pg. Results are given as means ± S.E.M., n = 5. *p < 0.05, **p < 0.01, ***p <
0.001 vs. vehicle (veh.); ###p < 0.001 vs. ArchA control (ArchA), one-way analysis of variance (ANOVA)
with Bonferroni test.
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Fig. 6. Effect of ArchA on the production of extracellular and intracellular COX-derived LM in human
monocytes. Human monocytes were pretreated with archazolid A (ArchA,10 nM) or vehicle for 15
min before stimulation with LPS (100 ng/ml) for 24 hrs. A) LM from extracellular (cell supernatant)
and intracellular (intact cell) origin were isolated by solid phase extraction and analyzed by UPLC-
MS-MS; detection limit: 0.5 pg. B) LM from extracellular (cell supernatant) and intracellular (intact
cell) origin after exposure to E. coli (ratio 1:50, 90 min) were isolated by solid phase extraction and
analyzed by UPLC-MS-MS; detection limit: 0.5 pg. Results are given as means ± S.E.M., n = 3. *p
< 0.05, **p < 0.01, ***p < 0.01 vs. vehicle (veh.), one-way analysis of variance (ANOVA) with
Bonferroni test.
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Fig. 7. COX-2 activity is regulated by V-ATPase through modulation of the intracellular pH. Human
monocytes were pretreated with archazolid A (ArchA, 10 nM), choloroquine (CQ, 100 µM) or vehicle
(DMSO 0.1%) for 15 min before stimulation with LPS (100 ng/ml) for 24 hrs. A) Cell viability
determined by propidium iodide staining analyzed by flow cytometry. Data are given as means ±
S.E.M. (viable cells as percentage of total cells), n = 3. B) Monocyte lysates were immunoblotted for
COX-2 and β-actin for densitometric analysis. Data are shown as means ± S.E.M from n = 3. C) LM
present in cell supernatants were isolated by solid phase extraction and analyzed by UPLC-MS-MS;
detection limit: 0.5 pg. Results are given as means ± S.E.M in bar charts and as ratio to vehicle in
heat-map. n = 3. D) LM generated from monocytes after exposure to E. coli (ratio 1:50, 90 min) were
isolated by solid phase extraction and analyzed by UPLC-MS-MS; detection limit: 0.5 pg. Results are
given as means ± S.E.M in bar charts and as ratio to vehicle in a heatmap. n = 3. *p < 0.05, **p <
0.01, ***p < 0.001 vs. vehicle (veh.), one-way analysis of variance (ANOVA) with Bonferroni test.
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Selective upregulation of TNFα expression in classically-activated 
human monocyte-derived macrophages (M1) through 
pharmacological interference with V-ATPase 
Lea Thomas, Zhigang Rao, Jana Gerstmeier, Martin Raasch, Christina Weinigel, 
Silke Rummler, Dirk Menche, Rolf Müller, Carlo Pergola, Alexander Mosig, Oliver 
Werz (2017) 
Biochemical Pharmacology 130 (2017) 71–82 
We show that targeting V-ATPase by the selective inhibitor archazolid (ArchA) 
upregulates TNF-α mRNA levels and TNF-α secretion in LPS- or LPS/INFγ-activated 
human M1 macrophages. In contrast, ArchA failed to increase TNF-α levels in 
uncommitted (M0) or IL-4-treated human M2 macrophages. Secretion of other relevant 
cytokines like IL-1β, IL-6, IL-10 or chemokines as IL-8 and monocyte chemotactic 
protein-1 from M1 macrophages was not affected by ArchA. Notably, the 
phosphorylation and nuclear translocation of the p65 subunit of NF-κB as well as 
phosphorylation of SAPK/JNK that are responsible for TNF-α expression was 
enhanced by ArchA. In a microfluidically-supported three-dimensional human tumor 
biochip model, ArchA-treated human M1 macrophages significantly reduced MCF-7 
tumor cell viability via increased secretion of TNFα, whereas in models containing M2 
macrophages or in models devoid of macrophages, ArchA failed in this respect. 
Conclusively, pharmacologically targeting V-ATPase with ArchA activates NF-κB and 
SAPK/JNK pathways and thus elevates TNF-α levels, which supports the anti-tumoral 
effects of human M1 macrophages. 
Contribution (35%): Cell culture and performance of blood cell isolation, 
determination of cytokine/chemokine levels, measurement of ROS formation, the 
microfluidically supported biochip assay, analysis of data and preparation of graphs, 
analysis of statistics, writing the manuscript. 
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a b s t r a c t
Pharmacological interference with vacuolar-type H(+)-ATPase (V-ATPase), a proton-translocating
enzyme involved in protein transport and pH regulation of cell organelles, is considered a potential strat-
egy for cancer therapy. Macrophages are critically involved in tumor progression and may occur as pro-
tumoral M2 phenotype, whereas classically-activated M1 can inhibit tumor development for example by
releasing tumor-suppressing molecules, including tumor necrosis factor (TNF)a. Here, we show that tar-
geting V-ATPase by selective inhibitors such as archazolid upregulates the expression and secretion of
TNFa in lipopolysaccharide (LPS)- or LPS/interferon (INF)c-activated M1-like macrophages derived from
human blood monocytes. In contrast, archazolid failed to elevate TNFa production from uncommitted
(M0) or interleukin (IL)-4-treated M2-like macrophages. Secretion of other relevant cytokines (i.e., IL-
1b, IL-6, IL-10) or chemokines (i.e. IL-8 and monocyte chemotactic protein-1) from M1 was not affected
by archazolid. Though V-ATPase inhibitors elevated the lysosomal pH in M1 comparable to chloroquine
or ammonium chloride, the latter agents suppressed TNFa secretion. Archazolid selectively increased
TNFamRNA levels, which was abolished by dexamethasone. Interestingly, archazolid enhanced the phos-
phorylation and nuclear translocation of the p65 subunit of NFjB and stimulated phosphorylation of
SAPK/JNK. In a microfluidically-supported human tumor biochip model, archazolid-treated M1 signifi-
cantly reduced tumor cell viability. Together, our data show that V-ATPase inhibition selectively upreg-
ulates TNFa production in classically-activated macrophages along with NFjB and SAPK/JNK activation.
Such increased TNFa release caused by V-ATPase inhibitors may contribute to tumor suppression in addi-
tion to direct targeting cancer cells.
 2017 Elsevier Inc. All rights reserved.
1. Introduction
Combination of direct cytotoxic activity against tumor cells
with concomitant capacity to favorably modify the tumor microen-
vironment might be an appealing option for pharmacological treat-
ment of diverse cancers with clinical relevance [1]. For example,
the clinically used chemotherapeutic agent trabectedin, in addition
to killing cancer cells, depletes monocytes and tumor-associated
macrophages (TAMs) in tumor patients as a key component of its
anti-tumor activity [2]. However, the discovery of relevant targets
in this respect is still in demand in order to simultaneously repress
http://dx.doi.org/10.1016/j.bcp.2017.02.004
0006-2952/ 2017 Elsevier Inc. All rights reserved.
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nuclear factor kappa B; p38 MAPK, p38 mitogen-activated protein kinase; PBMC,
peripheral blood mononuclear cells; SAPK/JNK, stress-activated protein kinase/Jun
amino-terminal kinases; TAM, tumor-associated macrophage; TNFa, tumor necro-
sis factora; V-ATPase, vacuolar-type H(+)-ATPase.
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the viability of cancer cells and to modulate tumor-associated
mononuclear cells by a single agent.
The vacuolar-type H(+)-ATPases (V-ATPases) are ATP-
dependent proton translocating macromolecular complexes that
acidify lysosomes, endosomes, Golgi apparatus, and certain
secretory granules in all eukaryotes [3,4]. V-ATPases participate
in physiological processes such as cellular pH homeostasis,
receptor-mediated endocytosis, virus and toxin entry, intracellular
trafficking as well as protein degradation and processing [3]. Aber-
rant regulation of pH by V-ATPases is implicated in several diseases
including osteoporosis, renal tubular acidosis, and malignant neo-
plasms [5,6]. V-ATPase is highly expressed on the plasma mem-
brane of tumor cells and particularly contributes to the
acidification of tumor microenvironments, thus supporting tissue
damage, acquisition of metastatic cell phenotypes, and tumor inva-
siveness [6,7]. Accordingly, specific inhibitors of V-ATPase that
decrease the acidity of tumors, reduced the survival of tumor cells
and tumor metastasis, and impaired chemoresistance [6,8]. In fact,
V-ATPase is considered as promising target in various types of can-
cer [6].
Cytokines and chemokines significantly impact the tumor
microenvironment to which TAMs are exposed, and represent
essential factors that impact the heterogeneity of TAM functions
[9]. TAMs consist of different phenotypes with partly opposite
impact on tumors: the M2-like subtypes play pivotal roles in tumor
progression by promoting cancer cell survival, angiogenesis, and
immunosuppression, and they represent - as major part of TAMs
– a remarkable fraction of tumor-infiltrating immune cells [9,10].
In contrast, classically-activated M1-like subsets are indispensable
innate immune cells with microbicidal and tumoricidal activity
that produce high levels of anti-tumoral molecules such as tumor
necrosis factor (TNF)a, thus opposing cancer cells and preventing
the establishment and progression of cancers [1,10].
The role of V-ATPase in cytokine secretion was studied in peri-
toneal macrophages from mice or rabbits before [11–13]. Here, we
aimed to obtain insights into the role of V-ATPase in cytokine and
chemokine secretion from human macrophages derived from
peripheral blood monocytes, taking into account macrophage plas-
ticity and occurrence as different phenotypes. As a suitable tool to
studying the role of V-ATPase we used the myxobacterial com-
pound archazolid [14] that binds to V-ATPase [15–17]. Archazolid
has been intensively investigated as anti-tumoral agent that
induced apoptosis of cancer cells and reduced migration of inva-
sive tumor cells in vitro, and decreased metastatic dissemination
of breast tumors in vivo [18–20]. In various highly invasive tumor
cell lines and leukemic cells, archazolid led to apoptosis due to
activation of the hypoxia-inducible factor-1a (HIF1a) [18,21],
and to anoikis induction [22]. Thus, archazolid represents a
promising candidate for direct targeting of tumor cells via
V-ATPase inhibition. We recently reported that archazolid reduces
the secretion of cytokines and chemokines in primary human
monocytes due to accumulation at the endoplasmic reticulum
[23]. However, effects of archazolid on macrophages have not been
addressed, and phenotype-specific functions of V-ATPase in cyto-
kine/chemokine secretion from human macrophages have not
been reported yet.
2. Materials and methods
2.1. Materials
Archazolid B was isolated from Archangium gephyra as previ-
ously described [14]. Apicularen A was from the natural compound
library of HZI/HIPS (Braunschweig, Germany). RPMI 1640 with
L-glutamine, penicillin, streptomycin, and fetal calf serum (FCS)
were from PAA Laboratories (Pasching, Germany). For in-house
made ELISA, the capture and detection antibodies were from R&D
Systems (Abington, UK). U0126, SB203580, nigericin, and
SP600125 were from Enzo Life Sciences (Lörrach, Germany),
LY294002 from BIOZOL Diagnostica Vertrieb GmbH (Eching,
Germany), actinomycin D from Cayman Chemical (Ann Arbor,
MI), staurosporine from Calbiochem (Merck, Darmstadt, Germany),
interferon (INF)c and interleukin (IL)-4 from PeproTech (Hamburg,
Germany), macrophage colony-stimulating factor (M-CSF) from
Cell Guidance Systems Ltd (Cambridge, UK), Calcein-AM and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) from Thermo Fisher Scientific Inc. (Waltham, MA), Lyso-
Tracker dye from Life Technologies (Schwerte, Germany) and
ammonium chloride, bafilomycin A1, chloroquine, dexamethasone,
diphenyleneiodonium chloride (DPI), LPS, parthenolide, propidium
iodide and all other fine chemicals were from Sigma-Aldrich
(Steinheim, Germany), unless indicated otherwise.
2.2. Isolation of monocytes, differentiation to macrophages and
macrophage activation
The protocols for experiments with human monocytes were
approved by the ethical commission of the Friedrich-Schiller-
University Jena. All methods were performed in accordance with
the relevant guidelines and regulations. Leukocyte concentrates
from peripheral blood of healthy human donors which did not take
anti-inflammatory medication for the last ten days were obtained
from the Institute of Transfusion Medicine, University Hospital
Jena, and prepared as described [23]. Peripheral blood mononu-
clear cells (PBMC) were isolated by dextran sedimentation and
density centrifugation on lymphocyte separation medium (LSM
1077, PAA Laboratories, Pasching, Austria). Monocytes from the
PBMC fraction were isolated by adherence for 1 h at 37 C and 5%
CO2 to culture flasks (2  107 cells/mL RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin) [24].
For differentiation towards macrophages, freshly isolated
monocytes were incubated for 6 days in RPMI 1640 supplemented
with 5% FCS and human recombinant M-CSF (25 ng/mL) [25]. To
obtain classically-activated macrophages (M1-like), cells were fur-
ther treated with 100 ng/mL LPS (designated MLPS) or 100 ng/mL
LPS plus 100 ng/mL human recombinant IFNc (M1) for 24 h. To
obtain M2-like cells, macrophages were incubated with human
recombinant IL-4 (20 ng/mL) for 24 h [25,26]. To assure correct
polarization, cells were assessed by flow cytometry for expression
of the M2 surface markers CD163 and CD206, while M1 and MLPS
were characterized by expression of CD40 and higher expression
of HLA-DR (MHC class II receptor) than M2 [26].
2.3. Determination of cell viability
The viability of humanmacrophages was assessed by MTT assay
as described [27]. Briefly, macrophages after 6 days of differentia-
tion of monocytes were pre-incubated with compounds for
30 min at 37 C (5% CO2) and treated for 24 h with (I) 100 ng/mL
LPS (MLPS), (II) 100 ng/mL LPS plus 100 ng/mL INFc (M1), (III)
20 ng/mL IL-4 (M2) or left untreated (M0). MTT was added, cells
were further incubated for 4 h, and lysed in a buffer containing
10% (w/v) SDS. Staurosporine, a pan-kinase inhibitor and inducer
of apoptosis, was used as positive control.
2.4. Immunofluorescence microscopy and live cell imaging
Macrophages (2.5  105/mL) were seeded on glass coverslips
and incubated for 1 h at 37 C and 5% CO2. After attachment, cells
were pre-incubated with test compounds (as indicated) and
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stimulated with LPS (100 ng/mL), with LPS (100 ng/mL) plus IFNc
(100 ng/mL) or with IL-4 (20 ng/mL) for the indicated times at
37 C and 5% CO2. Then, cells were fixed with 4% (v/v)
paraformaldehyde solution, autofluorescence of free formaldehyde
was quenched with 50 mM ammonium chloride, and macrophages
were permeabilized with 0.2% (v/v) Triton X-100. After blocking
with 10% (v/v) non-immune goat serum (Invitrogen, Darmstadt,
Germany), samples were incubated with antibodies against the
c-subunit of V-ATPase (1:1000 anti-ductin, Biozol, Eching,
Germany), LAMP-1 (1:1000, Abcam, Cambridge, UK), IjBa (1:125,
mouse monoclonal anti-IjBa, Cell Signaling Technology, Danvers,
MA) and NFjB (1:100, rabbit monoclonal anti-NFjB p65, Cell Sig-
naling Technology) over night at 4 C. The samples were washed
and then stained with the fluorophore-labeled secondary antibod-
ies Alexa Fluor 488 goat anti-rabbit IgG (1:500) and Alexa Fluor
555 goat anti-mouse IgG (1:500) (Invitrogen) for 10 min at RT in
the dark. DNA was stained using DAPI (0.7 mg/mL) for 3 min at
RT. Samples were placed on microscope slides (Roth, Karlsruhe,
Germany) using Mowiol containing 0.25% n-propyl gallate
(Sigma-Aldrich). The fluorescence was visualized with a Zeiss Axio
Observer.Z1 inverted microscope (Carl Zeiss, Jena, Germany) and a
LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 objective. Images
were taken with an AxioCam MR3 camera and were acquired,
cut, linearly adjusted in the overall brightness and contrast, and
exported by the AxioVision 4.8 software.
For imaging of living cells, macrophages (2.5  105/mL) were
plated into glass bottom dishes (MatTek Corporation, Ashland,
MA). After adherence, cells were treated with archazolid (100
nM) or vehicle for 30 min and stimulated for 24 h with either (I)
100 ng/mL LPS, (II) 100 ng/mL LPS plus 100 ng/mL INFc, or (III)
20 ng/mL IL-4.
For imaging of fluorescein isothiocyanate (FITC) dextran
(Thermo Fisher Scientific Inc.) uptake into macrophages, cells were
treated as described in pH measurements. Cells were imaged
immediately using the Axio Observer Z1 inverted microscope and
a Plan-Apochromat 40/1,3 Oil DIC M27 objective or a LCI Plan-
Neofluar 63/1.3 Imm Corr DIC M27 objective.
2.5. Determination of cytokine/chemokine levels
After 6 days of differentiation of monocytes to macrophages
with M-CSF (25 ng/mL) at 37 C and 5% CO2, test compounds or
vehicle were added to macrophages and 30 min later, cells were
incubated for 24 h with either (I) 100 ng/mL LPS, (II) 100 ng/mL
LPS plus 100 ng/mL INFc, or (III) 20 ng/mL IL-4. For measurement
of extracellular cytokine levels, supernatants were collected by
centrifugation (2000g, 4 C, 10 min). Cytokines and chemokines
were either analyzed by using commercially available ELISA kits
(IL-8, Assaypro, St. Charles, MO) according to manufacturer’s
specifications, or by in-house made ELISA (IL-1b, IL-6, IL-10, TNFa,
monocyte chemotactic protein (MCP)-1).
2.6. pH measurements in macrophages
pH measurements were performed according to [28], and com-
positions of sodium and potassium buffers were used as described
[29]. For measurements of the vesicular pH, macrophages were
incubated with 0.5 mg/mL FITC-dextran (70,000 MW, Sigma-
Aldrich) for 1 h. Cells were washed with PBS, pre-incubated with
test compounds or vehicle for 30 min and stimulated with
100 ng/mL LPS for 24 h. The pH values were calculated from the
ratio of fluorescence intensities excited at 480 nm and 450 nm
and emission at 520 nm. In situ fluorescence calibration was per-
formed with the ionophore nigericin (10 mM) in potassium buffer
at pH values between 4.5 and 7.5.
For analysis by LysoTracker staining, macrophages (2.5 105/mL)
were plated into glass bottom dishes (MatTek Corporation). After
adherence, cells were treated with test compounds or vehicle for
30 min and stimulated with 100 ng/mL LPS for 24 h. Macrophages
were then stained with the fluorescent LysoTracker dye (50 nM)
for 1 h. After washing, the red fluorescence of the accumulated
probe in acidic cell organelles was imaged using the Axio Observer
Z1 microscope and a LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27
objective.
2.7. Relative quantification of TNFa and IL-1b mRNA levels in
macrophages and determination of TNFa mRNA degradation
After 6 days of differentiation of monocytes to macrophages
with M-CSF (25 ng/mL), macrophages were pre-incubated with
test compounds or vehicle for 30 min and stimulated with
100 ng/mL LPS for the indicated times at 37 C and 5% CO2. For
measurement of TNFa mRNA degradation, macrophages were
stimulated with 100 ng/mL LPS for 24 h and incubated with archa-
zolid or vehicle for 1 h. Then, transcription was blocked by addition
of actinomycin D (5 mg/mL) and cells were incubated for the indi-
cated times. Total RNA was isolated using the E.Z.N.A. Total RNA
Kit I (Omega Biotek, Norcross, GA) and cDNA was generated by
reverse transcription with SuperScript III First-Strand Synthesis
SuperMix (Invitrogen). cDNA was amplified by PCR and quantified
using Maxima SYBR Green/ROX qPCR Master Mix (Fermentas,
Darmstadt, Germany). To calculate the relative TNFa mRNA
expression (normalized to B2 M) the 2(DDC(T)) method was applied
[30]. Primers used: human beta-2-microglobulin (B2 M)
forward primer 50-CTCCGTGGCCTTAGCTGTG-30, human B2 M
reverse primer 50-TTTGGAGTACGCTGGATAGCCT-30, human
TNFa forward primer 50-CCCAGGGACCTCTCTCTAATC-30, human
TNFa reverse primer 50-ATGGGCTACAGGCTTGTCACT-30, human IL-1b
forward primer 50-ACAGATGAAGTGCTCCTTCCA-30, human IL-1b
reverse primer 50-GTCGGAGATTCGTAGCTGGAT-30 (Tib Molbiol,
Berlin, Germany).
2.8. Determination of phosphorylation of protein kinases and
transcription factors by Western blot analysis
Macrophages, obtained by differentiation of monocytes with M-
CSF (25 ng/mL) at 37 C and 5% CO2 for 6 days, were first starved
for 6 h (AKT, ERK-1/2, p38 MAPK, MEK1/2, SAPK/JNK, MKK3/6) or
directly pre-incubated (NFjB p65, STAT-1, STAT-3) with archazolid
(100 nM) or vehicle (0.1% DMSO) for 30 min at 37 C, 5% FCS was
added and cells were stimulated with LPS (100 ng/mL) for
15 min. Macrophages were placed on ice, washed once with PBS
and lysed with a NP-40 lysis buffer (1% (v/v) NP-40, 1 mM sodium
vanadate, 10 mM sodium fluoride, 5 mM sodium pyrophosphate,
25 mM b-glycerophosphate, 5 mM EDTA, and freshly added
10 mg/mL leupeptin hemisulfate salt, 60 mg/mL trypsin inhibitor
from soybean, 1 mM phenylmethylsulfonyl fluoride in TBS, pH
7.4). Lysates were centrifuged (10,000g, 4 C, 5 min), and protein
concentrations in the supernatants were determined using a Pro-
tein Assay (Bio-Rad Laboratories, Hercules, CA). After addition of
4 SDS loading buffer (50 mM Tris-HCl, pH 6.8, 2% (w/v) SDS,
10% (v/v) glycerol, 1% (v/v) b-mercaptoethanol, 12.5 mM EDTA,
0.02% (w/v) bromophenol blue) to the lysates, samples were boiled
for 5 min at 95 C. Proteins were separated by SDS-PAGE and blot-
ted onto nitrocellulose membranes (Amersham Biosciences, Little
Chalfont, UK). After blocking with 5% (w/v) bovine serum albumin
or low-fat milk powder (Roth, Karlsruhe, Germany), membranes
were incubated with primary antibodies overnight at 4 C. Anti-
bodies, obtained from Cell Signaling Technology (Danvers, MA),
were used as follows: NFjB p65, 1:500, rabbit monoclonal
anti-NFjB p65; phospho-NFjB p65, 1:500, mouse monoclonal
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anti-phospho-NFjB p65; phospho-STAT-1, 1:1000, rabbit poly-
clonal anti-phospho-STAT-1; phospho-STAT-3, 1:1000, rabbit
monoclonal anti-phospho-STAT-3; p38 MAPK, 1:1000, rabbit mon-
oclonal anti-p38 MAPK; phospho-p38 MAPK, 1:1000, rabbit poly-
clonal anti-phospho-p38 MAPK; ERK-1/2, 1:1000, rabbit
polyclonal anti-p44/42 ERK; phospho-ERK-1/2, 1:1000, mouse
monoclonal anti-phospho-p44/42 ERK; Akt, 1:1000, mouse mono-
clonal anti-Akt; phospho-Akt, 1:1000, rabbit polyclonal anti-
phospho-Akt; MEK1/2, 1:1000, rabbit polyclonal anti-MEK1/2;
phospho-MEK1/2, 1:1000, rabbit polyclonal anti-phospho-
MEK1/2; phospho-MKK3, 1:1000, rabbit monoclonal anti-
phospho-MKK3/6; phospho-SAPK/JNK, 1:1000, mouse monoclonal
anti-phospho-SAPK/JNK. Antibodies against GAPDH: 1:1000,
mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology, Heidel-
berg, Germany) and b-actin, 1:1000, mouse monoclonal anti-
b-actin (Santa Cruz Biotechnology). Membranes were washed
and incubated with fluorescently-labeled secondary antibodies
(LI-COR Biosciences, Bad Homburg, Germany) for 1 h at RT in the
dark. Proteins were detected using the Odyssey imaging system
(LI-COR Biosciences, Bad Homburg, Germany).
2.9. Measurement of ROS formation
ROS levels were assessed as reported before [31]. Briefly,
macrophages were incubated with test compounds or vehicle
(0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for
24 h or left untreated. Cells were washed and incubated in HBSS
buffer containing 20-70-dichlorofluorescein diacetate (DCFH-DA,
Sigma-Aldrich) (10 mM) for 30 min at 37 C/5% CO2. To detect and
quantify intracellular formation of ROS, the fluorescence of the
deacetylated dye (20-70-dichlorofluorescein) was measured at an
excitation wavelength of 485 nm and an emission wavelength of
535 nm using a NOVOstar microplate reader (BMG Labtechnolo-
gies GmbH, Offenburg, Germany).
2.10. Microfluidically supported biochip assay
Biochips were prepared by injection moulding from cyclo olefin
polymer (COP) Zeonor, obtained from microfluidic ChipShop
GmbH (Jena, Germany), and manufactured as described previously
[32]. MCF-7 cells were obtained at LGC Standards (Wesel,
Germany). Authentication of MCF-7 was carried out by STR analy-
ses (LGC Standards) and experiments were completed within
4 months of receipt of the cell line. Human umbilical vein endothe-
lial cells (HUVEC) were isolated from human umbilical cords and
cultured for up to four passages as described previously [32].
Donors were informed about the aim of the study and gave written
consent. HUVEC were seeded at top of the biochip-embedded
membrane, MCF-7 cells were seeded at the lower compartment
of the biochip. Monocytes (in a six well plate) were differentiated
towards macrophages in presence of M-CSF for 6 days, and M1
polarization was induced by addition of LPS plus IFNc while M2
polarization was induced by addition of IL-4 for 24 h. These M1
and M2 were then added to the HUVEC into the biochip. After
24 h co-culture with HUVECs, medium containing 30 nM archa-
zolid or vehicle (0.1% DMSO) was added, and after 30 min, it was
replaced by fresh medium (without archazolid). Then, cells
perfused over the vascular layer with a shear stress rate of
3 dyn/cm2 for 30 min, followed by 24 h incubation with medium.
In control experiments, macrophages were omitted and only
HUVECs were used in the upper compartment. The viability of
the cells was analyzed by immunofluorescence microscopy using
Calcein-AM (viable cells, green) and propidium iodide (dead cells,
red) staining. Mean fluorescence intensity (MFI) of the Calcein-
AM staining was measured by random field analysis of 40 regions
of interest per experiment.
2.11. Statistics
Data are presented as mean + standard error of the mean (SEM)
of n experiments, where n represents the number of experiments.
Statistical data were calculated using GraphPad InStat program
(GraphPad Software, CA), and were analyzed by Student’s t test
for paired groups and by one-way ANOVA for independent or
correlated samples followed by a Bonferroni (<5 groups) or
Tukey-Kramer (>5 groups) post hoc test for multiple comparisons.
A P value of <0.05 (⁄) was considered significant.
3. Results
3.1. Expression of V-ATPase in macrophages and effects of the
V-ATPase inhibitor archazolid on the viability and morphology of
macrophages
According to well-established protocols, we induced M-CSF-
treated macrophages (designated M0) with LPS/INFc towards
classically-activated M1 or with IL-4 towards M2-like subsets
[33]. Moreover, M-CSF-treated macrophages were activated by
LPS alone (designated MLPS), which strongly resemble M1 [26] sim-
ilar to macrophages activated by INFc alone [33]. Previous studies
showed that macrophages from different origins and species
express V-ATPase and respond to V-ATPase inhibitors in different
ways [13,31,34–39]. We first confirmed V-ATPase expression in
human monocyte-derived macrophages [40] by Western blot
(not shown) and by using immunofluorescence microscopy where
no obvious differences regarding V-ATPase subcellular localization
between the macrophage phenotypes were immediately apparent
(Fig. 1A). Side-by-side analysis of LAMP-1, a marker protein for
lysosomes, revealed colocalisation with V-ATPase (merge, Fig. 1B),
suggesting that V-ATPase might be located to vesicles.
The V-ATPase inhibitor archazolid effectively induces apoptosis
in cancer cells leading to cell death [18,19]. Since we aimed at
using arachzolid as tool compound to study V-ATPase in various
human macrophage phenotypes, we first analyzed whether archa-
zolid may affect the viability of macrophages. Incubation of acti-
vated macrophages (MLPS, M1 or M2) with archazolid (1, 10, or
100 nM) revealed no loss of cell viability within 24 h, whereas
the pan-protein kinase inhibitor and apoptosis inducer stau-
rosporine (3 mM) efficiently reduced cell viability, as expected
(Fig. 1C). Microscopic analysis confirmed cellular integrity of MLPS,
M1, and M2 upon archazolid treatment but revealed obvious alter-
ations of the cell shape for MLPS and M1 that was not evident for
M2, for which the morphology was seemingly not affected by arc-
hazolid (Fig. 1D).
3.2. V-ATPase inhibitors induce TNFa secretion in classically-activated
macrophages
Having confirmed that archazolid is not detrimental for cellular
integrity and viability of macrophages, we next tested whether the
compound could modulate cytokine and chemokine release. Differ-
entiated macrophages (M0) were pretreated with archazolid and
then either activated by LPS/INFc (M1) or IL-4 (M2) for 24 h. Anal-
ysis of IL-1b, IL-6, IL-8, IL-10 and MCP-1 in the medium revealed no
significant modulation of the release of these proteins by archa-
zolid neither in M1 nor in M2 (Fig. 2A). However, the levels of TNFa
were upregulated by archazolid (100 nM) about 2.4-fold in M1,
whereas the compound failed to alter TNFa levels in M2 (Fig. 2A)
and in M0 (not shown). More detailed concentration response
experiments showed that for MLPS or M1 the maximal effect (2.9-
to 3.4-fold) on TNFa release was obtained at 30 nM archazolid
and slightly declined at 100 nM (Fig. 2B). In contrast to archazolid
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and as expected, dexamethasone repressed TNFa levels in MLPS and
M1 (Fig. 2B). To confirm that the observed effect of archazolid is
related to interference with V-ATPase, we tested other V-ATPase
inhibitors, that is, apicularen A and bafilomycin A1 (1, 10 and
100 nM, each) in the same experimental settings. For both com-
pounds upregulation of TNFa levels was evident in MLPS and M1
with maximal effects at 10 nM (Fig. 2C), supporting that suppres-
sion of V-ATPase accounts for increased TNFa release.
Fig. 1. Expression and subcellular localization of V-ATPase in macrophages and effects of archazolid on macrophage viability and morphology. (A) Macrophages, obtained
from human blood monocytes after differentiation with M-CSF (25 ng/mL) for six days, were stimulated with LPS (100 ng/mL), with LPS (100 ng/mL) plus IFNc (100 ng/mL) or
with IL-4 (20 ng/mL) for 24 h. Cells were permeabilized and incubated with an antibody against V-ATPase (green), followed by Alexa Fluor 488 goat anti-rabbit IgG. Nuclei
were stained with DAPI (blue). (B) Macrophages were stimulated with LPS (100 ng/mL) plus IFNy (100 ng/mL) for 24 h, permeabilized and incubated with antibodies against
v-ATPase (green) or LAMP-1 (red), followed by Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-rabbit IgG; nuclei were stained with DAPI (blue); differential
interference contrast. (C, D) Macrophages were pre-incubated with archazolid (1, 10, 100 nM (C) and 100 nM (D)), staurosporine (3 mM) or vehicle (0.1% DMSO) for 30 min
and stimulated with LPS (100 ng/mL), with LPS (100 ng/mL) plus IFNc (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. (C) Cell viability was determined by MTT assay. (D) Effects
of archazolid (100 nM) on the morphology of macrophages. Microscopic images are shown as differential interference contrast. All results are representative of three
independent experiments. Values are given as percentage of vehicle control (=100%), means + SEM; n = 3. ***P < 0.001 vs. vehicle. ANOVA + Bonferroni post hoc test. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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3.3. Archazolid causes elevation of the lysosomal pH in classically-
activated macrophages
Blocking V-ATPase is well-known to cause an elevated lysoso-
mal pH in various cell types [16,41,42], and along these lines, arc-
hazolid led to significantly increased lysosomal pH in MLPS as
evidenced by the pH-dependent internalization of FITC-labeled
dextran (Fig. 3A). Elevation of the lysosomal pH by archazolid
was pronounced at 100 nM but only slightly affected at 10 nM.
In agreement with the literature [43,44], chloroquine (100 mM)
and NH4Cl (50 mM), used as control tools, elevated the lysosomal
pH in MLPS to a comparable degree as 10 nM archazolid (Fig. 3A).
Fig. 2. Effects of V-ATPase inhibitors on cytokine and chemokine release from human macrophages. Human isolated blood monocytes were differentiated to macrophages
with M-CSF (25 ng/mL) within six days. For analysis of cytokine release, macrophages were pre-incubated with archazolid, apicularen A, or bafilomycin A1 at the indicated
concentrations, with dexamethasone (1 mM) or with vehicle (0.1% DMSO) for 30 min and then stimulated with LPS (100 ng/mL), LPS plus IFN-c, or IL-4 (20 ng/mL) for another
24 h. Cytokines and chemokines in the supernatants were analyzed by ELISA. Values shown are percentages of vehicle control, means + SEM. *P < 0.05, **P < 0.01, ***P < 0.001
vs. vehicle (DMSO). Paired t-test (A) or ANOVA + Tukey post hoc test (B, C). (A) Archazolid was used at 100 nM. Absolute values of LPS + IFNc-stimulated vehicle (100%)
control: MCP-1: 98.3 ± 43.4 ng/mL, IL-1b: 1709 ± 1465 pg/mL, IL-6: 30.8 ± 9.3 ng/mL, IL-8: 52.2 ± 4.8 ng/mL, IL-10: 1211 ± 256 pg/mL, TNFa: 1992 ± 653 pg/mL. Absolute
values of IL-4-stimulated vehicle (100%) control: MCP-1: 86.1 ± 34.6 ng/mL, IL-1b: 601 ± 403 pg/mL, IL-6: 11.3 ± 1.9 ng/mL, IL-8: 45.1 ± 4.8 ng/mL, IL-10: 819 ± 240 pg/mL,
TNFa: 259 ± 87 pg/mL; n = 4. (B, C) Absolute value of LPS-stimulated vehicle (100%) control: 1383 ± 229 pg/mL (n = 6), absolute value of LPS + IFNc-stimulated vehicle (100%)
control: 1906 ± 273 pg/mL (B, n = 3) and 2347 ± 632 pg/mL (C, n = 6).
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A similar result was obtained, when changes of pH in organelles
were monitored using the pH sensitive LysoTracker probe and flu-
orescence microscopy (Fig. 3B). Note that the structurally distinct
V-ATPase inhibitor apicularen A also elevated the pH in organelles
of MLPS, just like archazolid.
In order to investigate whether the increased release of TNFa by
archazolid and other V-ATPase inhibitors was due to lysosomal pH
alterations, we took advantage of chloroquine and NH4Cl as tool
compounds (that also elevated the lysosomal pH) and tested if
these agents could increase TNFa release from MLPS and M1 as
well. Surprisingly, chloroquine (100 mM) and NH4Cl (50 mM) failed
to enhance TNFa release, but instead markedly repressed it in both
MLPS and M1 (Fig. 3C). Therefore, the data suggest that other mech-
anisms than solely elevation of lysosomal pH is responsible for the
TNFa-upregulatory effects by archazolid and other V-ATPase
inhibitors.
3.4. Archazolid affects TNFa release on the mRNA level and increases
TNFa mRNA expression in classically-activated macrophages
The stimulatory effect of archazolid on TNFa release in
classically-activated M1 was abrogated by co-incubation with dex-
amethasone (Fig. 4A), a glucocorticoid that interferes with TNFa
gene expression. This finding led us to assume that archazolid
may affect the expression of TNFa at the mRNA level. M(0) were
pretreated with or without archazolid in the presence or absence
of dexamethasone and 30 min later, LPS was added to obtain MLPS.
TNFa mRNA levels after 4 and 8 h were significantly higher in the
presence of archazolid versus cells treated with LPS alone, and also
after 1 and after 16, 20 and 24 h, archazolid led to elevated levels of
TNF mRNA (Fig. 4B). Note that mRNA of IL-1b, studied as control,
was not increased by archazolid (Fig. 4B). Coincubation with
dexamethasone effectively repressed the up-regulatory effect of
a
g
Fig. 3. Effects of V-ATPase inhibition on the lysosomal pH of humanmacrophages and correlation with cytokine release. Human isolated blood monocytes were differentiated
to macrophages with M-CSF (25 ng/mL) within six days. (A) Macrophages were incubated with FITC-dextran (0.5 mg/mL) for 60 min, preincubated with archazolid at the
indicated concentrations, ammonium chloride (50 mM), chloroquine (100 mM), or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h. FITC-Dextran
uptake into lysosomes was determined by measurement of emission at 520 nm or by analysis of immunofluorescence pictures (FITC-dextran: green; differential interference
contrast). (B) Macrophages were pre-incubated with archazolid (100 nM), apicularen A (100 nM), ammonium chloride (50 mM) or vehicle (DMSO) for 30 min and stimulated
with LPS (100 ng/mL) for 24 h. Macrophages were incubated with LysoTracker (50 nM; red) for 60 min and staining of acidic organelles was observed using a fluorescence
microscope. (C) Macrophages were pre-incubated with archazolid (10 nM), ammonium chloride (50 mM), chloroquine (100 mM) or vehicle (DMSO) for 30 min and stimulated
with LPS (100 ng/mL) or LPS (100 ng/mL) plus IFNc (100 ng/mL) for 24 h. TNFa levels in supernatants were analyzed by ELISA. Values are given as percentage of vehicle
control (=100%), means + SEM; n = 8 (A, left panel), n = 3 (C). *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS-stimulated vehicle (=100%). ANOVA + Bonferroni post hoc test. Pictures
shown are representative of three independent experiments.
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archazolid on TNFa mRNA expression (Fig. 4B). Experiments using
actinomycin D that blocks mRNA transcription showed that archa-
zolid does not affect TNFa mRNA degradation as possible reason
for elevation of mRNA levels (Fig. 4C).
3.5. Effects of archazolid on protein kinases and transcription factors
involved in LPS-signaling and on ROS formation
Because archazolid seemingly enhances the LPS-induced
expression of TNFa mRNA in MLPS, it appeared possible that the
compound modulates LPS-induced signal transduction pathways.
We thus analyzed the phosphorylation of typical protein kinases
(PK) that are integrated in LPS-induced TNFa expression. M(0)
were pre-treated with archazolid or respective reference PK
inhibitors, stimulated with LPS for 15 min and analyzed for the
phosphorylated form of the kinases by Western blot. LPS caused
phosphorylation of Akt, ERK-1/2, p38 MAPK, MEK-1/2, and MEK-
3/6 (Fig. 5A) but archazolid (10 or 100 nM) failed to modulate their
phosphorylation. The reference inhibitors LY294002 for Akt phos-
phorylation, U0126 for ERK, and SB203580 for p38 MAPK, used
to validate the identity of respective phosphorylated kinases/
proteins detected by Western blot, blocked LPS-induced phospho-
rylation, as expected (Fig. 5A). A tendency for stimulated SAPK/JNK
phosphorylation (reference inhibitor SP600125) was observed for
10 and 100 nM archazolid, although statistical significance was
not reached (Fig. 5A). However, archazolid (10 and 100 nM) clearly
elevated the phosphorylation of the p65 subunit of the transcrip-
tion factor NFjB in MLPS without marked elevation of NFjB p65
expression (Fig. 5B). An NFjB-stimulatory effect of archazolid
was also observed when the translocation of activated NFjB to
the nucleus was monitored using immunofluorescence micro-
scopy, in agreement with disappearance of the NFjB chaperon
IjB (Fig. 5C). Note that the LPS-induced phosphorylation of other
relevant transcription factors, that is, STAT-1 and STAT-3 in M1
was not elevated by archazolid (Fig. 5D).
Because ROS production is closely linked to NFjB and SAPK/JNK
signaling [45], we investigated if archazolid could modulate LPS-
induced ROS formation in macrophages. Pre-incubation of macro-
phages with 10 or 30 nM archazolid prior to LPS significantly
increased ROS levels within 24 h whereas the NADPH oxidase inhi-
bitor DPI diminished ROS formation induced by LPS, as expected,
and also abrogated the elevated ROS levels caused by archazolid
(Fig. 6A). Finally, we investigated if the elevated ROS and NFjB
activation are involved in archazolid-induced TNFa release. In fact,
DPI (5 mM) that reduced archazolid-elicited ROS formation as well
as the NFjB activation inhibitor parthenolide (10 mM) efficiently
prevented the stimulatory effects of archazolid plus LPS on TNFa
release from macrophages (Fig. 6B).
3.6. Archazolid enhances M1-mediated cytotoxicity against MCF-7
cells in a microfluidically biochip assay
To investigate if treatment of macrophages by archazolid influ-
ences cancer cell viability in co-cultures, we utilized a
microfluidically-supported biochip assay [32], designed as a
dynamically perfused three-dimensional human tumor model
(Fig. 7A). Macrophages, polarized towards M1 or M2 were added
to endothelial cells (ECs) and co-cultured in the upper chamber.
The ECs are thought to separate the tumor from the blood cells
mimicking the physiological barrier. MCF-7 cells, resembling the
tumor component, were cultured underneath the EC-macrophage
cell layer. EC-macrophage cell layers treated with archazolid
(30 nM) for 30 min and subsequent incubation for 24 h signifi-
cantly reduced the viability of MCF-7 cells in models containing
M1, whereas in models containing M2 or in models devoid of
macrophages, archazolid failed in this respect (Fig. 7B, C).
4. Discussion
Here we show that pharmacological targeting of V-ATPase
causes selective elevation of TNFa production in classically-
activated (i.e., M1 and MLPS) human macrophage phenotypes.
Intriguingly, the concomitant release of other cytokines (i.e. IL-
1b, IL-6, IL-10) or chemokines (i.e. IL-8, MCP-1) in M1 and MLPS
was not elevated, and the corresponding cytokine/chemokine
secretion of uncommitted M(0) and of alternatively activated M2
was not affected by archazolid. Because also other V-ATPase inhi-
bitors such as bafilomycin and apicularen led to comparable
effects, we suggest that interference with V-ATPase but not with
an off-target of archazolid [46] is causative for the elevated TNFa
levels. It appears that V-ATPase inhibition enhances the LPS- or
LPS/INFc-induced response of macrophages for TNFa expression,
seemingly by augmenting LPS-evoked NFjB activation and ROS
formation. Finally, in a biochip tumor model, archazolid caused
reduced viability of MCF-7 breast cancer cells in co-culture with
M1, but not with M2 or in absence of macrophages. Our data
suggest that V-ATPase in classically-activated macrophages may
play a regulatory role in TNFa expression implying a therapeutic
Fig. 4. Effects of archazolid on TNFamRNA expression and degradation. (A) Macrophages, obtained from human bloodmonocytes after differentiation withM-CSF (25 ng/mL) for six
days, were pre-incubated with archazolid (100 nM), with or without dexamethasone (1 mM) or with vehicle (0.1% DMSO) for 1 h and then stimulated with LPS (100 ng/mL) for
8 h. Levels of TNFa protein in supernatants were analyzed by ELISA. Values are given as percentage of vehicle control (100%, DMSO), means + SEM; n = 3. *P < 0.05, **P < 0.01,
***P < 0.001 vs. the LPS-stimulated vehicle control. ANOVA + Bonferroni post hoc test. (B) Macrophages were pre-incubated with archazolid (100 nM), with archazolid
(100 nM) plus dexamethasone (1 mM) or with vehicle (0.1% DMSO) for 1 h and then stimulated with LPS (100 ng/mL). At the indicated time points mRNA was extracted and
determined by RT-qPCR. mRNA levels of TNFa were normalized against those of B2 M. Values shown are given as fold increase over control, means + SEM; n = 4. **P < 0.01,
***P < 0.001 vs. the unstimulated archazolid-treated sample at time point = 0 h. ANOVA + Tukey post hoc test. (C) Macrophages were stimulated with LPS (100 ng/mL) for 24 h
and incubated with archazolid (10 nM) or vehicle (0.1% DMSO) for 60 min. Transcription was stopped by actinomycin D (5 mg/mL) and macrophages were further incubated
for the indicated times. TNFa mRNA levels were determined by RT-qPCR. Values are given as percentage of control (100%), means + SEM; n = 4.
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Fig. 5. Effects of archazolid on activation of protein kinases and transcription factors involved in LPS Signaling pathways. (A) Macrophages, obtained from human blood
monocytes after differentiation with M-CSF (25 ng/mL) for six days, were first starved for 6 h and then pre-incubated with archazolid at the indicated concentrations,
LY294002 (10 mM), U0126 (3 mM), SB203580 (10 mM), SP600125 (10 mM), or vehicle (0.1% DMSO) for 30 min, and stimulated with LPS (100 ng/mL) for 15 min. Protein
phosphorylation or expression in cell lysates was analyzed by Western blotting; GAPDH or the respective unphosphorylated proteins were used for normalization.
Representative Western blots of 4 independent experiments are shown; data (densitometric analysis) are means + SEM; n = 4. (B, D) Macrophages were pre-incubated with
archazolid at the indicated concentrations, parthenolide (10 mM) or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 15min. (B) NFjB p65
phosphorylation (left panel) and expression (right panel) or (D) STAT-1 and -3 phosphorylation in cell lysates was analyzed by Western blotting; b-actin was used for
normalization. Representative Western blots of 4 independent experiments are shown; data (densitometric analysis) are means + SEM; n = 4 (C) Macrophages were seeded onto
coverslips, pre-incubated with archazolid (10 nM), or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 15min. Fixed and permeabilized cells were
stained with antibodies against IjB (Alexa Fluor 555, red) and NFjB p65 (Alexa Fluor 488, green), nuclei were stained with DAPI (blue). Representative immunofluorescence
images of three independent experiments are shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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potential for V-ATPase inhibitors to intervene with diseases where
increased TNFa levels might be beneficial, such as cancer.
V-ATPase is ubiquitously expressed in mammals and was stud-
ied in macrophages before, where it was shown to play roles in
lysosomal and cytoplasmic pH homeostasis [34,42,47,48]. Also in
our study, using archazolid for the first time as tool for investigat-
ing V-ATPase functions in macrophages, modulation of lysosomal
pH homeostasis was apparent, since archazolid caused elevation
of the pH in lysosomes. Of interest, in contrast to cancer cells that
overexpress V-ATPase [5,6] and where V-ATPase inhibition by arc-
hazolid induces cell death [18–20,22,49], the viability of human
monocyte-derived macrophages was not impaired in response to
V-ATPase interference by archazolid. Similarly, archazolid failed
to reduce the viability of human primary monocytes [23].
Pharmacological manipulation of V-ATPase in macrophages by
respective inhibitors such as bafilomycin A1 was reported before
[13,31,35,37,38,48,50]. Many of these studies focused on osteo-
clasts [51], macrophage cell lines [31] and macrophages from
rodents [37,39,48] and from other animals [52], but only few
studies addressed V-ATPase functions in human primary macro-
phages [40,50], and to the best of our knowledge there are no
reports that studied the role of V-ATPase on cytokine/chemokine
secretion of different macrophage phenotypes, such as M1 and
M2. Therefore, one significant novelty of our study is the consider-
ation of distinct human macrophage subtypes, that is, uncommit-
ted M(0), classically-activated M1-like and so-called ‘‘resolving”
M2-like macrophages that significantly differ in their bioactions
[53]. In fact, we show here that blocking V-ATPase upregulates
TNFa expression in classically-activated M1-like but not so in
M(0) and M2 subtypes.
A previous study demonstrated that bafilomycin A1 reduced the
amount of TNFa in LPS-activated alveolar macrophages from rab-
bits [11], and we recently found that archazolid suppresses TNFa
secretion from human monocytes [23]. These opposing results
versus our present data emphasize the need of distinguishing
between monocyte/macrophage subsets. Recently, a differential
role of V-ATPase in M1 and M2 was observed in phagosome pH
regulation [40]. In line with our data are previous findings showing
that V-ATPase suppresses NFjB and cytokine expression in LPS- or
INFc-activated macrophages [12]. It is noteworthy that among var-
ious cytokines and chemokines, solely TNFawas affected by archa-
zolid. The reason for this effect is unknown but selective elevation
of TNFa without concomitant increase of Il-1b via NFjB was also
observed in LPS-stimulated murine peritoneal macrophages
treated with the protein biosynthesis inhibitor cycloheximide
[54]. Of interest, V-ATPase might be of importance for polarization
towards M2 subsets. Thus, the lysosomal adaptor protein Lamtor1,
which forms an amino-acid sensing complex with V-ATPase, was
recently shown to be required for M2 polarization [55]. Moreover,
V-ATPase was reported to modulate macrophage polarization in
tumor-bearing mice [56], and inhibition of the V-ATPase a2 iso-
form in murine tumor cells delayed tumor growth by decreasing
M2-like TAMs in the tumor microenvironment [57].
In our study, targeting of V-ATPase in classically-activated
macrophages caused marked elevation of lysosomal pH, a typical
effect of V-ATPase inhibitors that block the proton-pumping activ-
ity of V-ATPase [16,41,42]. Therefore, it appeared possible that
lysosomal pH elevation is causative for increased TNFa expression.
However, the control tool compounds chloroquine and NH4Cl that
are known to increase lysosomal pH in macrophages [43,44], also
elevated the pH in lysosomes of MLPS comparable as archazolid,
but TNFa release was not increased but rather impaired. These
data suggest that simply elevation of lysosomal pH is probably
not the cause for increased TNFa expression by targeting V-ATPase.
Our detailed analysis of PKs and transcription factors that are
potentially involved in induction of TNFa expression [58] excluded
the MEK1/2 – ERK, MEK3/6 – p38 MAPK, and Akt pathway as well
as STAT-1 and -3 as signaling molecules since archazolid treatment
of MLPS did not increase phosphorylation/activation of these pro-
teins. Instead, phosphorylation of the p65 subunit of NFjB and
the nuclear translocation of NFjB p65 were markedly promoted
by archazolid, along with almost complete disappearance of the
NFjB chaperon IjB. Since NFjB regulates TNFa expression in
macrophages at the transcriptional level [59,60], we concluded
that interference with V-ATPase by archazolid leads to elevation
of TNFa mRNA expression. This is supported by the finding that
the glucocorticoid dexamethasone which diminishes NFjB levels
[59], completely prevented archazolid-induced TNFamRNA levels.
Note that besides NFjB also the SAPK/JNK was slightly activated by
archazolid, a signaling molecule controlling TNFa translation in
macrophages susceptible to dexamethasone [61]. Based on our
experiments with actinomycin D the stability of TNFa mRNA was
not affected by archazolid. Although TNFa is well known to aug-
ment NFjB signaling [62], it is unlikely that archazolid-induced
TNFa is causative for increased NFjB activation, as the later was
elevated already 15 min upon exposure to archazolid while TNFa
induction was delayed up to hours. Macrophages substantially pro-
duce ROS during bacterial killing to clear infections. In agreement
with increased ROS formation in murine macrophages exposed to
the V-ATPase inhibitors bafilomycin A1 or to concanamycin A
[31], archazolid enhanced LPS-induced ROS formation in human
macrophages, which was sensitive to the NDAPH oxidase inhibitor
DPI. Of interest, DPI also blocked archazolid-induced TNFa release
implying a requirement of ROS in this respect. In fact, ROS produc-
tion was shown to be closely linked to NFjB and SAPK/JNK activity
[45].
In summary, we showed that pharmacological targeting of
V-ATPase has phenotype-specific consequences for human macro-
phage functions. Substantial secretion of TNFa is a hallmark of
activated macrophages which is increased by V-ATPase inhibition.
Although TNFa is a potent pro-inflammatory cytokine that con-
tributes to excessive and unresolved inflammation, controlled
temporal and spatial elevation of TNFamay be beneficial in cancer
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Fig. 6. Archazolid elevates ROS formation in LPS signaling macrophages; effects of
ROS and NFjB inhibitors on archazolid-induced TNFa release. (A) Macrophages,
obtained from human blood monocytes after differentiation with M-CSF (25 ng/mL)
for six days, were pre-incubated with archazolid at the indicated concentrations,
DPI (5 mM), or with vehicle (0.1% DMSO) for 30 min and stimulated with LPS
(100 ng/mL) for 24 h. Fluorescence of the oxidised 20 ,70-dichlorofluorescin diacetate
(5 mg/mL) was measured at an excitation wavelength of 485 nm and an emission
wavelength of 535 nm. Values shown are percentages of vehicle control, means
+ SEM; n = 4. *P < 0.05, ***P < 0.001 vs. the LPS-stimulated vehicle control (100%,
DMSO); ##P < 0.01 vs. cells treated with LPS plus 10 nM archazolid. (B) Macro-
phages were pre-incubated with DPI (5 mM), parthenolide (10 mM, parth) or vehicle
(0.1% DMSO) for 15 min. Then, cells were treated with vehicle or archazolid
(30 nM), and after another 15 min, cells were treated with LPS (100 ng/mL) for 24 h.
TNFa in the supernatants was analyzed by ELISA. Values shown are percentages of
LPS-stimulated controls (=100%), means + SEM. ***P < 0.001 vs. LPS plus vehicle
(DMSO); ###P < 0.001 vs. cells treated with LPS plus archazolid. ANOVA + Tukey
post hoc test.
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treatment. In fact, attempts have been made to stimulate macro-
phages for higher TNFa production, for example by TLR-9 activa-
tors and CpG oligodeoxynucleotides [63,64] in order to promote
immune reactions against the tumor. Our results from the biochip
tumor model support anti-tumoral properties of archazolid in
combination with M1 but not with M2. Together, V-ATPase inhibi-
tors may have the appeal to act at least in two ways that could syn-
ergize in cancer therapy: (i) direct anti-tumoral effects against
susceptible cancer cells and (ii) beneficial impact against tumors
by phenotype-specific manipulation of macrophages in the tumor
microenvironment.
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Vacuolar (H+)-ATPase Critically Regulates Specialized
Proresolving Mediator Pathways in Human M2-like
Monocyte-Derived Macrophages and Has a Crucial Role
in Resolution of Inflammation
Zhigang Rao,* Simona Pace,* Paul M. Jordan,* Rossella Bilancia,† Fabiana Troisi,*
Friedemann Börner,* Nico Andreas,‡ Thomas Kamradt,‡ Dirk Menche,x Antonietta Rossi,†
Charles N. Serhan,{ Jana Gerstmeier,* and Oliver Werz*
Alternative (M2)-polarized macrophages possess high capacities to produce specialized proresolving mediators (SPM; i.e., resolvins,
protectins, and maresins) that play key roles in resolution of inflammation and tissue regeneration. Vacuolar (H+)-ATPase
(V-ATPase) is fundamental in inflammatory cytokine trafficking and secretion and was implicated in macrophage polarization
toward the M2 phenotype, but its role in SPM production and lipid mediator biosynthesis in general is elusive. In this study, we
show that V-ATPase activity is required for the induction of SPM-biosynthetic pathways in human M2-like monocyte-derived
macrophages (MDM) and consequently for resolution of inflammation. Blockade of V-ATPase by archazolid during IL-4–induced
human M2 polarization abrogated 15-lipoxygenase-1 expression and prevented the related biosynthesis of SPM in response to
pathogenic Escherichia coli, assessed by targeted liquid chromatography–tandem mass spectrometry–based metabololipidomics.
In classically activated proinflammatory M1-like MDM, however, the biosynthetic machinery for lipid mediator formation was
independent of V-ATPase activity. Targeting V-ATPase in M2 influenced neither IL-4–triggered JAK/STAT6 nor the mTOR complex
1 signaling but strongly suppressed the ERK-1/2 pathway. Accordingly, the ERK-1/2 pathway contributes to 15-lipoxygenase-1
expression and SPM formation in M2-like MDM. Targeting V-ATPase in vivo delayed resolution of zymosan-induced murine
peritonitis accompanied by decreased SPM levels without affecting proinflammatory leukotrienes or PGs. Together, our data propose
that V-ATPase regulates 15-lipoxygenase-1 expression and consequent SPM biosynthesis involving ERK-1/2 during M2 polarization,
implying a crucial role for V-ATPase in the resolution of inflammation. The Journal of Immunology, 2019, 203: 000–000.
M
acrophages are innate immune cells with marked
plasticity that, depending on their phenotype, promote
acute inflammation and host defense but also can
support the resolution of inflammation and the return to homeo-
stasis (1–3). Polarization of macrophages toward proinflammatory
M1-like and proresolving M2-like phenotypes is governed by
epigenetic and cell survival pathways, tissue microenvironment,
and extrinsic factors like microbial products and secreted cyto-
kines (3). CD4+ T cell subtype-derived cytokines determine
macrophage polarization, in which the M1 phenotype is obtained
by exposure to TH1-related IFN-g, particularly in the presence of
the TLR agonist LPS, whereas the M2 subtype is achieved upon
exposure to TH2-derived IL-4 or IL-13 (3, 4).
One hallmark characteristic of the opposing functions of M1 and
M2 is their differential lipid mediator (LM) profile that they
produce, due to their subtype-specific expression of LM-biosynthetic
enzymes that distinguish their proinflammatory or proresolv-
ing phenotypes (1, 5, 6). Whereas M1 are characterized by
marked expression of proinflammatory 5-lipoxygenase (LOX)/
5-LOX–activating protein (FLAP), and cyclooxygenase (COX)
pathways with substantial leukotriene (LT)B4 and PGE2 produc-
tion, the LM profile of M2 is dominated by the 15-LOX-1 pathway
along with strong biosynthesis of specialized proresolving medi-
ators (SPM) (6). These SPM encompass a novel superfamily of
highly potent bioactive LM, including lipoxins (LX), resolvins
(Rv), maresins (MaR), and protectins (PD), that terminate
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inflammation and promote tissue regeneration (7, 8). Accumu-
lating evidence suggests that the ability of M2 to generate SPM
critically determines their inflammation-resolving features (9).
However, the signaling pathways involved in SPM biosynthesis
during M2 polarization are incompletely understood and remain to
be elucidated.
In this article, we show that the vacuolar (H+)-ATPase (V-ATPase)
plays a crucial role in the induction of SPM–biosynthetic path-
ways during polarization of monocyte-derived macrophages
(MDM) to the M2 phenotype. V-ATPases are ATP-dependent
proton-translocating macromolecular complexes that acidify
lysosomes, endosomes, Golgi apparatus, and certain secretory
granules in eukaryotic cells and participate in cellular pH ho-
meostasis, receptor-mediated endocytosis, virus and toxin entry,
intracellular trafficking, and protein degradation and processing
(10). In macrophages, V-ATPase regulates lysosomal and cyto-
plasmic pH homeostasis with consequences for reactive oxygen
species formation, bactericidal activity, and lysosomal enzyme
secretion (11–13). However, little is known about the role of
V-ATPase in either LM biosynthesis or the polarization of human
macrophages. V-ATPase was shown to participate at M2 polari-
zation in mice, but SPM biosynthesis or expression of 15-LOX-1
was not addressed (14). For human polarized M1 and M2, con-
trasting phagosome pH regulation and maturation related to
V-ATPase was demonstrated (15), and targeting of V-ATPase
during polarization of human MDM elevated TNF-a release and
ROS formation in M1, but not in M2 (16). Hence, V-ATPase might
impact human M1/M2 polarization, but whether V-ATPase is in-
volved in the regulation of LM-biosynthetic pathways related to
inflammation and its resolution is unknown. Therefore, we here
aimed to reveal the role of V-ATPase in the induction of
phenotype-specific profiles of LM with proinflammatory and
proresolving properties during human MDM polarization. Our
results show that V-ATPase regulates 15-LOX-1 expression and
consequent SPM biosynthesis in an ERK-1/2-dependent fashion
during acquiring an M2 phenotype and thus imply critical roles of
this signaling pathway in the resolution of inflammation.
Materials and Methods
Materials
Deuterated and nondeuterated LM standards for ultra-performance liquid
chromatography–tandem mass spectrometry (UPLC–MS-MS) quantification
were purchased from Cayman Chemical/Biomol (Hamburg, Germany).
Archazolid A (ArchA) was isolated from Archangium gephyra as previously
described (17). Bafilomycin A1 was obtained from Sigma-Aldrich (Tauf-
kirchen, Germany), CP-690,550 and GSK-2033 were obtained from Tocris
Bioscience (Bristol, U.K.), JQ-1 was from AdooQ Bioscience (Irvine, CA),
LY294002 was from Cytoskeleton (Denver, CO), skepinone-L and Torin 1
were from Cayman Chemical (Ann Arbor, MI), and U0126 was from Enzo
Life Sciences (Farmingdale, NY). AS1517499 and all other reagents were
obtained from Sigma-Aldrich unless mentioned otherwise.
Animals
Male CD-1 mice (33–39 g, 6–8 wk; Charles River Laboratories, Calco,
Italy) were housed in a controlled environment (21 6 2˚C) and provided
with standard rodent chow and water. Animals were allowed to acclimate
for 4 d prior to experiments and were subjected to a 12 h light/12 h dark
schedule. Mice were randomly assigned for the experiments, which were
conducted during the light phase. The experimental procedures were ap-
proved by the Italian Ministry according to International and National
law and policies (European Union Directive 2010/63/EU and Italian DL
26/2014 for animal experiments.
Cell isolation and polarization of MDM
Leukocyte concentrates from freshly withdrawn peripheral blood of male
and female healthy adult human donors (age 18–65 y) were provided by the
Institute of Transfusion Medicine at the University Hospital Jena, Jena,
Germany. The experimental protocol was approved by the ethical com-
mittee of the University Hospital Jena. All methods were performed in
accordance with the relevant guidelines and regulations. PBMC were
separated using dextran sedimentation, followed by centrifugation
on lymphocyte separation medium (Histopaque-1077; Sigma-Aldrich).
PBMC were seeded in RPMI 1640 (Sigma-Aldrich) containing 10% (v/v)
heat-inactivated FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin in
cell culture flasks (Greiner Bio-One, Frickenhausen, Germany) for 1.5 h at
37˚C and 5% CO2 for adherence of monocytes. For differentiation of
monocytes to MDM and polarization toward M1 and M2, published criteria
were used (4). M1 were generated by incubating monocytes with 20 ng/ml
GM-CSF (PeproTech, Hamburg, Germany) for 6 d in RPMI 1640 supple-
mented with 10% FCS, 2 mmol/L glutamine (Biochrom/Merck, Berlin,
Germany), and penicillin–streptomycin (Biochrom/Merck), followed by
treatment with 100 ng/ml LPS and 20 ng/ml INF-g (PeproTech). M2 were
generated by incubating monocytes with 20 ng/ml M-CSF (PeproTech) for
6 d, followed by treatment with 20 ng/ml IL-4 (PeproTech). Routinely, cells
were polarized for 48 h unless stated otherwise. ArchA (30 nM) and other
inhibitors were added 15 min prior to addition of polarization agents (INF-g,
LPS, IL-4) unless mentioned otherwise.
Incubation of MDM for LM formation and
LM metabololipidomics
MDM (2 3 106/ml) were incubated in PBS containing 1 mM CaCl2. To
evoke LM biosynthesis pathogenic Escherichia coli (serotype O6:K2:H1,
ratio 1:50) was added for 180 min at 37˚C. The supernatants were then
transferred to 2 ml of ice-cold methanol containing 10 ml of deuterium-
labeled internal standards (200 nM d8-5S-HETE, d4-LTB4, d5-LXA4,
d5-RvD2, d4-PGE2 and 10 mM d8–arachidonic acid [AA]) to facilitate
quantification and sample recovery. Sample preparation was conducted by
adapting published criteria (6). In brief, samples were kept at 220˚C for
60 min to allow protein precipitation. After centrifugation (1200 3 g, 4˚C,
10 min), 8 ml acidified H2O was added (final pH = 3.5), and samples were
subjected to solid phase extraction. Solid phase cartridges (Sep-Pak Vac
6cc 500 mg/6 ml C18; Waters, Milford, MA) were equilibrated with 6 ml
methanol and 2 ml H2O before samples were loaded onto columns. After
washing with 6 ml H2O and additional 6 ml n-hexane, LM were eluted
with 6 ml methyl formate. Finally, the samples were brought to dryness
using an evaporation system (TurboVap LV; Biotage, Uppsala, Sweden)
and resuspended in 100 ml methanol–water (50/50, v/v) for UPLC–MS-
MS automated injections. LM profiling was analyzed with an Acquity
UPLC system (Waters) and a QTRAP 5500 Mass Spectrometer (AB Sciex,
Darmstadt, Germany) equipped with a Turbo V Source and electrospray
ionization. LM were eluted using an Acquity UPLC BEH C18 column
(1.7 mm, 2.1 3 100 mm; Waters, Eschborn, Germany) at 50˚C with a flow
rate of 0.3 ml/min and a mobile phase consisting of methanol–water–acetic
acid of 42:58:0.01 (v/v/v) that was ramped to 86:14:0.01 (v/v/v) over 12.5
min and then to 98:2:0.01 (v/v/v) for 3 min. The QTrap 5500 was operated
in negative ionization mode using scheduled multiple reaction monitoring
coupled with information-dependent acquisition. The scheduled multiple
reaction monitoring window was 60 s, optimized LM parameters (collision
energy, entrance potential, declustering potential, collision cell exit po-
tential) were adopted (18), and the curtain gas pressure was set to 35 c.
The retention time and at least six diagnostic ions for each LM were
confirmed by means of an external standard (Cayman Chemical/Biomol).
Quantification was achieved by calibration curves for each LM.
SDS-PAGE and Western blot
Cell lysates of MDM, corresponding to 2 3 106 cells, were separated on
8% (for cPLA2-a), 10% (for 5-LOX, 15-LOX-1, 15-LOX-2, COX-1, COX-
2, STAT6, phospho-STAT6, Akt, phospho-Akt, p70S6K, phospho-p70S6K,
cRaf, phospho-cRaf, MEK, phospho-MEK, ERK-1/2, phospho-ERK-1/2,
p38 MAPK, phospho-p38 MAPK, c-Myc, b-actin, and GAPDH), and 16%
(for FLAP and late endosomal and lysosomal adaptor and MAPK and
mTOR activator 1 [Lamtor1]) polyacrylamide gels and blotted onto
nitrocellulose membranes (Amersham Protran supported 0.45 mm nitro-
cellulose; GE Healthcare, Freiburg, Germany). The membranes were in-
cubated with the following primary Abs: rabbit polyclonal anti-cPLA2-a,
1:1000 (2832S; Cell Signaling Technology); rabbit polyclonal anti-5-LOX,
1:1000 (to a peptide with the C-terminal 12 aa of 5-LOX: CSPDRIPNSVA;
kindly provided by Dr. M. E. Newcomer, Louisiana State University, Baton
Rouge, LA); mouse monoclonal anti-15-LOX-1, 1:500 (ab119774; Abcam,
Cambridge, U.K.); rabbit polyclonal anti-15-LOX-2, 1:500 (ab23691;
Abcam); rabbit polyclonal anti-COX-1, 1:1000 (4841S; Cell Signaling
Technology); rabbit polyclonal anti-COX-2, 1:1000 (4842S; Cell Signaling
Technology); mouse polyclonal anti-STAT6, 1:1000 (ab88540; Abcam);
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rabbit polyclonal anti–phospho-STAT6 (Tyr641), 1:1000 (ab28829; Abcam);
mouse monoclonal anti-Akt, 1:1000 (2920; Cell Signaling Technology);
rabbit polyclonal anti-phospho-Akt, 1:1000 (9271S; Cell Signaling Tech-
nology); rabbit monoclonal anti-p70S6K, 1:1000 (2708T; Cell Signaling
Technology); mouse monoclonal anti–phospho-p70S6K (Thr389)
1:1000 (9206S; Cell Signaling Technology); rabbit polyclonal anti-
MEK1/2, 1:1000 (9122; Cell Signaling Technology); rabbit polyclonal
anti–phospho-MEK1/2 (Ser217/Ser221), 1:1000 (9121S; Cell Signaling
Technology); rabbit monoclonal anti-ERK1/2, 1:1000 (4695S; Cell Signal-
ing Technology); mouse monoclonal anti–phospho-ERK1/2 (Thr202/
Tyr204), 1:1000 (9106; Cell Signaling Technology); rabbit monoclo-
nal anti-p38 MAPK, 1:1000 (8690S; Cell Signaling Technology);
rabbit polyclonal anti–phospho-p38 MAPK (Thr180/Tyr182), 1:1000
(9211S; Cell Signaling Technology); rabbit monoclonal anti-cMyc,
1:1000 (5605S; Cell Signaling Technology); rabbit polyclonal anti-
FLAP, 1:1000 (ab85227; Abcam); rabbit monoclonal anti-Lamtor1
1:1000 (8975T; Cell Signaling Technology); mouse monoclonal anti-
b-actin, 1:1000 (3700S; Cell Signaling); rabbit polyclonal anti–b-actin,
1:1000 (4967S; Cell Signaling Technology) and rabbit monoclonal anti-
GAPDH, 1:1000 (5174S; Cell Signaling). Immunoreactive bands were
stained with IRDye 800CW Goat anti-Mouse IgG (H+L), 1:10,000
(926-32210; LI-COR Biosciences, Lincoln, NE), IRDye 800CW Goat
anti-Rabbit IgG (H+L), 1:15,000 (926 32211; LI-COR Biosciences)
and/or IRDye 680LT Goat anti-Mouse IgG (H+L), 1:40,000 (926-
68020; LI-COR Biosciences), and visualized by an Odyssey infrared
imager (LI-COR Biosciences). Data from densitometric analysis were
background corrected.
Determination of cytokine levels
UnpolarizedMDMwere treated with ArchA (30 nM) or vehicle (0.1%DMSO)
30 min before cells were polarized to M1 or M2 for 48 h. For measurement of
extracellular cytokine levels, supernatants were collected by centrifu-
gation (20003 g, 4˚C, 10 min). The cytokines IL-6, IL-10, and TNF-a were
analyzed by in-house–made ELISA kits (R&D Systems, Bio-Techne).
Flow cytometry
Fluorescent staining for flow cytometric analysis of M1 or M2 was per-
formed in FACS buffer (PBS with 0.5% BSA, 2 mM EDTA, and 0.1%
sodium azide). MDM were treated either with vehicle or 30 nM ArchA
during 48 h polarization. Nonspecific Ab binding was blocked by using
mouse serum for 10 min at 4˚C prior Ab staining. Subsequently, MDM
were stained with fluorochrome-labeled Ab mixtures at 4˚C for 20 min.
The following Abs were used: FITC anti-human CD14 (2 mg/test, clone
M5E2; BioLegend, San Diego, CA), PE anti-human CD54 (1 mg/test,
clone HA58; eBioscience, San Diego, CA), allochycocyanin-H7 anti-
human CD80 (0.25 mg/test, clone L307.4; BD Bioscience), PE-Cy7 anti-
human CD163 (2 mg/test, clone RM3/1; BioLegend), PerCP-eFluor710
anti-human CD206 (0.06 mg/test, clone 19.2; eBioscience). Upon stain-
ing, MDM (M1 or M2) were analyzed using a FACS Canto Plus flow
cytometer (BD Bioscience), and data analyzed using FlowJo X Software
(BD Bioscience).
Determination of cell viability
The viability of MDM was assessed by MTT assay as described (16).
Briefly, MDM after 6 d of differentiation of monocytes were preincubated
with test compounds for 15 min at 37˚C (5% CO2), polarization agents
were added, and cells were incubated for 48 h. Staurosporine (1 mM), a
pan-kinase inhibitor and inducer of apoptosis, was used as positive control.
MTT solution was added, and cells were further incubated for 4 h and
lysed in a buffer containing 10% (w/v) SDS.
Immunofluorescence microscopy
MDM after 6 d of differentiation of monocytes were pretreated with ArchA
(30 nM) for 30 min before polarization for 48 h to M1 andM2, and 106 cells
were seeded onto glass coverslips. Lysotracker (1:100 dilution; Invitrogen,
Thermo Fisher Scientific) was added to the cells for 1 h at 37˚C. The
fluorescence was visualized with a Zeiss Axio Observer.Z1 inverted mi-
croscope (Carl Zeiss, Jena, Germany) and an LCI Plan-Neofluar 633/1.3
Imm Corr DIC M27 objective. Images were taken with an AxioCam MR3
camera and were acquired, cut, linearly adjusted in the overall brightness
and contrast, and exported by the AxioVision 4.8 software (Carl Zeiss).
Zymosan-induced peritonitis in mice
For the zymosan-induced peritonitis, mice (n = 6 per experimental group)
received ArchA (1 mg/kg) or vehicle (0.5 ml of 0.9% saline solution
containing 2% DMSO) i.p., 60 min prior to peritonitis induction by zy-
mosan, as previously described (19). Zymosan (Sigma-Aldrich) was pre-
pared as a final suspension (2 mg/ml) in 0.9% (w/v) saline and injected i.p.
(0.5 ml), followed by a peritoneal lavage with 3 ml of cold PBS. Cells in
the inflammatory exudates were immediately counted (dilution 1:10) by
using a Bürker chamber and vital trypan blue staining, and then samples
were centrifuged (18,000 3 g, 5 min, 4˚C). The blood (∼0.7–0.9 ml) was
collected by intracardiac puncture using citrate as anticoagulant, and
plasma was obtained by centrifugation at 800 3 g at 4˚C for 10 min. LM
levels in the supernatants of peritoneal exudates as well as in the plasma
were assessed by UPLC–MS-MS analyses as described above (LM
metabololipidomics).
Statistical analyses
Results are expressed as mean 6 SEM of n observations, where n repre-
sents the number of experiments with separate donors performed on dif-
ferent days, or the number of animals per group (n = 6), as indicated.
Analyses of data were conducted using GraphPad Prism 7 software
(San Diego, CA). LM data were log transformed for statistical analysis
and analyzed by paired t test. For multiple comparisons, ANOVA with
Bonferroni or Dunnett post hoc tests were applied as indicated. Two-tailed
t test was used for comparison of two groups. The criterion for statistically
significant is p , 0.05.
Results
V-ATPase activity is essential for SPM biosynthesis and
15-LOX-1 expression in human M2-like MDM
To study the requirement of V-ATPase activity during polarization
of MDM toward proinflammatory M1- and proresolving M2-like
phenotypes with focus on their differential LM profiles they
produce, we took advantage of the selective V-ATPase inhibitor
ArchA (17). Human monocytes were differentiated for 6 d with
GM-CSF toward MGM-CSF MDM and with M-CSF toward MM-CSF
MDM. Although these MDM are not primary (alveolar or peri-
toneal) macrophages, for which others have reported LM forma-
tion before (20, 21), they are suitable for studying the induction of
LM pathways during the acquirement of different human macro-
phage phenotypes (5, 6). ArchA (30 nM) was added to MDM 30
min prior to 48 h polarization of MGM-CSF with LPS plus INFg to
M1 or of MM-CSF with IL-4 to M2, according to our previous
report (6). To study the LM profiles by targeted LM metab-
ololipidomics using UPLC–MS-MS, the polarized MDM were
incubated with and without pathogenic E. coli (serotype
O6:K2:H1, ratio 1:50) for 180 min (6). Upon exposure to E. coli,
M1 and M2 produced opposing LM profiles that clearly distin-
guish their proinflammatory and proresolving phenotypes: M1
mainly formed COX-derived PGE2 and 5-LOX/FLAP–derived
LTs/5-hydroxyeicosatatraenoic acid (5-HETE), whereas M2 gen-
erated SPM (e.g., RvD5, MaR1, PD1, and RvE3), their precur-
sors (i.e., 17-hydroxydocosahexaenoic acid [HDHA], 14-HDHA,
7-HDHA), and 15-LOX-1–derived products (e.g., 15-HETE,
15-HEPE) with low PG and LT/5-HETE levels (Fig. 1A–C,
Supplemental Table I). During M1 polarization, ArchA had little
impact on LM biosynthesis and caused no significant reduction in
LOX products but slightly elevated PGD2 and TxB2 levels. By
contrast in M2, inhibition of V-ATPase completely prevented the
formation of all SPM, their precursors, and 15-LOX-1–derived
mediators (Fig. 1B, 1C, Supplemental Table I). Although some
monohydroxy 5-LOX products were lowered, formation of LTB4
was not affected in M2. Moreover, solely in M2, the release of
AA, eicosapentaenoic acid, and DHA was significantly impaired
because of ArchA treatment (Fig. 1B, Supplemental Table I). In
agreement with our previous work (16) ArchA increased the ly-
sosomal pH during M1 and M2 polarization (Fig. 1D), assuring
that V-ATPase activity was blocked in both macrophage pheno-
types. To confirm on-target effects of ArchA, we used the struc-
turally unrelated V-ATPase inhibitor bafilomycin that caused the
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FIGURE 1. Targeting of V-ATPase suppresses SPM formation in human M2. (A) Schematic representation of the investigated LM-biosynthetic pathways
involving COX, 5-LOX/FLAP, or 15-LOX-1, leading to respective LM. (B–D) Human monocytes were differentiated by GM-CSF or M-CSF (20 ng/ml,
each) for 6 d to get MGM-CSF or MM-CSF MDM, respectively. After pretreatment with 30 nM ArchA or vehicle (veh., 0.1% DMSO) for 30 min, the MGM-CSF
were polarized for 48 h with 100 ng/ml LPS plus 20 ng/ml IFN-g to get M1 whereas the MM-CSF were polarized with 20 ng/ml IL-4 to get M2. (B) M1 and
M2 (23 106, each) were incubated for 180 min with pathogenic E. coli (serotype O6:K2:H1, ratio 1:50) at 37˚C. Biosynthesized LM were isolated from the
supernatants by SPE and analyzed by UPLC–MS-MS; detection limit: 0.5 pg. Results are given as means 6 SEM (n = 6 separate donors). Data were log-
transformed for statistical analysis and analyzed by paired t test. *p , 0.05, **p , 0.01, ***p , 0.001, ArchA versus vehicle. (C) Amounts of produced
RvD5, LTB4, and PGE2 are shown as pie chart in pg/23 10
6 cells (i.e., M1, M2, and M2 plus ArchA, as indicated). (D) Acidic vesicles (red) in M1 and M2
were stained with the LysoTracker probe for 1 h. Fluorescence microscopy pictures are representative of four independent experiments. Scale bar, 20 mm,
contrast: differential interference contrast. The fluorescence was visualized with a Zeiss Axio Observer.Z1 microscope and an LCI Plan-Neofluar 633/1.3
Imm Corr DIC M27 objective or a Plan-Apochromat 1003/1.40 Oil DIC M27 objective. Images were taken with an AxioCam MR3 camera and were
acquired, cut, linearly adjusted in the overall brightness and contrast, and exported to TIF by the AxioVision 4.8 software.
4 V-ATPASE REGULATES PRORESOLVING LIPID MEDIATORS
60
same pattern of LM modulation as ArchA, that is, strongly im-
paired formation of SPM and their precursors with minor effects
on 5-LOX and COX products in M2, but rather increased PG in
M1 (Supplemental Fig. 1). MTT assays revealed no detrimental
effects of ArchA and bafilomycin (up to 100 nM, each) on the
viability of MDM during 48 h polarization (not shown).
In line with lower SPM, the protein levels of 15-LOX-1 were
strongly impaired in M2 by ArchA (Fig. 2A). In contrast, 15-LOX-
2 as well as 5-LOX and FLAP were not markedly affected, neither
in M1 nor in M2. COX-1 protein levels were moderately de-
creased in M2, whereas COX-2 was elevated in M1 by ArchA.
Finally, in M2, ArchA downregulated cPLA2 protein expression,
but not so in M1. Again, comparable effects were obtained with
bafilomycin instead of ArchA, that is, impaired 15-LOX-1 levels
in M2 and elevated COX-2 in M1 without change of 5-LOX in
either phenotype (Supplemental Fig. 1). Note that in control ex-
periments, addition of ArchA to polarized M1 or M2 and subse-
quent exposure to E. coli for 180 min did not affect biosynthesis of
LM formation or the expression of respective biosynthetic en-
zymes (not shown). Together, V-ATPase activity is critically re-
quired during M2 polarization for 15-LOX-1 protein induction,
accompanied by increased levels of cPLA2 and COX-1 protein,
but with minor importance for expression of LM pathways during
M1 polarization.
To investigate if V-ATPase inhibition by ArchA would com-
promise M2 polarization per se, flow cytometry analysis of the
phenotype-characteristic surface markers CD54 and CD80 for M1,
and CD163 and CD206 for M2, was performed. In M2, ArchA had
no effects on CD206 and CD163 expression, excluding a general
influence on M2 polarization. However, ArchA suppressed the
release of the M2-related protein IL-10 in M2 but not in M1
(Fig. 2C). In M1, considerable modulation of any macrophage
phenotype markers by ArchAwas not evident either (Fig. 2B), and
M1-like cytokines such as TNF-a and IL-6 were not impaired
(Fig. 2C). In conclusion, whereas classical human macrophage
phenotype markers are hardly affected by V-ATPase inhibition
during polarization, the LM profile in M2 with high SPM levels
that distinguishes this proresolving phenotype from the proin-
flammatory M1 subset is strikingly compromised, suggesting a
critical role of V-ATPase in the induction of the SPM-biosynthetic
pathway.
Temporal modulation of LM-biosynthetic pathways depending
on V-ATPase activity
Previous data show that the expression of the LM-biosynthetic
enzymes COX-2 and 15-LOX-1 are temporally modulated dur-
ing macrophage polarization (6). Thus, we studied manipulation of
LM-biosynthetic enzyme expression by ArchA during M1/M2
polarization in more detail. In M2, the protein levels of 15-
LOX-1 and COX-1 continuously increased during polarization up
to 72 h, whereas 5-LOX slightly decreased, and cPLA2 peaked at
24 h and then declined (Fig. 3A). ArchA did not affect the ex-
pression of these enzymes at 6 h but prevented the subsequent
polarization-induced increase in the expression of 15-LOX-1,
COX-1, and cPLA2 starting at 24 up to 72 h (Fig. 3A). In M1,
COX-2 was strongly induced after 6 h with slightly increased
cPLA2 levels followed by a continuous decline of both proteins up
to 72 h; COX-1 levels were unchanged and 15-LOX-1 protein was
not detectable in M1 [Fig. 3B, see also (6)]. In contrast to M2,
ArchA failed to decrease COX-1 and cPLA2 levels in M1, and
COX-2 levels were rather increased at 24–48 h (Fig. 3B). Like in
M2, 5-LOX expression in M1 was unaffected by ArchA. Control
experiments assessing V-ATPase protein expression (using Abs
against V0 or V1 subunit) revealed continuous presence of the
protein during M1 and M2 polarization, without significant in-
fluences of ArchA (Fig. 3C, 3D).
Abrogation of 15-LOX-1 expression and SPM formation by
targeting V-ATPase is independent of the JAK/STAT6 and the
PI3K/Akt–mTOR complex 1–liver X receptor pathways
Induction of M2 polarization and 15-LOX-1 expression is mediated
by the JAK/STAT6 pathway that activates transcription of the human
ALOX15A gene (Fig. 4A) (22–24). We hypothesized that V-ATPase
activity could be required for JAK/STAT6–mediated 15-LOX-1
expression in IL-4–stimulated MDM. However, V-ATPase block-
age failed to abolish phosphorylation of STAT6 at Tyr641, and thus
its activation, upon 48 h of IL-4 treatment (Fig. 4B) or at other time
points (6, 24, or 72 h) during polarization (Fig. 4C). In contrast, the
JAK-3 inhibitor CP-690,550 (25), which in analogy to ArchA
blocked 15-LOX-1 (but not 5-LOX) expression (Fig. 4D) and thus
reduced SPM formation (Fig. 4E), abolished STAT6 phosphoryla-
tion in M2 (Fig. 4D), as expected. This confirms that the JAK/
STAT6 pathway regulates 15-LOX-1 expression and reveals its in-
volvement in SPM formation but excludes a role for V-ATPase in
JAK/STAT6-mediated 15-LOX-1 expression during M2 polariza-
tion. Although 5-LOX protein levels were unaffected by CP-
690,550 (Fig. 4D), 5-LOX product formation was slightly reduced
owing to JAK-3 inhibition (Fig. 4E).
IL-4 was also shown to induce M2 polarization via signaling
molecules including PI3K, Akt, mTOR complex 1 (mTORC1),
p70S6K, Lamtor1/V-ATPase complex, and liver X receptor (LXR)
stimulation (14, 26) (Fig. 5A). Therefore, V-ATPase might be
integrated in these downstream signaling pathways of IL-4 to
accomplish 15-LOX-1 expression and SPM formation. ArchA
impaired phosphorylation of Akt (PI3K substrate) and p70S6K
(mTORC1 substrate) in M2 (Fig. 5B, 5C), with minor or no effects
in M1, whereas expression of Lamtor1, the activator of mTORC1,
was not affected (Fig. 5B). In control experiments, inhibitors of
PI3K (i.e., LY294002) and of mTORC1 [i.e., Torin 1 (27)] re-
duced the phosphorylation of their substrates Akt and p70S6K,
respectively (Fig. 5D), without affecting the viability of M2 within
48 h (data not shown). However, in contrast to ArchA, neither the
PI3K inhibitor LY294002 nor the mTORC1 inhibitor Torin 1 pre-
vented 15-LOX-1 expression (Fig. 5E) or SPM formation (Fig. 5F)
in M2; also, the LXR antagonist GSK-2033 failed in this respect.
These data suggest that V-ATPase might be of importance for
PI3K/Akt and mTORC1 signaling, but these molecules as well as
LXR are dispensable for IL-4–induced 15-LOX-1 protein ex-
pression and SPM biosynthesis during M2 polarization.
15-LOX-1 expression and SPM formation in M2 involves
MEK/ERK-1/2 signaling
IL-4 activates the MEK/ERK-1/2 pathway (28), and a regulatory
role for ERK-1/2 in mediating 15-LOX-1 expression in monocytes
was shown (29). Thus, we speculated that the MEK/ERK-1/2
pathway is involved in 15-LOX-1 expression and SPM forma-
tion in M2 and that targeting of V-ATPase may suppress the MEK/
ERK-1/2 pathway (Fig. 6A). Preincubation with ArchA prior to
M2 polarization strongly impaired the phosphorylation of ERK-1/2
and of its upstream kinase MEK at 24, 48, and 72 h (Fig. 6B, 6C),
whereas phosphorylation of p38 MAPK was rather increased
(Supplemental Fig. 2). Use of NH4Cl, another tool to elevate the pH
in organelles, mimicked the effects of ArchA and suppressed ERK-
1/2 phosphorylation in M2 (Supplemental Fig. 3), as expected.
Noteworthy, in M1, phosphorylation of ERK-1/2 and MEK was not
affected by ArchA.
We next exploited the ERK-1/2 activation inhibitor U0126 (30)
to test if ERK-1/2 is required for IL-4–induced 15-LOX-1
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expression and SPM formation. Pretreatment with U0126 prior to
M2 polarization reduced ERK-1/2 phosphorylation as expected
and significantly prevented the expression of 15-LOX-1 without
affecting 5-LOX protein levels (Fig. 6D). In contrast, the p38
MAPK inhibitor skepinone-L (31) failed to influence 15-LOX-1
levels or LM biosynthesis (Supplemental Fig. 2). The transcription
FIGURE 2. Targeting of V-ATPase suppresses 15-LOX-1 expression in human M2. MGM-CSF and MM-CSF were pretreated with 30 nM ArchA or vehicle
(veh., 0.1% DMSO) for 30 min prior to polarization to M1 and M2 for 48 h. (A) Protein expression and densitometric analysis of 15-LOX-1, 15-LOX-2, cPLA2-
a, 5-LOX, FLAP, COX-1, and COX-2, normalized to b-actin. Western blots are shown as representatives and data are means 6 SEM (n = 4 separate donors).
*p , 0.05, **p , 0.01, ArchA versus vehicle analyzed by two-tailed t test. (B) Expression of surface macrophage polarization markers for M1 (CD54, CD80)
and M2 (CD206, CD163) analyzed by flow cytometry; representative pseudocolor dot plots from n = 3 separate donors; quantification is given as bar charts,
data are means6 SEM. Zombie Aqua Fixable viability kit (BioLegend) was used to assess live versus dead status. MDM were first gated using forward scatter
and side scatter and then gated on living cells by Zombie Aqua fixable staining. Living cells were gated on CD14 positive and then gated on specific M1 (CD80
and CD206) and M2 (CD163 and CD206) marker. (C) Effects of ArchA on cytokine release. Supernatants were analyzed for TNF-a, IL-6 and IL-10 by ELISA
and shown in pg/2 3 106 cells; means 6 SEM (n = 3 separate donors). *p , 0.05 compared with vehicle, two-tailed t test.
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factor c-Myc downstream of the MEK/ERK-1/2 pathway has been
shown to regulate 15-LOX-1 expression in macrophages (32), and
ArchA downregulated c-Myc in leukemic cells (33) (Fig. 6B).
Thus, we tested if the selective c-Myc inhibitor JQ-1 (34) would
suppress 15-LOX-1 protein levels (Fig. 6E). As expected, SPM
formation and 15-LOX-1-related LM were markedly impaired by
U0126 as well as by JQ-1, whereas PG and fatty acid release were
unaffected (Fig. 6F). Also, 5-LOX product formation was reduced
by U0126 (Fig. 6F) but not so 5-LOX protein expression (Fig.
6D). Finally, the STAT6 inhibitor AS1517499, used to reinforce
the link between STAT6 and 15-LOX-1, blocked phosphoryla-
tion of STAT6 and expression of 15-LOX-1 (but not 5-LOX)
and also ERK-1/2 phosphorylation was moderately inhibited
(Supplemental Fig. 3). Together, our data show that V-ATPase is
required for functional MEK/ERK-1/2 pathway to accomplish
15-LOX-1 expression and SPM formation during M2 polarization.
Targeting V-ATPase in vivo delays resolution and suppresses
SPM formation
To study the consequence of V-ATPase interference for SPM
biosynthesis and resolution of inflammation in vivo, we made
use of zymosan-induced peritonitis in mice (Fig. 7A), a well-
established model of self-limited acute inflammation (19, 35).
Application of ArchA (1 mg/kg, i.p., 1 h prior zymosan) caused
marked elevation of neutrophil numbers in the peritoneum in the
resolving phase 24 h postzymosan versus vehicle-treated mice,
reflecting continuation of inflammation, whereas the number of
neutrophils during the acute phase (4 h postzymosan) was hardly
FIGURE 3. Temporal modulation of LM-biosynthetic pathways by targeting V-ATPase. MGM-CSF and MM-CSF were pretreated with 30 nM ArchA or
vehicle (veh., 0.1% DMSO) for 30 min prior to polarization to M1 and M2 for the indicated periods (0–72 h). (A and B) Protein expression and densi-
tometric analysis of 15-LOX-1 (only for M2), COX-2 (only for M1), COX-1, 5-LOX, and cPLA2-a, normalized to b-actin in (A) M2 and (B) M1. (C and D)
V-ATPase protein expression during macrophage polarization was assessed by immunoblotting for ATP6V1B2 (V1 subunit), and ATP6V0D1 (V0 subunit)
in (C) M2 and (D) M1, and normalized to b-actin for densitometric analysis. Western blots are shown as representatives and results are given as means 6
SEM (n = 4 separate donors). *p , 0.05, **p , 0.01, ArchA versus vehicle determined by two-tailed t test.
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affected by ArchA (Fig. 7B). LM metabololipidomics of the exudates
of these mice revealed strongly reduced levels of the SPM RvD2,
RvD4, PD1, and LXA4 in ArchA-treated animals, and also RvD5 and
MaR1 levels tended to be lower (Fig. 7C). Moreover, all 15-LOX-1–
related SPM precursors (17-HDHA, 14-HDHA, 15-HETE, 15-HEPE,
12-HETE, 12-HEPE, 7-HDHA) were lower in exudates of mice that
received ArchA, whereas the levels of 5-LOX-derived LTB4 and
5-HETE as well as of COX-derived PGs were not different between
ArchA- and vehicle-treated groups (Fig. 7C). Similarly, the amounts
of various circulating SPM (e.g., RvD1, RvD5) and their precursors
in plasma were significantly lower 24 h post zymosan when mice
received ArchA, whereas PG and LTB4 were not reduced but rather
elevated (Fig. 7D). Collectively, targeting V-ATPase during inflam-
mation in vivo locally and systemically suppresses SPM biosynthesis
and delays resolution of inflammation.
Discussion
One of the hallmarks of host defense during infectious inflam-
mation is the engulfment of invaders by macrophages that transport
the invader to the phagosome, an acidic digestive compartment,
where the pathogen is degraded to regain homeostasis of the host.
Efficient phagosome maturation requires active V-ATPase upon
fusion with compartments of the endolysosomal pathway (11, 15).
Also, V-ATPase plays a fundamental role in cytokine trafficking
and secretion in inflammation (16, 36). However, the function of
V-ATPase in the biosynthesis of either proinflammatory or pro-
resolving LM and in resolution of inflammation has not been
reported yet.
In this study, our results reveal a novel and critical role for
V-ATPase in the biosynthesis of SPM in humanM2-likeMDMwith
potential consequences for resolution of inflammation. Alternative
FIGURE 4. Abrogation of 15-LOX-1 expression and SPM formation by targeting V-ATPase is independent of the JAK/STAT6 pathway in M2. (A)
Schematic draft of the JAK/STAT6 pathway in M2. (B and C) MGM-CSF and MM-CSF were pretreated with 30 nM ArchA or vehicle for 30 min prior to
polarization toward M2 for (B) 48 h or for (C) 0–72 h. Cell lysates were immunoblotted for phospho-STAT6, STAT6, and b-actin, and densitometric
analysis thereof was performed. Results are given as means 6 SEM (n = 4 separate donors). (D and E) MM-CSF were pretreated with the JAK-3 inhibitor
CP-690,550 (CP, 100 nM) for 30 min prior to polarization to M2 for 48 h. (D) Cell lysates were immunoblotted for phospho-STAT6, STAT6, 15-LOX-1,
5-LOX, and cPLA2-a, and normalized to b-actin for densitometric analysis. Results are given as means 6 SEM of n = 4 separate donors. *p , 0.05,
**p , 0.01, CP-690,550 versus vehicle; two-tailed t test. (E) Effects of CP-690,550 on LM biosynthesis in M2 that were incubated for 180 min with
pathogenic E. coli (serotype O6:K2:H1, ratio 1:50) at 37˚C. LM were isolated by SPE and analyzed by UPLC–MS-MS, detection limit: 0.5 pg. Results are
given as means 6 SEM of n = 5 separate donors. *p , 0.05, CP versus vehicle. Data were log transformed for statistical analysis, paired t test.
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activation of macrophages by IL-4 results in proresolving M2
phenotypes that are featured by high capacities to generate SPM
upon challenge with pathogenic bacteria (6) or during effer-
ocytosis of apoptotic neutrophils (1, 5). SPM actively terminate
inflammation and promote its resolution by inhibiting neutrophil
infiltration, sequestering proinflammatory cytokines, promoting
phagocytosis, and finally by clearance of apoptotic cells or cel-
lular debris (7, 8). Moreover, SPM accelerate tissue repair and
regeneration (37), typical features promoted by M2 macrophages.
Intriguingly, M2-derived SPM, in particular the maresins, switch
polarization of M1 toward the M2 phenotype (9). Our results from
a pharmacological approach of targeting V-ATPase by two
structurally different V-ATPase inhibitors (ArchA and bafilomy-
cin) provide evidences for a critical role of V-ATPase in the in-
duction of the expression of 15-LOX-1, the key enzyme in SPM
biosynthesis, which is specifically upregulated during polarization
toward M2 (6). Notably, the expression of 15-LOX-2 was not
impaired by V-ATPase inhibition, corroborating the specificity of
V-ATPase in regulating the 15-LOX-1 isoform. V-ATPase was
shown to be required for IL-4–induced murine M2 polarization,
but SPM biosynthesis or expression of 15-LOX-1 was not
addressed (14). Our results with mice demonstrate a role of
FIGURE 5. Abrogation of 15-LOX-1 expression and SPM formation by targeting V-ATPase is independent of the PI3K/Akt–mTORC1–LXR pathway in
M2. (A) Schematic draft of the PI3K/Akt–mTORC1–LXR pathway in M2. (B and C) MGM-CSF and MM-CSF were pretreated with 30 nM ArchA or vehicle
for 30 min prior to polarization to M1 and M2 (B) for 48 h or (C) for 0–72 h. Cell lysates were immunoblotted for phospho-Akt, Akt, phospho-p70S6K,
p70S6K, and Lamtor1 and normalized to b-actin for densitometric analysis. Data are given as means 6 SEM. n = 4 separate donors, two-tailed t test. *p ,
0.05, **p , 0.01, ArchA versus vehicle. (D) MM-CSF were pretreated with the PI3K inhibitor LY294002 (LY, 3 mM) or the mTORC1 inhibitor Torin 1 (Tor,
5 nM) for 30 min prior to polarization with IL-4 for 0, 15, and 30 min or (E) for 48 h, including also the LXR inhibitor GSK-2033 (GSK, 20 mM). Cell
lysates were immunoblotted for phospho-Akt, Akt, phospho-p70S6K, p70S6K, 15-LOX-1, and 5-LOX and normalized to b-actin for densitometric
analysis. (F) MM-CSF were pretreated for 30 min with LY (3 mM), Torin 1 (5 nM), and GSK (20 mM) prior to polarization for 48 h to M2, and then incubated
with E. coli (serotype O6:K2:H1, ratio 1:50) for 180 min at 37˚C for LM biosynthesis. Formed LM were isolated by SPE and analyzed by UPLC–MS-MS.
Results are given as percentage of vehicle control (= 100%), means 6 SEM (n = 4 separate donors).
The Journal of Immunology 9
65
V-ATPase in SPM biosynthesis also in vivo and implicate its ne-
cessity for resolution of inflammation, reflected by unhindered
neutrophil infiltration in ArchA-treated mice during peritonitis.
Note that besides 15-LOX-1 and SPM, other LM pathways such as
PGs and LTs were not affected by V-ATPase inhibition, neither in
murine peritonitis nor in human M1. Furthermore, classical M1
and M2 polarization markers or cell viability were not influenced
by V-ATPase inhibition and LM formation in the M1 phenotype;
where PGs and LTs dominate (5, 6), ArchA had little to no impact.
Instead, blocking V-ATPase in M1 increased COX-2 expres-
sion accompanied by elevated PG levels, in agreement with (16),
a tendency observed also in our present in vivo experiments.
Conclusively, V-ATPase is specifically required for induction of
15-LOX-1 and related SPM biosynthesis during M2 polarization and
thus may be key for ensuring effective resolution of inflammation.
However, 15-LOX-1 is a versatile enzyme, with roles not only in the
termination but also in the onset of inflammation (38) and has been
implicated in the pathogenesis of chronic inflammatory diseases,
particularly related to the airways (39, 40). The induction of 15-LOX-
1 expression by IL-4 in various cell types, including primary cultures
of human monocytes, strongly depends on STAT6 (22, 23, 29).
Therefore, interference with V-ATPase may prevent 15-LOX-1 in-
duction by suppression of STAT6 signaling. However, targeting
V-ATPase did neither influence STAT6 expression nor its phosphor-
ylation, suggesting the existence of a STAT6-independent signaling
route induced by IL-4 for 15-LOX-1 expression. Another prominent
FIGURE 6. 15-LOX-1 expression and SPM formation is accomplished by the MEK/ERK pathway in M2. (A) Schematic draft of the Raf–MEK–ERK-1/2
cascade. (B and C) MGM-CSF and MM-CSF were pretreated with 30 nM ArchA or vehicle for 30 min prior to polarization (B) for 48 h to M2 or (C) for a period
of 0–72 h to M2. Cell lysates were immunoblotted for phospho-ERK-1/2, ERK-1/2, phospho-MEK, MEK, and c-Myc and normalized to b-actin for
densitometric analysis. Data are means 6 SEM (n = 4 separate donors for 48 h and n = 3 separate donors for 0–72 h), two tailed t test. *p , 0.05, **p ,
0.01. (D–F) MM-CSF were pretreated with the ERK-1/2 activation inhibitor U0126 (3 mM) and the c-Myc inhibitor JQ-1 (100 nM) or vehicle for 30 min
prior to polarization toward M2 for 48 h. (D and E) Cell lysates were immunoblotted for phospho-ERK-1/2, ERK-1/2, MEK, 15-LOX-1, 5-LOX, phospho-
STAT6, and cMyc and normalized to b-actin for densitometric analysis. Data are means6 SEM (n = 4 separate donors), two tailed t test. *p, 0.05, **p,
0.01, ***p, 0.001. (F) Formed LM after incubation of polarized M2 with E. coli (serotype O6:K2:H1 ratio 1:50) for 180 min at 37˚C. LM were isolated by
SPE and analyzed by UPLC–MS-MS. Results are given as percentage of vehicle control (= 100%); means 6 SEM (n = 3 separate donors); data were log
transformed for statistical analysis. *p , 0.05, **p , 0.01, U0126 and JQ-1 versus vehicle. Data were log transformed for statistical analysis, paired t test.
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IL-4–induced pathway in mice that governs expression of classical
M2 signature genes such as arginase-1, the mannose receptor
(CD206), and IL-10, is the PI3K/Akt–mTORC1–LXR cascade in
which Lamtor1 forms a complex with active V-ATPase (14). In our
study using human MDM, ArchA inhibited phosphorylation of Akt
and of the mTORC1 substrate p70S6K in M2, but the expression of
Lamtor1, the target of mTORC1, was not affected. Moreover, inhi-
bition of PI3K, of mTORC1, or of LXR did not influence 15-LOX-1
protein levels and SPM formation, suggesting that this pathway is
negligible for the SPM-biosynthetic machinery in human M2.
FIGURE 7. Targeting of V-ATPase in vivo delays resolution and suppresses SPM formation in mice. (A) Male adult CD1 mice were treated i.p. with
ArchA (1 mg/kg) or vehicle 1 h before zymosan-induced peritonitis (1 mg, i.p.). Mice were sacrificed after 4 or 24 h with CO2, and peritoneal exudates were
collected by lavage with 3 ml of PBS, and blood was obtained by cardiac puncture. (B) Cell numbers in the peritoneal cavity after 4 and 24 h. (C) LM
profiles of exudates and (D) of plasma after 24 h ArchA treatment. The results are given in picogram per milliliter as means 6 SEM (n = 6 animals each
group). Data were log transformed for statistical analysis, two-tailed t test. *p , 0.05, **p , 0.01, ***p , 0.001, ArchA versus vehicle.
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Our results propose that the MEK/ERK-1/2 pathway mediates
IL-4–induced 15-LOX-1 expression during M2 polarization and
that targeting of V-ATPase prevents 15-LOX-1 induction by
blocking MEK/ERK-1/2 signaling. In fact, phosphorylation of
ERK-1/2 by MEK was shown to mediate IL-13–induced 15-LOX-
1 expression in human monocytes (22, 41). In our hands, the ERK-
1/2 activation inhibitor U0126 reduced 15-LOX-1 expression and
suppressed SPM biosynthesis, similar to V-ATPase inhibition. As
mentioned above, ArchA inhibited Akt phosphorylation, and in
fact, the PI3K/Akt cascade is known to activate ERK-1/2. Re-
cently, a direct interaction of phosphorylated PI3K, Akt, and ERK
with the subunit E of the V-ATPase V1 domain was reported in
cancer cells (42). Thus, the MEK/ERK-1/2 cascade appears to be
a focal point for cross-cascade regulation in M2 polarization in-
volving V-ATPase. Along these lines, the transcription factor
c-Myc downstream of the MEK/ERK-1/2 pathway was suppressed
by ArchA in leukemic cells (33) as well as in our hands in M2,
and the c-Myc inhibitor JQ-1 (32) abrogated 15-LOX-1 protein
expression and SPM formation. Conclusively, our results suggest
that induction of 15-LOX-1 in human M2-like MDM is accom-
plished by the MEK/ERK-1/2 pathway that requires V-ATPase
activity.
In addition to SPM and 15-LOX–derived precursors, 5-LOX
products were also reduced by either inhibition of V-ATPase,
JAK-3, or ERK-1/2, without impairing 5-LOX protein levels.
Cellular 5-LOX activity depends mainly on AA supply, FLAP,
Ca2+, and phosphorylations by MAPKAPK-2 and ERK-1/2 (43).
ArchA, CP-690,550, or U0126 reduced AA supply and ERK-1/2,
and possibly other processes required for substantial 5-LOX
product formation, without altering 5-LOX protein levels. More-
over, the ERK-1/2 pathway related to 5-LOX activation and LT
biosynthesis is subject of a sex dimorphism due to transient
modulation by testosterone in leukocytes (44), implying potential
sex differences also for ERK-1/2–mediated 15-LOX-1 regulation.
However, the lengthy monocyte/MDM culture conditions in sex
hormone-containing FCS (10%) may mask potential sex-dependent
modulation and was not explored in this study. Ongoing studies
with male and female mice indicate the existence of sex-biased
15-LOX regulation in macrophages in accordance with obser-
vations by others (45).
Genetic or pharmacological interference with V-ATPase has
been linked to defective wound healing events (46) in which
V-ATPase was necessary for the ERK-1/2–dependent transcrip-
tional activation of the repair response around the wound epider-
mis, and nonhealing chronic wounds display extracellular pH
gradients that disrupt epidermal repair (47). This supports our
hypothesis on a role of V-ATPase in resolution of inflammation,
especially by ensuring effective SPM biosynthesis, because SPMs
were shown to effectively increase tissue remodeling and regen-
eration together with superior wound healing events (48). In fact,
we demonstrate in this study that targeting V-ATPase in zymosan-
induced peritonitis in vivo, a self-limited model of acute inflam-
mation (19, 35), delays resolution of inflammation reflected by
impaired clearance of leukocytes from the inflamed cavity and by
reduced SPM levels in both exudates and plasma. Again, other
LM such as LTs and PGs were unaltered by V-ATPase inhibition
in this model, supporting the selectivity of this pathway for SPM
biosynthesis.
Taken together, we show that V-ATPase activity is essential for
induction of 15-LOX-1 during polarization of humanMDM toward
the proresolving M2 phenotype and the consequent capacity to
generate SPM. In particular, V-ATPase appears to be crucial for
IL-4–induced MEK/ERK-1/2 signaling, which is directly con-
nected to induction of 15-LOX-1 protein expression. We conclude
that V-ATPase may be a key component in alternative macrophage
activation by regulating 15-LOX-1 expression and related SPM
biosynthesis and thus in the resolution of inflammation.
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Supplemental Data 
Vacuolar (H+)-ATPase critically regulates specialized pro-resolving mediator pathways 
in human M2-like monocyte-derived macrophages and resolution of inflammation 
Rao Z. et al.  
Supplementary Table 1. LM profile of ArchA- and vehicle-treated M1 and M2. Human monocytes 
were differentiated by GM-CSF or M-CSF (20 ng/ml, each) for 6 days to get MGM-CSF or MM-CSF 
macrophages, respectively. After pretreatment with 30 nM ArchA or vehicle for 30 min, the MGM-CSF 
were polarized with LPS and INFγ for 48 h towards M1 while the MM-CSF were polarized with IL-4 for 
48 h towards M2. The cells were then incubated for 180 min with pathogenic E. coli (serotype 
O6:K2:H1, ratio 1:50) or vehicle at 37 °C. Formed LM were isolated from the supernatants by solid 
phase extraction and analyzed by UPLC-MS-MS; detection limit: 0.5 pg. Results are given as means ± 
S.E.M., n = 6 separate donors. * P<0.05, ** P<0.01, *** P<0.001 ArchA vs. vehicle control, data were 
log-transformed for statistical analysis; paired t-test. 
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Figure S1. Effects of the vATPase inhibitor bafilomycin on LM formation and LM-biosynthetic enzyme 
expression in M1 and M2. Human monocytes were differentiated by GM-CSF or M-CSF (20 ng/ml, 
each) for 6 days to get MGM-CSF or MM-CSF macrophages and then pretreated with bafilomycin (Bafi, 30 
nM, red) for 30 min prior to polarization for 48 h to M1 and M2. LM produced from (a) M2 and (b) M1 
after exposure to E. coli (ratio 1:50) were isolated by solid phase extraction and analyzed by UPLC-MS-
MS; detection limit: 0.5 pg. Results are given as means ± S.E.M., n = 4 separate donors; data were log-
transformed for statistical analysis; * P<0.05 Bafi vs. vehicle, paired t-test. (c) Cell lysates of M2 were 
immunoblotted for 15-LOX-1, 5-LOX, and cPLA2-α and normalized to β-actin for densitometric 
analysis. (d) Cell lysates of M1 were immunoblotted for COX-2, 5-LOX, and cPLA2-α and normalized 
to β-actin. Results are given as means ± S.E.M., n = 3 separate donors; * P<0.05, Bafi vs. vehicle; paired 
t-test.  
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Figure S2. Effect of p38 MAPK inhibitor skepinone-L in M2 on LM formation and LM-biosynthetic 
enzyme expression. (a) Schematic draft of the hypothetic role of p38 MAPK in 15-LOX-1 expression. 
(b) Human monocytes were differentiated by M-CSF (20 ng/ml) for 6 days to get MM-CSF macrophages, 
and then pre-treated with ArchA (30 nM) for 30 min prior to polarization for 48 h to M2. Cell lysates 
were immunoblotted for phospho-p38 MAPK and p38 MAPK and normalized to β-actin for 
densitometric analysis. Data are means ± S.E.M., n = 4 separate donors, two tailed t-test *P<0.05. (c/d) 
Human macrophages were pretreated with skepinone-L (1 µM) or vehicle (veh.) for 30 min prior to 
polarization towards M2 for 48 h. (c) Cell lysates were immunoblotted for 15-LOX-1, normalized to β-
actin. Data are means ± S.E.M., n = 4 separate donors. (d) Formed LM after incubation of polarized M2 
with E. coli (serotype O6:K2:H1 ratio 1:50) for 180 min at 37 °C. LM were analyzed by UPLC-MS-
MS. Results are given as percentage of control; means ± S.E.M., n = 4 separate donors. 
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Figure S3. Effects of NH
4
Cl and of the STAT6 inhibitor AS1517499 in M2. (a) Human monocytes were 
differentiated by M-CSF (20 ng/ml, each) for 6 days to get M
M-CSF
 macrophages and then pretreated 
with ArchA (30 nM), UO126 (3 µM), NH
4
Cl (50 mM) for 30 min prior to activation with IL-4 (20 
ng/ml) for 15 min. Cell lysates were immunoblotted for phospho-ERK, ERK and GAPDH, and 
densitometric analysis was performed. Results are means ± S.E.M., n = 3 separate donors; * P<0.05, 
*** P<0.001, vs. control (IL-4 vehicle); one-way analysis of variance (ANOVA) with Bonferroni test. 
(b) Schematic draft of the hypothetic connection between STAT6 and ERK in 15-LOX-1 expression.  
(c) Human monocytes were differentiated by M-CSF (20 ng/ml, each) for 6 days to get M
M-CSF
 
macrophages and then pretreated with AS1517499 (AS, 1 µM) for 30 min prior to polarization with IL-
4 (20 ng/ml) for 48 h. Cell lysates were immunoblotted for phospho-STAT6, STAT6, 15-LOX-1, 5-
LOX, phospho-ERK, ERK, cPLA2-α, ATP6V0D1 and β-actin, and densitometric analysis was 
performed. Results are given as means ± S.E.M., n = 4 separate donors; * P<0.05, *** P<0.001, vs. 
vehicle control; paired t test.  
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4. DISCUSSION 
Inflammation is a process during which the immune system defends against exterior 
harmful stimuli and helps the body to return to its healthy state. Acute inflammation is 
governed by the excessive production of pro-inflammatory mediators such as LTs and 
PGs as well as of cytokines [1]. Upon challenge, monocytes and macrophages as main 
human innate immune cells play indispensable roles in both the initiation phase and 
the resolution of inflammation and release cytokines and chemokines as well as LM 
including eicosanoids and SPM. The active resolution of inflammation depends largely 
on the phagocytosis of exterior bacteria during infection, which is facilitated by the 
function of the V-ATPase-regulated phagolysosome [168]. As a universal pH-regulating 
proton pump, V-ATPase is involved in multiple cellular processes and thus, V-ATPase 
is emerging as interesting research target in inflammation and cancer [6, 7, 138, 145, 
162, 169, 170]. In this thesis we studied how targeting V-ATPase regulates 
inflammation-related lipid mediators in human monocytes, M1 macrophages and M2 
macrophages. 
 
4.1 Inhibition of V-ATPase in human monocytes  
As professional innate immune cells with pivotal functions in the immune defense, 
human monocytes produce abundant levels of pro-inflammatory mediators including 
cytokines as well as eicosanoids like LTs and PGs. Our previous research indicates 
that V-ATPase is crucial for cytokine and chemokine trafficking in human monocytes 
[6]. Targeting V-ATPase elevates the lysosomal pH and acidifies the intracellular 
cytosol. Lowered intracellular pH causes endoplasmic reticulum (ER) stress and limits 
the secretion of cytokines like IL-8. However, how V-ATPase regulates the biosynthesis 
of LM, especially pro-inflammatory eicosanoids in human monocytes, remained elusive. 
Our data imply crucial but differential roles of V-ATPase in the regulation of the COX-2 
pathway in human monocytes (manuscript I). While V-ATPase has a negative impact 
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on prostanoid biosynthesis by limiting the de novo-induced COX-2 protein levels, this 
proton pump accomplishes efficient COX-2-derived prostanoid formation by favoring 
cellular COX-2 activity.  
We hypothesized that V-ATPase negatively regulates the de novo biosynthesized 
COX-2 protein levels in monocytes by rapidly lowering the protein amount of this 
inducible enzyme over time. Actually, it was reported that V-ATPase inhibition by 
bafilomycin elevates COX-2 levels in RAW264 macrophages of murine origin [6]. 
Besides higher COX-2 levels, V-ATPase inhibition also increased the amounts of TNF-
α and IL-1β that were shown to stimulate COX-2 expression [171, 172] involving p38 
MAPK [173], and this kinase seemingly mediates the increased COX-2 levels in the 
present scenario as well. In fact, several studies reported a crucial role of p38 MAPK 
in LPS-induced COX-2 expression in human monocytes [174-176], and it was shown 
before that both p38 MAPK and ERK-1/2 are essential in the induction of COX-2 protein 
in LPS-stimulated human neutrophils [177]. In our hands, ArchA increased the 
phosphorylation of p38 MAPK after 24 h LPS stimulation in human monocytes, and 
activated ERK-1/2, whereas other relevant signaling pathways for COX-2 expression 
like NF-κB and SAPK/JNK were not affected. This suggests that V-ATPase limits p38 
MAPK and ERK-1/2 activation in monocytes. Since the p38 MAPK inhibitor skepinone-
L as well as the ERK-1/2 inhibitor U0126 abrogated the LPS-induced COX-2 
expression, we propose that the enhancement of the p38 MAPK and ERK-1/2 pathway 
by ArchA is causative for the elevated COX-2 levels in human monocytes.  
Although targeting of V-ATPase increased COX-2 protein levels in human monocytes, 
the concomitant biosynthesis of COX-2-derived prostanoids was surprisingly 
decreased, suggesting that V-ATPase is overall beneficial for cellular COX-2 activity. 
Results from previous studies exclude direct interference of the V-ATPase inhibitors 
like ArchA, bafilomycin A and apicularen with the enzymatic activity of COX-2 activity 
[178], indicating that the suppression of prostanoid formation in monocytes is not the 
consequence of direct inhibition of the COX-2 enzyme. In contrast to monocytes, in M1 
macrophages ArchA (and bafilomycin) elevated COX-2 activity, suggesting that the 
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PG-suppressive effects of V-ATPase inhibitors in monocytes is cell type-dependent and 
due to modulation of processes that govern cellular COX-2 activity. Since V-ATPase 
was shown to regulate cytokine and chemokine trafficking in monocytes, where ArchA 
treatment led to accumulation of IL-8 in the endoplasmic reticulum (ER) [179], it 
appeared possible that de novo biosynthesized prostanoids might be trapped inside 
the cell. However, only low amounts of intracellular PGs were evident in E. coli-
stimulated monocytes whereas high levels were released into the cell supernatant, 
regardless of V-ATPase inhibition.  
 
Fig.4.1 Proposed mechanism of V-ATPase inhibition in affecting COX-2 pathways in human 
monocytes.  
The main function of V-ATPase is to regulate cellular pH homeostasis by promoting the 
transport of protons from the cytosol to lysosomes that become acidic [4], and 
accordingly, targeting of V-ATPase in monocytes led to an elevated lysosomal pH [179]. 
Therefore, we hypothesized that the reduction of COX-derived prostanoids might be 
due to intracellular pH changes upon V-ATPase inhibition. Indeed, the pH modulator 
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chloroquine that alkalizes lysosomes and acidifies the cytosol [180] mimicked the 
effects of V-ATPase inhibitors on the LM profile, as it strongly suppressed COX-
dependent LM formation without suppressing 12/15-LOX products and with only minor 
impairment of 5-LOX-derived LM. Cellular activity of 5-LOX is affected by many factors 
including AA supply, its helper protein FLAP, phosphorylation by MAPKAPK-2 and 
ERK-1/2 [14]. Note that ArchA did not alter 5-LOX, FLAP or cPLA2-α expression and 
substrate supply. Thus, the intracellular pH might be crucial for the activity of both the 
COX-2 and the 5-LOX pathway. In fact, the pH optimum for the enzymatic activities of 
COX-2 and 5-LOX in cell-free assays is around pH 8.0 [181, 182], implying that 
cytosolic or nuclear membrane-associated 5-LOX [14] and ER/nuclear envelope-
inserted COX-2 [183] may benefit from V-ATPase activity, accomplishing alkaline pH (> 
pH 7.2) in the cytosol. It appeared possible that changes in the intracellular pH might 
be also the cause for the increased COX-2 expression by ArchA, implying a detrimental 
role of V-ATPase in this respect. In fact, it was reported before for a human osteoblastic 
cell line that sensing of pH changes would regulate COX-2 expression and PGE2 
formation [184]. However, the pH modulator chloroquine did not induce COX-2 
expression but rather abrogated it, suggesting other mechanisms are responsible for 
the elevation of COX-2 protein levels by ArchA in human monocytes which are 
mediated by the p38 MAPK and ERK-1/2 pathway.  
Collectively, we reveal a crucial role of V-ATPase in the regulation of the biosynthesis 
of COX-2- and, to a minor extent, in 5-LOX-derived LM in human monocytes. Inhibition 
of V-ATPase results in contrasting requirements of this proton pump: V-ATPase causes 
an impairment of the protein levels of COX-2 seemingly by suppression of p38 MAPK 
and ERK-1/2 signaling but accomplishes substantial cellular activity of COX-2 possibly 
by adjusting a favorable intracellular pH for this enzyme. 
 
4.2 Inhibition of V-ATPase in human M1 macrophages 
We showed that targeting V-ATPase activity with ArchA selectively elevates the release 
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of TNF-α without significant effects on other cytokines like IL-1β, IL-6, IL-10 or 
chemokines like MCP-1 and IL-8 in both LPS-stimulated macrophages and LPS/IFN-
γ-stimulated M1 macrophages (manuscript II). Comparable effects were achieved 
using two structurally different V-ATPase inhibitors bafilomycin and apicularen, which 
indicates a class effect on TNF-α release through inhibition of V-ATPase. V-ATPase, 
as a proton pump, is also well known to regulate lysosomal pH in macrophages. V-
ATPase inhibitors including ArchA and bafilomycin were shown to block the function of 
the proton pump in macrophages and thus elevated the lysosomal pH [6, 162]. To 
address the involved mechanisms in elevating TNF-α levels, we explored two common 
pH modulators chloroquine and NH4Cl on TNF-α release in M1 macrophages [180, 
185]. These two tool compounds showed comparable effects on elevating lysosomal 
pH like ArchA but failed to increase the production of TNF-α. Actually, chloroquine was 
shown to inhibit the production of LPS-stimulated pro-inflammatory cytokines including 
TNF-α, IL-1β and IL-6 in a concentration-dependent manner in human whole blood 
[186]. This report supports our data, which excludes the involvement of pH modulation 
on elevated TNF-α levels caused by V-ATPase inhibition.  
 
Fig.4.2 Proposed mechanism of V-ATPase inhibition in regulating TNF-α and COX-2 pathways in 
human M1 macrophages.  
Additionally, ArchA significantly upregulated the mRNA levels of TNF-α but not of IL-1β 
in M1 macrophages. Studies by others revealed various signaling transduction 
pathways including the SAPK/JNK, NF-κB/IκB, MKK3/6-p38 and MEK/ERK-1/2 
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cascades that are involved in the production of TNF-α in various cellular systems [187-
190]. Analysis of possible involved protein kinases signaling pathways revealed that 
targeting V-ATPase by ArchA elevated the phosphorylation of NF-κB. 
Immunofluorescence microscopy results showed that ArchA treatment promoted the 
translocation of the p65 subunit of NF-κB to nucleus as well as inhibition of IκB. Notably, 
the phosphorylation of SAPK/JNK was also moderately affected by ArchA treatment. 
Other kinases were not significantly affected by the treatment with ArchA. Moreover, 
the elevated TNF-α release and TNF-α mRNA expression was abrogated by 
parthenolide [191], which inhibits NF-κB phosphorylation and the expression of TNF-α.  
Upon bacterial infection, macrophages produce reactive oxygen species (ROS) to 
clear the trapped bacteria [192]. Consistent with findings by others that V-ATPase 
inhibitors bafilomycin and concanamycin A increased ROS production in RAW 264 cells 
[193], we confirmed that V-ATPase inhibition with ArchA also increased the LPS-
induced ROS production in M1 macrophages, which was inhibited by the NADPH 
oxidase inhibitor DPI. Interestingly, DPI also inhibited the ArchA-induced TNF-α release, 
which indicates an involvement of ROS in TNF-α release. Studies indicated that the 
regulation of ROS production involves NF-κB and SAPK/JNK signaling [194]. Hence, 
we concluded that targeting V-ATPase elevated TNF-α expression and ROS 
production through NF-κB/IκB and SAPK/JNK signaling pathways. 
V-ATPase is overexpressed in the plasma membrane in various cancer cells and 
targeting V-ATPase with specific inhibitors induce apoptosis of tumor cells [144, 145]. 
Besides tumor cells, the tumor milieu is composed of tumor associated macrophages 
(TAMs) as well as tumor supporting mediators, which support tumor cells growth and 
angiogenesis [113]. TAMs are recognized to be M2 macrophages that are anti-
inflammatory but pro-tumoral. While classically activated M1 macrophages are well 
recognized to be more pro-inflammatory but anti-tumoral. Combination of direct 
cytotoxicity towards tumor cells with modification of tumor environment would be 
beneficial for anti-cancer therapy [195]. As mentioned previously, we revealed that 
targeting V-ATPase with ArchA elevated the release of pro-inflammatory TNF-α in M1 
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macrophages. Next, we utilized a three-dimensional human tumor biochip model to 
investigate if ArchA affects cancer cell viability in macrophage-tumor cell co-culture 
system. Human M1 or M2 macrophages were pre-treated with ArchA for 24 h before 
co-culture with MCF-7 cells for another 24 h. To avoid direct cytotoxicity towards MCF-
7 cells, ArchA was removed from the system before the co-culture of macrophages and 
tumor cells. Of interest, ArchA pre-treatment reduced the viability of MCF-7 cells in the 
co-culture with M1 but not M2 macrophages. Moreover, elevated TNF-α production 
was detected in tumor cells co-cultured with M1 macrophages. Thus, our study showed 
that pharmacological targeting V-ATPase elevated TNF-α release and supported the 
anti-tumoral effects of M1 macrophages in the tumor milieu. Together, inhibition of V-
ATPase with ArchA not only induced direct cytotoxicity towards tumor cells, but also 
achieved beneficial anti-tumoral effects through manipulation of the tumor 
microenvironment. 
Studies by others showed that TNF-α binds the Toll like receptor (TLR)-2 [196] and 
thus stimulates COX-2 expression as well as the production of prostaglandins [172, 
197]. Our time-course study revealed that COX-2 expression peaked after the 6 h 
stimulation of LPS stimulation, and was reduced again after 24, 48 or 72 h in human 
M1 macrophages, which is consistent with our data in human monocytes. Interestingly, 
pretreatment with ArchA prevented the rapid degradation of COX-2 protein, which kept 
significantly higher protein levels of COX-2 enzyme up to 72 h. This is consistent with 
other reports, which indicated that V-ATPase inhibition by bafilomycin induces COX-2 
expression in RAW264 macrophages of murine origin [198]. In line with higher COX-2 
expression, biosynthesis of COX-related prostanoids were elevated by ArchA 
pretreatment. By contrast, 15-LOX/12-LOX-related products and 5-LOX/FLAP-related 
LM remained unchanged.  
Compared to M2, LPS-stimulated M1 macrophages are pro-inflammatory but anti-
tumoral with higher pro-inflammatory cytokines release, higher COX-2 expression and 
higher levels of pro-inflammatory PGs [8]. Together, our data revealed that targeting V-
ATPase in M1 macrophages promoted the pro-inflammatory phenotype of M1 
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macrophages in terms of TNF-α release, ROS formation, COX-2 expression and COX-
related PG biosynthesis. Moreover, targeting V-ATPase in M1 macrophages enhanced 
the anti-tumoral effects of M1 macrophages in macrophages-tumor cell coculture 
through manipulation of the tumor microenvironment. 
 
4.3 Inhibition of V-ATPase in human M2 macrophages 
During inflammation, V-ATPase is required for the maturation of the phagolysosome, 
which is crucial for the phagocytic functions of human macrophages to degrade and 
clear pathogen invaders [169, 199]. Our previous data showed that V-ATPase 
regulates cytokine trafficking in human primary monocytes [6]. However, how V-
ATPase is involved in the biosynthesis of LM and in the resolution of inflammation 
remained elusive. Different from the pro-inflammatory M1 macrophages, M2 are 
generally anti-inflammatory with the capacity to produce abundant levels of SPM during 
efferocytosis of apoptotic neutrophils or upon challenge with pathogenic bacteria [8, 
200]. SPM as biological functional mediators trigger both anti-inflammatory and 
proresolving actions in both acute inflammation and resolution of inflammation [3]. 
They are actively involved in various processes like neutrophil transepithelial migration, 
phagocytosis and tissue regeneration during inflammation [3]. SPM terminate 
neutrophil transmigration, promote phagocytosis and accelerate tissue regeneration 
[10]. Here we focused on exploring the roles of V-ATPase in the biosynthesis of LM, 
especially SPM, in M2. 
We show that targeting V-ATPase with two structurally different V-ATPase inhibitors 
ArchA and bafilomycin significantly suppressed the biosynthesis of SPM, SPM 
precursors, 15-LOX-1-derived LM as well as fatty acid substrates (manuscript III). In 
alternative-activated M2 macrophages, IL-4 polarization induces the expression of 15-
LOX-1, which is a key enzyme in biosynthesis of SPM precursors and related SPM [8]. 
In line with lower SPM and 15-LOX-1-related metabolites, inhibition of V-ATPase 
abrogated the expression of 15-LOX-1 in M2. However, V-ATPase inhibition did not 
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affect the expression of the other LOXs, namely 15-LOX-2, 12-LOX and 5-LOX. 
Blockade of V-ATPase also inhibits the expression of cPLA2-α as well as 
phosphorylation of cPLA2-α and thus might be responsible for lower fatty acids supply. 
Moreover, biosynthesis of 5-LOX/FLAP-related LM was also inhibited by ArchA in M2 
and V-ATPase inhibition suppressed the production of all PGs in M2. Also, ArchA 
pretreatment moderately suppressed the expression of COX-1 that was shown before 
to be induced by IL-4 in murine bone-marrow-derived macrophages [29] and also in 
our hands in human M2. Thus, we propose that lower PG levels correlate to lower fatty 
acid supply as well as lower COX-1 expression in M2.  
 
Fig.4.3 Proposed mechanism of V-ATPase inhibition in regulating 15-LOX-1 pathways and 
biosynthesis of SPM in human M2 macrophages.  
Additionally, we investigated the role of V-ATPase in an in vivo murine zymosan-
induced peritonitis model, where abrogation of 15-LOX-1-related metabolites and SPM 
in both, exudates of the peritoneal cavity and plasma, by ArchA treatment was 
addressed. The zymosan-induced peritonitis is a self-resolving model of acute 
inflammation that peaks within few hours governed by neutrophil infiltration, while later 
inflammation is resolved after a period of 24 - 72 h [201]. Our in vivo data showed that 
V-ATPase inhibition delayed the resolution phase accompanied by higher numbers of 
infiltrated cells into the peritoneal cavity. This was in line with lower SPM levels in the 
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exudates of the peritoneal cavity. The SPMs were shown to impede neutrophils 
transmigration and accelerate resolution of inflammation [3]. By contrast, pro-
inflammatory PGs and LTs were not affected by V-ATPase inhibition with ArchA in vivo. 
Of note, biosynthesis of PGs and LTs were moderately suppressed in M2 macrophages 
but elevated in M1 macrophages by V-ATPase inhibition. The effects on PGs and LTs 
by V-ATPase inhibition might be compromised by the consistence of both M1 and M2 
phenotypes in the in vivo system.  
Our previous results suggested that V-ATPase regulates specifically the expression of 
the 15-LOX-1 isoform (not 15-LOX-2 or 5-LOX) in M2. The regulation of IL-4-stimulated 
15-LOX-1 involves multiple possible signaling pathways. The classical IL-4-JAK-
STAT6 pathway was shown to regulate 15-LOX-1 expression in various cell systems 
[110, 202, 203]. By use of the JAK inhibitor CP-690550 and STAT6 inhibitor AS1517499 
we confirmed that inhibition of STAT6 phosphorylation abrogated the expression of 15-
LOX-1 in IL-4 stimulated M2. However, our data revealed that targeting V-ATPase did 
not suppress phosphorylation of STAT6. Recently, V-ATPase was shown to be involved 
in the assembly and activation of mechanistic target of rapamycin complex 1 
(mTORC1), which is required in the polarization of IL-4 stimulated murine bone-
marrow-derived macrophages [5]. The PI3K-Akt-mTORC-LXR pathway regulated the 
expression of various M2-specific genes including IL-10, CD206 and Arg-1. Our study 
in human M2 indicated that V-ATPase inhibition with ArchA inhibited phosphorylation 
of Akt and p70S6K (substrate of mTORC1 complex), with no effects on the expression 
of Lamtor1 (subset of mTORC1 complex). However, PI3K inhibitor LY294002, 
mTORC1 inhibitor Torin 1 or LXR inhibitor GSK-2033 failed to suppress the expression 
of IL-4-induced 15-LOX-1 expression in M2 macrophages. Thus, neither JAK-STAT6 
nor PI3K-Akt-mTORC-LXR pathway was involved in the V-ATPase regulated 15-LOX-
1 expression in M2 macrophages. 
Our results propose that inhibition of V-ATPase abrogates 15-LOX-1 expression and 
SPM biosynthesis through regulation of MEK/ERK-1/2 pathway. In fact, an requirement 
of ERK-1/2 MAPK activity for IL-13 stimulated ALOX15 gene expression in human 
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monocytes was shown before [112]. We showed that in human M2 macrophages, 
inhibition of V-ATPase by ArchA inhibited phosphorylation of MEK and ERK-1/2. The 
activity of p38 MAPK was not affected by ArchA and blockade of p38 MAPK activity 
with skepinone-L did not impair the expression of 15-LOX-1 enzyme in M2 
macrophages. However, blockade of the MEK/ERK-1/2 pathway using the MEK 
inhibitor U0126 suppressed the expression of 15-LOX-1 as well as biosynthesis of 
SPM and 15-LOX-1-derived LM in M2 macrophages. Note that a recent study revealed 
that V-ATPase in Drosophila embryos is required for the ERK-1/2 dependent wound-
healing [204] and SPM also possess the capacity in accelerating tissue regeneration 
[10]. These reports support our hypothesis that V-ATPase regulates MEK/ERK-1/2 
signaling and has a role on the resolution of inflammation. The expression of the 
transcription factor c-Myc, which is downstream of MEK/ERK-1/2, was inhibited by 
ArchA in leukemic cells [205]. In our hands in human M2, ArchA also inhibited the 
expression of c-Myc, and the c-Myc inhibitor JQ-1 suppressed 15-LOX-1 expression 
and SPM biosynthesis. In fact, c-Myc was reported to be a key player in IL-4/IL-13-
activated alternative polarization of macrophages and the cleaved product of c-Myc, 
Myc-nick promoted efferocytosis in M2 macrophages [206, 207]. Together, we show 
that V-ATPase regulates the MEK/ERK-1/2-c-Myc pathway and thus the expression of 
15-LOX-1 as well as SPM formation.  
As mentioned before, inhibition of V-ATPase reduced the production of 5-LOX/FLAP-
related LM in M2 macrophages, whereas the enzyme expression of 5-LOX nor its 
helper protein FLAP was affected. Since the activation of 5-LOX involves multiple 
cellular processes including the presence of FLAP, arachidonic acid (AA) supply, the 
presence of calcium ion (Ca2+) and ERK-1/2 activity [14, 208, 209], we hypothesized 
that 5-LOX activation was impaired by V-ATPase inhibition. In M2 macrophages, 
inhibition of ERK-1/2 activity by U0126 reduced production of 5-LOX-related LM, 
whereas inhibition of MEK/ERK-1/2 downstream c-Myc did not impair the biosynthesis 
of 5-LOX-related LM. In addition, both ERK-1/2 activity and AA supply were reduced 
upon treatment with ArchA (V-ATPase inhibitor), U0126 (MEK inhibitor), or AS1217499 
(STAT6 inhibitor). Moreover, due to differences in the levels of sex hormones between 
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male and female, the ERK-1/2-mediated 5-LOX activity and biosynthesis of 5-LOX 
metabolites is gender-dependent [210]. Thus, there might also be a potential sex-bias 
for the MEK/ERK-1/2 regulated 15-LOX-1 expression and SPM formation. However, in 
our study, since M2 were obtained after long-term polarization (MCSF for 6-7 days) 
and stimulation (IL-4 for 48 h) from human PBMC in culture with 10% FCS, the sex-
differences can mostly be excluded during the long-period incubation. However, the 
potential sex-differences of 15-LOX-1 regulation are further explored in other cellular 
and in vivo systems and are still ongoing. Collectively, we conclude that V-ATPase 
critically regulates 15-LOX-1 expression and SPM formation through the MEK/ERK-
1/2-c-Myc pathway in M2 macrophages and thus has a crucial role in resolution of 
inflammation.  
Taken together, this thesis revealed pivotal but differential and complex roles of V-
ATPase on the biosynthesis of bioactive lipid mediators in human monocytes and 
macrophage phenotypes. It appears that V-ATPase is crucial for the M2 macrophage-
related resolution of inflammation due to accomplishing the expression of 15-LOX-1 
and the capacity for SPM formation during M2 polarization. In monocytes, V-ATPase 
promotes the biosynthesis of pro-inflammatory PG by stimulating COX-2 activity; in 
contrast, V-ATPase seemingly limits the expression of COX-2 enzyme and production 
of PG in M1 macrophages. Since V-ATPase is considered as pharmacological target, 
in particular for cancer therapy where LM play important roles in disease progression, 
our data will be of importance to judge the outcome of pharmacological intervention 
with V-ATPase.     
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